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A b str a c t
Down’s syndrome (DS) is the most common congenital cause of mental retardation and 
is caused by trisomy of chromosome 21. Initially prenatal diagnosis of chromosome 
abnormalities was offered only to pregnant women aged 35 years or over. In the last 
decade, maternal serum screening programmes have been introduced across the UK to 
give a risk of a pregnancy being affected of DS. These screening programmes are 
largely based on measurement of maternal serum concentrations o f alpha-fetoprotein, 
human chorionic gonadotrophin (hCG) and also, in some cases, unconjugated estriol 
and inhibin-A, combined with maternal age. Despite being routinely used to screen for 
DS pregnancies, little is understood about the mechanisms that underlie the alterations 
in maternal serum levels of these markers. It was the aim of this study to examine 
maternal serum markers of DS synthesised by the placenta. This mainly focused on the 
elevation in hCG and inhibin-A in DS pregnancies.
Placental levels and localisation of inhibin-A and activin-A were studied in control and 
DS pregnancies, as well as the maternal serum concentrations o f both markers. Levels 
of inhibin-A and activin-A were significantly elevated in DS placental extracts 
(1.46MoM and 1.62MoM respectively) and staining intensity o f the inhibin/activin (3a 
and a  subunits tended to be stronger in DS placentae. This suggested that elevated 
maternal serum levels of both markers in DS had their origin in increased placental 
synthesis, similar to previous observations on elevated placental production o f hCG in 
DS. Dimeric inhibin-A has recently been introduced as a screening marker of DS in 
some programmes and the elevation in maternal serum inhibin-A to 2.06MoM reported 
in the current study is similar to previous reports. The use of activin-A as a screening 
marker for DS was investigated by other groups during the course of the current study 
and it was noted that the small degree of elevation and the overlap in levels between 
control and DS makes it o f little use as a screening marker. This was independently 
confirmed by the current study which noted an elevation in maternal serum level of 
activin-A in DS pregnancies to 1.26MoM.
Growth factors Imown to have opposing effects on hCG secretion from placental 
trophoblast cells (epidermal growth factor (EGF) and transforming growth factor Pi 
(TGFpi)) were studied in maternal serum, placentae, maternal urine and amniotic fluid 
from control and DS pregnancies. ItwVas discovered that amniotic fluid levels of EGF
and TGFp] were significantly reduced in DS pregnancies to 0.5MoM and 0.685MoM 
respectively. Maternal urine levels of EGF were significantly reduced (0.726MoM), as 
were placental levels of TGFpi (0.675MoM) in DS pregnancies. It was postulated that 
reduced TGPPi levels in DS placentae could have a bearing on placental hCG secretion 
since TGFPi has an inhibitory effect on hCG secretion from and differentiation of 
cytotrophoblast cells. Reduced TGFPi could result in a diminished inhibitory effect of 
this growth factor on hCG secretion. A reduction in amniotic fluid EGF and TGFPi was 
an interesting finding, particularly in the case of EGF. EGF is not produced by the 
placenta suggesting that amniotic fluid EGF is likely to be of fetal origin, with reduced 
levels of EGF indicating abnormal fetal synthesis of this factor. Reduced urinary EGF 
but normal maternal serum levels o f EGF was a surprising finding since maternal urine 
is a filtrate of maternal blood. It was postulated that this could be due to rapid maternal 
cleai'ance of EGF secreted by the fetus resulting in the reduction in EGF secretion by 
the fetus being detectable only in amniotic fluid and maternal urine. This is the first 
study to analyse EGF and TGFPi in control and DS pregnancies and the results suggest 
that fetal and placental growth may be affected by altered levels of these growth factors. 
However, it was also recognised that altered levels of EGF and TGFpi may be a result 
of abnormal placental or fetal function in DS.
To fuither study placental function in normal and DS pregnancies, a widely used 
method of isolating and culturing placental trophoblasts was optimised using term 
placentae. Further immunopurification of the isolated cells by immunodepletion was 
also carried out and the percentage purity o f the cytotrophoblasts before and after 
immunopurification was confirmed using a panel of antibodies. The differentiation of 
cytotrophoblasts was monitored by immunocytochemistry and hCG and placental 
alkaline phosphatase (FLAP) secretion into the culture medium. The effect of 
cryopreservation on hCG and FLAP secretion by trophoblast cultures was also studied 
and it was found that hCG secretion from the cultures was significantly inhibited 
(p=0.025) and the viability o f the cells was reduced by cryopreservation although FLAP 
secretion was unaltered (p>0.05). It was the aim of this study to use the isolated cells to 
study hCG secretion by differentiating cytotrophoblasts under different culture 
conditions.
Because of the limited availability of trophoblast cells, different methods of determining 
hCG mRNA concentrations were compared: northern blot analysis. Real Time FOR and
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a custom developed ELISA based assay. It was found that northern blot analysis was 
impractical because too much RNA was required for each analysis and it was extremely 
time consuming to carry out. The ELISA based method that was developed was a 
specific and quick method o f mRNA quantification and results from this assay 
correlated with those obtained using Real Time PCR. The most efficient method of 
mRNA quantification was Real Time PCR because it required the least amount of 
starting RNA and was quick to carry out. Availability of the equipment to carry out this 
method of mRNA quantification could, however, prove difficult.
The genes for interferon (IFN) a  and p receptors are localised to chromosome 21. It was 
postulated that over-expression of these receptors could contribute to altered placental 
function in DS, as there is evidence that IFNa administration increases hCG secretion 
from hCG secreting bladder carcinoma cell lines. The effect o f IFN a on hCG secretion 
from normal placentae is poorly understood, consequently the current study investigated 
the effect of IFNa on hCG secretion by normal term placental trophoblast cultures. It 
was discovered that IFNa administration to trophoblasts failed to alter hCG secretion 
(p>0.05) or hCG mRNA production (p>0.05). The situation in mid trimester placentae 
could however be different because the rate of hCG secretion at this stage is higher than 
at term and also the largest difference between control and DS maternal serum hCG 
levels is found at this stage of gestation.
In conclusion, this study has illustrated that the DS placenta and fetus do not function 
normally in DS and that maternal serum levels of the markers studied appear to reflect 
altered placental secretion of these factors. Further studies that focus on chromosome 21 
markers (e.g. IFN receptors, superoxide dismutase or stress 70 protein chaperone) may 
help to further understand the link between the extra copy of cliromosome 21 and the 
alterations seen in maternal serum markers in DS pregnancies.
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“None but those who have experienced them can 
conceive of the enticements of science.
In other studies you go as far as others have gone 
before you, and there is nothing more to know; 
but in a scientific pursuit there is a continual food for
discovery and wonder.”
Dr Victor Frankenstein
In Frankenstein or The Modern Prometheus, 
Mary Shelly (1831).
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Section i
Introduction
1.1 D o w n 's  S y n d r o m e
1.1.1 C ytogenetic B asis o f  D ow n ’s Syndrom e
Down's Syndrome (DS) is the most common congenital cause of severe mental 
retardation. Without the intervention of prenatal screening and diagnosis, between 1 in 
600 and one in 700 births would be affected with DS (Crawfurd, 1988). Most cases are 
the result o f trisomy 21, with the extra chromosome usually arising due to non­
disjunction. In two thirds of cases, non-disjunction occurs during the first meiotic phase 
in females with the remainder of cases split equally between the second phase of 
meiosis in the female and both meiotic phases in the male. In 5% of cases, the extra 
genetic material arises due to a translocation, when part o f chromosome 21 is attached 
to another chromosome. This is usually a Robertsonian translocation that can only occur 
between acrocentric cliromosomes. It is thought that a specific region o f the long arm of 
chi'omosome 21 (band 21q22), often called the “Down’s syndrome critical region”, is 
sufficient to produce the DS phenotype when it is present in extra dosage.
1.1.2 D ow n ’s Syndrom e P henotype
The phenotype of an individual affected with DS is expressed both physically and 
mentally. These individuals have severe mental handicap, with an IQ of around fifty. 
They tend to have a shorter stature and a shorter, broader face with flat features. Their 
eyes are slanted with white spots on the iris and they have a characteristic simian palm. 
Weak muscles often make physical development of DS children slower than normal and 
around forty to fifty percent have congenital heart defects. They have an increased 
susceptibility to respiratory infections due to small air passages, and an impaired 
immune system which can also lead to persistent ear infections. They are also prone to 
developing acute lymphatic leukaemia, early onset Alzheimer’s type dementia and type 
1 diabetes, all o f which have been associated with genes on chromosome 21 (Burch and 
Milunsky, 1969). Those with DS tend to have a shorter than average life span, although 
some do live to beyond middle age when hypothyroidism and dementia become a 
problem (Scoggin and Patterson, 1982). Most are sexually underdeveloped and sterile 
however some women with DS have children fifty percent o f whom would also be 
expected to have DS.
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1.1.3 In cid en ce o f  D ow n ’s Syndrom e
The incidence of DS, like other chiomosomal abnormalities such as trisomy 18, trisomy 
13 and Kleinfelter’s syndrome (47XXY), increases with the mother’s advancing age. 
The risk increases from 1 in 1,528 at the age o f twenty to 1 in 384 at thirty five, and 1 in 
6 at fifty years of age (Cuckle et al. 1987). Over the last decade, more and more 
couples have been waiting until their mid thirties before having a child. The proportion 
of women at an increased risk of having a DS has therefore increased and many of these 
women opt for prenatal diagnosis. The fact that there is no way to prevent or cure this 
disorder also means that following prenatal diagnosis of DS, avoidance of the birth of 
an affected child is dependant upon termination of pregnancy.
1 .2  P r e n a ta l  D ia g n o s is
1.2.1 A m n iocen tesis
The most common way of detecting chromosomally abnormal pregnancies is to perform 
an amniocentesis. This is usually carried out at around fifteen to sixteen weeks of 
pregnancy and involves removing 10 to 20 ml of amniotic fluid (AF) via a needle 
inserted through the abdominal wall into the amniotic sac. The fluid contains enzymes, 
skin cells and excretions from the fetus. The fetal cells (amniocytes) are cultured to 
allow fetal chromosome analysis. Alternatively, a quicker method of detecting 
chromosomal abnormality is to use fluorescence in situ hybridisation (FISH) on 
uncultured amniocytes. The presence of extra or missing chromosomes is detected using 
probes, specific for certain areas of a chromosome, coupled to a fluorochrome (Morris 
et al. 1999).
1.2.2 C horionic V illou s Sam pling (CVS)
To allow fetal karyotyping in the first trimester of pregnancy, a different method called 
chorionic villous sampling (CVS) may be employed. This involves the removal of some 
chorion frondosum, either transcervically via a cannula or endoscope, or 
transabdominally as with amniocentesis. Fetal chromosome analysis is carried out using 
direct analysis of metaphases or following culturing of villi. The results o f this test are 
available much earlier than those from amniocentesis, at around ten to fourteen weeks 
of gestation compared to around sixteen weeks of gestation. This early
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diagnosis means that a termination is much safer to carry out using aspiration methods 
rather than induction o f labour, should the chromosome analysis show an abnormality.
1.2.3 D raw backs o f  D iagn ostic  T ests
There are risks to the developing fetus associated with performing both tests. There is 
an additional miscarriage risk o f approximately 1 percent associated with performing an 
amniocentesis (Smidt-Jensen et al. 1992). It has been shown that a transabdominal CVS 
carries a risk of miscarriage of around 2 percent, while a transcervical CVS carries a 
risk of around 7 percent (Smidt-Jensen et al. 1992). These risks combined with the 
financial cost of carrying out many tests means that it is desirable to select mothers who 
ai'C believed to be at high risk of having an abnormal pregnancy before offering fetal 
chi'omosome analysis. Initially, selection was based solely on the mother’s age but this 
only detected around 30 percent of DS pregnancies (Wald et al. 1988b). Now the result 
of biochemical tests carried out on the mother’s blood, combined with maternal age, is 
used to select those at high risk of carrying a chromosomally abnormal fetus. If a high 
risk is reported following these screening tests, then an invasive diagnostic procedure is 
offered to either confirm or rule out fetal abnormality.
1.3  P r e n a ta l  S c r e e n in g
As part of routine prenatal care, all expectant mothers in Scotland aie offered a serum 
screening test for neural tube defects and DS in the second trimester of pregnancy. 
Because only a small sample o f maternal blood is required to perform these tests, there 
is no risk to the pregnancy. Prenatal screening tests have been developed over a number 
of years with input from different groups working in this field. (Aitken and Crossley,
1992). These tests involve measuring maternal serum concentrations of factors secreted 
into the maternal circulation following synthesis by either the fetus or placenta. These 
results are converted to an odds ratio that the pregnancy is affected and combined with 
the maternal age risk (Spencer, 1995; Zimmermami et al. 1996). In the west of Scotland 
the biochemical screening programme, which started in 1991, measures the maternal 
serum concentrations of alpha-fetoprotein (AFP) and intact human chorionic 
gonadotrophin (ihCG). If a risk equal to or greater than 1:220 is determined, an 
amniocentesis is offered. This test detects 68% of DS pregnancies, with a false positive
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rate of 5.2% (Aitken and Crossley, 1997), compared with only 30-35% of DS 
pregnancies being detected by offering an amniocentesis based solely on a maternal age 
of greater than thirty-five years (Aitken and Crossley, 1992). In some other regions of 
the UK these markers are combined with unconjugated estriol (UE3) and/or inliibin-A. 
More recently, first trimester screening for chromosomal abnormalities has been 
introduced. The principal maternal serum markers of DS pregnancies in the first 
trimester are pregnancy associated plasma protein A (PAPP-A) and the free beta subunit 
of hCG (fp-hCG), combined with ultrasound measurements of fetal nuchal translucency 
and maternal age (Brizot et al. 1994). Recent advances have been made in the detection 
o f fetal cells in maternal circulation as a non-invasive diagnostic tool for genetic 
abnormalities. Although a promising technique, more reliable detection rates would be 
required before this could be used as a diagnostic test (Bianchi, 2000).
1.3.1 A lp h a-fetop rotein  (AFP)
1,3,1,! S tructure, L ocalisation  and Function
AFP is a 67-74 kDa protein that belongs to a superfamily of proteins including vitamin 
D and albumin. It has been shown to have homology in its primary, secondary and 
tertiary structure with serum albumin and, like albumin, has strong binding affinities 
with several ligands (Deutsch, 1991). The most notable binding molecules of AFP are 
polyunsaturated fatty acids, bilirubin, copper 2^ and estrogens, although the biological 
relevance of this binding remains unclear. It has been suggested that AFP may be 
involved in transporting these substances within or to the fetus, perhaps to nourish fetal 
tissue (Deutsch, 1991). It has also been suggested that AFP has some regulatory 
functions over the maternal immune system, particularly immunosuppression (Ruoslahti 
and Hirai, 1978b). The similarities between AFP and serum albumin are also evident at 
the genetic level, with both having structurally related genes on chromosome 4. It is 
thought that the genes may have arisen from a common ancestral gene via gene 
divergence (Harper and Dugaiczyk, 1983). Thi'ee different forms o f AFP have been 
isolated due to their varied ligand binding properties, caused by different glycosylation 
patterns. The different forms of AFP seem to be expressed by different tissues at various 
stages of gestation although all are detectable by immunological methods (Ruoslahti et 
al. 1978a).
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AFP is found only at trace levels in healthy humans, however AFP may be detected in 
the serum of individuals who have certain medical conditions such as liver cirrhosis, 
hepatitis or liver, germ cell and gastrointestinal tumours. During pregnancy, AFP is 
detectable in the developing fetus, the AF and maternal serum. The main sites of AFP 
production in pregnancy are the yolk sac, fetal liver and fetal gastrointestinal tract 
(Ruoslahti and Hirai, 1978b).
1,3,1,2 AFP Concentrations in pregnancy
The maternal serum concentration of AFP is elevated during pregnancy. Concentrations 
begin to rise above non-pregnant levels at approximately ten weeks of gestation, and 
continue to do so until around 32 weeks of gestation, after which time they begin to 
decrease until term. AFP is also detectable in the AF, peaking at around fourteen weeks 
of gestation. AF levels o f AFP are higher than those in maternal serum imtil just before 
partuiition when the situation reverses (Seppala and Ruoslahti, 1972; Ruoslahti and 
Hirai, 1978b; Wathen et al. 1991; Palomaki et al. 1993).
,3 AFP levels in DS pregnancies
Several studies established that the maternal serum concentration of AFP in the second 
trimester of DS pregnancies is significantly lower than that in normal pregnancies. The 
DS multiple of the control median value (MoM) is around 0.75. (Cuckle et al. 1984; 
Fulirmann et al. 1984; Merkatz et al. 1984; Tabor et al. 1984; Crandall et al. 1988; 
Spencer et al. 1992). It was demonstrated that measuring the maternal serum AFP 
concentration could be a useful method of selecting pregnancies for amniocentesis that 
have a high risk o f being affected with DS, particularly when the AFP measurements 
were combined with maternal age (Cuckle et al. 1987; Tabor et al. 1987; Zeitune et al.
1991).
Studies of AF from DS pregnancies confirmed that the AFP level was significantly 
reduced, to a similar degree to that observed in maternal serum samples (Merkatz et al. 
1984; Tabor et al. 1984; Cowchock and Ruch, 1984; Davis et al. 1985; Jones et al. 
1986; Kaffe et al. 1988; Crandall et al. 1988; Zeitune et al. 1989). The MoM values 
reported in these studies range from 0.6 (Zeitune et al. 1989) to 0.734 (Jones et al. 
1986) with a median of approximately 0.7MoM.
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The AFP concentration has also been reported as being reduced in the maternal serum 
of first trimester DS pregnancies (Aitken et al. 1993; Fuhrmann et al. 1993; Spencer et 
al. 1994; Berry et al. 1995; Haddow et al. 1998). The reported AFP MoMs in the first 
trimester of DS pregnancies ranged from 0.62 to 0.97 with an average of 0.78MoM. 
There has, however, been some conflict of opinions as to whether first trimester 
screening using maternal serum AFP would be effective or not (Cuckle et al. 1988; 
Brock et al. 1990; Aitken et al. 1993; Crandall et al. 1993; Fuhrmann et al. 1993; 
Haddow et al. 1998).
In contrast to the situation in maternal serum and AF, one study has shown that 
endogenous placental concentrations of AFP are significantly higher in DS pregnancies 
(Newby et al. 1997). This study showed a greater than two fold elevation in AFP levels 
in placental extracts from DS pregnancies when compared to chromosomally normal 
pregnancies, suggesting altered placental transport of AFP in DS. Other placental 
abnormalities are associated with altered maternal serum AFP concentrations and it has 
been suggested that this may be due to increased leakage of AFP from sites of placental 
damage (Bendon, 1991).
1.3.2 H u m an  C horionic G onadotrophin  (hCG)
Maternal serum levels of the peptide hormone, human chorionic gonadotrophin (hCG), 
are elevated in DS pregnancies (Bogart et ai. 1987). Elevated maternal serum levels of 
fp-hCG have also been reported in the first and second (Maori et al. 1990; Spencer et 
al. 1992; Spencer et al. 1994) trimesters of DS pregnancies.
1.3,2,! S tructure and Localisation
hCG is a heterodimeric glycoprotein hormone that has an alpha and a beta subunit 
covalently bonded to each other. The 15kDa alpha subunit is common to other 
glycoprotein hormones such as follicle stimulating hormone (FSH), leutenising 
hormone (LH) and thyrotrophin stimulating hormone (TSH). Part of the untranslated 
sequences o f the gene encoding this subunit also shows similarity to the human growth 
hormone genes (Fiddes and Goodman, 1981). In contrast, the 23kDa beta subunit is 
unique to hCG, thereby conferring the specificity of the hormone (Pierce and Parsons, 
1981). There are four breakdown products of hCG that are found in AF, serum and 
urine along with ihCG (the active hormone). These breakdown products are nicked hCG
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(hCG with a break in the p-subunit chain between residues 47 and 48 or 43 and 44), fp- 
hCG, free a-hCG and nicked fp-hCG (cut in the same positions as nicked hCG) (Cole et 
al. 1993). A fifth breakdown product of hCG called p-Core hCG (the terminally 
degraded product of the hormone), is detectable only in urine (Cole et al. 1997) and is 
the major form of hCG present in mine (Kato and Braunstein, 1988).
hCG is fomid in many tissues of the human body including the gonads, uterus, pituitary, 
digestive organs, lung, pancreas, placenta, fetal membranes and decidua (Braunstein et 
al. 1979). During the normal menstrual cycle and the early stages of pregnancy the 
corpus luteum is the primary site of hCG production. At around eight weeks of 
gestation, the placenta largely takes over the production of hCG. Immunohistochemical 
and RNA expression analysis of the placenta revealed that the predominant site o f hCG 
a-subunit production is the cytotrophoblast, while p-subunit production is mainly 
localised to the syncytiotrophoblast (Hay, 1988; Kelly et al. 1991). Formation of intact 
hCG (ihCG) from the two subunits has been localised mainly to the syncytiotrophoblast 
layer of the placenta (Hay, 1988) although in the early stages of pregnancy the 
cytotrophoblast is capable of hCG production. This finding is confirmed by the report 
noting p subunit localisation in the cytotrophoblast cells o f four to five week placentae, 
while from six weeks of gestation until term the syncytium is the primary site of p 
subunit localisation (Maruo et al. 1992). It is thought that the rate o f hCG production is 
dependant on the rate o f cytotrophoblast to syncytiotrophoblast differentiation (Hay, 
1988). As well as the reported localisation of hCG to trophoblastic cells, the hCG p 
subunit has also been localised to Hofbauer cells (fetal macrophages) present in the 
villous stroma (Katabuchi et al. 1994).
1,3,2,2 P hysiological actions ofhCG
One of the main physiological actions o f hCG in the early stages of pregnancy is to 
maintain the corpus luteum that otherwise would atrophy leading to the induction of 
menstruation. The corpus luteum plays an important role in the production of estrogens, 
progesterone, relaxin and inhibin during the early stages of pregnancy before the 
placenta and fetal membranes take over these functions. The roles of hCG in the later 
stages of pregnancy are largely unknown although it is thought to be involved in several 
processes including steroid biosynthesis, trophoblast differentiation, placental glycogen 
metaholism and placental function (Yen, 1991).
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1 >3*2,3 hCG levels in pregnan cy
Soon after conception, an increase in the maternal serum and urine concentrations of 
hCG becomes apparent. This increase may be observed as early as six days after 
conception and detection of increased hCG concentrations in these fluids is used as an 
indication of pregnancy. The serum concentration of hCG continues to rise through the 
first trimester of pregnancy until a peak is reached at around eight weeks of gestation. 
The concentration of hCG then drops rapidly until approximately eighteen weeks of 
gestation when the decline halts and the lower hCG concentration is maintained for the 
remainder of pregnancy (Braunstein et al. 1976). The levels of hCG p subunit 
production largely mirror the trends in ihCG production while the rate of a  subunit 
production increase throughout gestation until term. This indicates that production of 
the p suhunit of hCG is the rate limiting step in ihCG synthesis (Vaitukaitis, 1974).
hCG is also detectable in the AF, although at a lower concentration than in the maternal 
circulation. The concentration of hCG in the AF peaks, at around 11 to 14 weeks, after 
which time the hCG concentration falls steeply to a low level which is maintained until 
parturition (Clements et al. 1976). The AF levels of both total hCG and fp-hCG are 
higher in normal pregnancies where the fetus is female when compared with 
pregnancies when the fetus is male (Spencer et al. 1997a).
Relative levels of ihCG, a-hCG and fp-hCG vary in the placenta at different stages of 
gestation. In the first trimester o f pregnancy, the concentrations of all forms of hCG are 
high with a peak observed at around 7-10 weeks. The total hCG levels then drop until 
parturition. In the third trimester of pregnancy the concentration of a-hCG remains at a 
similar level to that observed in the second trimester, while the levels of both P-hCG 
and ihCG continue to decline. This results in the alpha subunit level exceeding that of 
the beta and intact forms of hCG in the third trimester of pregnancy (Vaitukaitis, 1974).
1,3,2,4 hCG Levels in  DS pregnancies
Numerous studies have confirmed that the second trimester maternal serum levels of 
both intact hCG and fp-hCG are elevated to ai'ound twice the normal MoM value in DS 
pregnancies (Bogail et al. 1987; Wald et al. 1988b; Macri et al. 1990; Norgaard- 
Pedersen et al. 1990; Crossley et al. 1991; Haddow et al. 1992; Ryall et al. 1992; 
Spencer et al. 1992; Stone et al. 1993). A meta analysis reported a DS maternai serum
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MoM of 1.83 for fphCG and 1.29 for ihCG (Wald et al. 1997b). The lai'ge elevation 
observed in DS pregnancies make hCG the hest second trimester serum marker for 
affected pregnancies, giving a detection rate of 30%, for a 3% false positive rate. 
Consequently, fp-hCG or ihCG measurements aie included in almost all biochemical 
screening programmes (Wald et al. 1996). It has been reported that the use of f]3-hCG 
in combined screening programmes provides a better detection rate of DS pregnancies 
compared with the use of ihCG with an approximately 10% increase in sensitivity 
(Macri et al. 1990; Spencer, 1991; Macri et al. 1994; Wald et al. 1997a). One study 
reported no difference in detection rate but a decreased false positive rate with the use 
of f]3“hCG in a combined screening programme for DS (Stone et al. 1993). Some 
studies have reported an increase in the maternal serum levels of free a-hCG in the 
second trimester of DS pregnancies (Bogart et al. 1987; Bogart et al. 1989; Ryall et al.
1992). Others failed to find any increase in the free a-hCG levels in maternal serum 
(Spencer, 1993).
In the first trimester o f DS pregnancies, the maternal serum level of fp-hCG is 
significantly elevated to almost twice the control level and is used in first trimester 
screening for DS (Ozturk et al. 1990; Aitken et al. 1993; Macri et al. 1993; Spencer et 
al. 1994; Haddow et al. 1998). The first trimester levels of ihCG were shown to be 
slightly elevated by some studies, whilst others found no significant increase in DS 
pregnancies (Cuckle et al. 1988; Brock et al. 1990; Aitken et al. 1993; Crandall et al. 
1993; Brizot et al. 1995). Some studies have looked at the first trimester concentrations 
of maternal serum free a-hCG in DS pregnancies. One study found a slight increase 
(Ozturk et al. 1990), while another noted no significant difference from normal levels 
(Bogart et al. 1989). In contrast, Kratzer et al { \99 \)  reported a significant decrease in 
the maternal serum levels of the alpha subunit. Table 1.3.2.4 summarises the average 
MoM levels of the different forms of hCG in first trimester DS pregnancies.
The AF of DS pregnancies was shown to have significantly increased levels o f ihCG, 
fp~hCG and total hCG (Newby et al. 1997; Spencer et al. 1997a). The degree of 
elevation in the different forms of hCG reported in these studies was slightly lower than 
the degree o f elevation observed in maternal serum in the second trimester o f DS 
pregnancies (table 1.3.2.4).
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Maternal urine concentrations of fp-hCG and (3-core hCG have been studied in DS 
pregnancies. Urinary f|3-hCG levels in both the first (Spencer et al. 1997b) and second 
trimesters (Spencer et al. 1996; Hayashi et al. 1996) of DS pregnancies are 
significantly elevated. The degree of elevation in fp-hCG levels in urine is more in the 
second trimester (table 1.3.2.4). It was suggested in these studies that this marker could 
be used in the detection of DS pregnancies in either trimester o f pregnancy. Maternal 
urine (3-core hCG levels are elevated to over three times the normal level in the second 
trimester of DS pregnancies (Cuckle et al. 1994; Hayashi and Kozu, 1995; Canick et al. 
1995; Spencer et al. 1996; Isozaki et al. 1997; Bahdo-Singh et al. 1999; Cuckle et al. 
1999). Only one study found significantly elevated first trimester levels of (3-core hCG 
in DS pregnancies (Spencer et al. 1997b) with others indicating no difference in the 
first trimester levels of this protein (Kornman et al. 1997; Macintosh et al. 1997). It has 
been suggested that (3-core hCG may be a useful screening marker for DS in the second 
trimester of pregnancy, however the lack of availability of an optimised assay for this 
protein in urine complicates its use in routine screening (Cole et al. 1997).
A study using placental homogenates from control and DS pregnancies has shown that 
the placental levels of hoth f|3-hCG and ihCG are subject to a three to four fold increase 
in DS pregnancies, mirroring the situation in maternal serum, urine and AF (Newby et 
al. 1997).
1 Trimester Jn^rim ester’
serum urine serum AF urine
ihCG 1.29* 2.06* 1.38 2.30
f(3hCG 1.83* 1.81 2 .20* 1.77 2.55
ahCG 1.00* 1.43*
(3-core hCG NP 3.08 NP NP 3.67*
Table 1.3,2.4 Summary o f  average DS median M oM values fo r  each form  o f  HCG 
studied in maternal serum, AF  and maternal urine in the first and second trimesters o f  
pregnancy. NP=not present in that fluid, ^Indicates M oM  values reported in the meta 
analysis by Wald et al (1997b). Others are calculated from  the references cited in the 
body text o f  section 1.3.2.4.
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1.3 3 U ncon ju gated  E strio l (UE3)
Unconjugated estriol (UE3) is a pregnancy associated steroid hormone synthesised in 
the placenta from precursors derived from the fetus. Low total estriol levels were first 
noted in the maternal urine of DS pregnancies (Jorgensen and Trolle, 1972). Later work 
indicated that lower than normal maternal serum levels of UE3 were associated with DS 
pregnancies (Canick et al. 1988). A meta analysis of several studies looking at second 
trimester UE3 levels in DS pregnancies gave a median DS median MoM of 0.72 based 
on 733 affected pregnancies (Wald et al. 1997b). It was suggested that this 
measurement be combined with AFP levels, hCG levels and maternal age to further 
improve the accuracy of prenatal screening tests (Canick et al. 1988; Wald et al, 
1988a; Wald et al. 1988b). The use of these tln*ee biochemical markers in combination 
with maternal age is commonly called the “triple test”. Wald (1998a) suggested that not 
only would the detection rate be improved if  these combined tests were adopted, but the 
false positive rate would also be reduced. The value of UE3 as a first trimester screening 
marker has also been studied (Cuckle et al. 1988) and it was found that levels were 
significantly lower in the first trimester. The average reduction observed in a series of 
studies looking at 210 DS pregnancies was 0.71MoM (Wald et al. 1997b). It was 
suggested that UE3, when used in combination with other markers, would form part o f a 
useful screening programme for DS in the first trimester (Cuckle et al. 1988; Crandall 
et al. 1993).
These observations were not supported by other studies carried out in the first and 
second trimesters of pregnancy. Despite reporting a significant reduction in the level of 
UE3 in both trimesters, these studies could not find any significant improvement in 
detection rates by combining these results with age, AFP and either ihCG or f[3hCG in 
prenatal screening programmes. This was because the change in UE3 concentration is 
correlated with the change in AFP concentration meaning alterations in the levels of 
UE3 in DS pregnancies merely reflect the changes seen in AFP levels (Crossley et al. 
1993; Aitken et al. 1993; Wenstrom et al. 1997; Haddow et al. 1998).
1.3.4 Inhibin-A
Several studies have reported a significant increase in the second trimester levels of the 
dimeric glycoprotein inhibin-A in maternal serum from women with DS pregnancies, 
when compared with the serum levels from apparently normal pregnancies (Aitken et al.
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1996; Wald et al. 1996; Cuckle et al. 1996; Wallace et al. 1996; Lambert-Messerlian 
et al. 1996a; Lambert-Messerlian et al. 1998). The DS level reported by these studies 
ranges from 1.62MoM (Cuckle et al. 1996) to 2.6MoM (Wallace et al. 1996). It has 
been suggested that inhibin-A be included in the second trimester prenatal screening 
programme for DS as it may increase the detection rate currently achieved when 
measuring hCG and AFP levels in maternal serum by approximately 10% (Cuckle et al. 
1996). In the first trimester inhibin-A levels have been reported as being significantly 
increased to 2.46MoM in one study (Wallace et al. 1995) while a different study 
reported no significant difference from the normal situation with a DS median MoM of 
1.38 (Aitken et al. 1996). A study by Wallace et al. (1997) discovered a significantly 
decreased level of inliibin-A in AF collected from DS pregnancies. This group reported 
that the median DS MoM was significantly decreased to 0.77 MoM, the opposite trend 
from that observed in the maternal serum.
1.3.5 S u p eroxid e D ism u tase  (SO D i)
None of the maternal serum screening markers described in previous sections has their 
gene on chromosome 21. One chromosome 21 specific marker, which has been 
evaluated as a potential screening mai’ker, is superoxide dismutase (SODI). Increased 
SOD 1 activity has heen observed in fetal erythrocytes (Portsmann et al. 1990), AF 
(Baeteman et al. 1985), maternal serum (Ognibene et al. 1999) and maternal blood 
(Cuckle and Arbuzova, 2000) from DS pregnancies. In general, this increase in activity 
was by a factor of 1.5 as would be expected for the increased gene dosage effect. The 
overlap between control and DS levels of activity indicates that this may not be a useful 
screening marker, although the number of cases on which these studies were based is 
limited. Elevated activity has also been reported in the tissues of DS individuals as 
would be expected for a gene expressed on chromosome 21 (Sinet, 1982). This elevated 
activity has been widely studied in the brains of DS patients where it is thought to play a 
key role in neuronal degradation leading to neural dysfunction and early onset 
Alzheimer’s type dementia (lannello et al. 1999).
SODI is a copper/zinc containing homo dimeric enzyme with each dimer having a mass 
of 15kDa. It is present in the cytosol o f cells where it catalyses a reaction that destroys 
free radicals produced during normal cellular reactions. These free radicals would 
otherwise be toxic to biological systems. The reaction takes two superoxide radicals and
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two protons and converts them into oxygen and hydrogen peroxide. The hydrogen 
peroxide is then metabolised to water by either glutathione peroxidase or catalase. 
Although this reaction is protective against oxidative damage caused hy superoxide 
radicals, excess SODI activity could lead to accumulation of hydrogen peroxide in the 
cell if  glutathione peroxidase or catalase do not upregulate to clear the extra hydrogen 
peroxide. Hydrogen peroxide is toxic to cells and can also react with superoxide radicals 
to give rise to the more dangerous hydroxyl radical leading to more oxidative damage. 
The extra copy of this gene in DS pregnancies could therefore have a bearing on the 
pathophysiology observed in these pregnancies.
1.3.6 P regnancy A ssoc ia ted  P lasm a P rotein  A  (PAPP-A)
Lower than normal levels o f placental derived PAPP-A have been noted in the first 
trimester of DS pregnancies. It was recently reported that PAPP-A is infact insulin like 
growth factor binding protein-4 (IGFBP-4) protease (Conover et al. 2001; Byun et al. 
2001). By cleaving IGFBP-4, PAPP-A enhances the activity o f insulin like growth 
factor because less IGFBP-4 is present to attenuate the activity o f IGF. Levels o f PAPP- 
A are less than half that in unaffected pregnancies (Wald et al. 1992; Spencer et al. 
1994; Brizot et al. 1994; Berry et al. 1997). A meta analysis of twelve studies reported 
an average DS median MoM of 0.38. Unlike hCG, this marker is only suitable for use in 
the first trimester of pregnancy because DS levels are normal in the second trimester of 
pregnancy (Berry et al. 1997; Wald et al. 1997b). For first trimester screening 
protocols PAPP-A levels are combined with f]3-hCG levels, an ultrasound measurement 
of nuchal translucency and maternal age to give a risk o f DS pregnancy (Wald et al. 
1997b).
1.3.7 O ther M aternal S eru m  M arkers o f  DS
Many other potential maternal serum markers of DS pregnancies have been investigated 
in both the first and second trimesters of pregnancy (table 1.3.7). Despite the majority of 
these markers proving to be of little clinical use in the detection of DS pregnancies, 
many of these markers are of placental origin or can influence placental growth 
suggesting altered function o f the placenta in DS pregnancies.
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Marker IFTH ni^ MoM 2"** Trimester MoM References
URNAP 1.65MoM (76) (Wald et al. 1997b)
SP-1 0.81M oM (lll) I.47M0M (379) (Wald et al. 1997b)
a  Inhibin 1.27MoM (34) 1.63MoM (64) (Wald et al. 1997b)
Activin-A I.36M0M (45) 1.04MoM (50) (Lambert-Messerlian et al. 
1998; Cuckle et al. 1999; 
Spencer et al. 2001b)
Pro MBP 0.73MoM(15) 1.62MoM(105) (Christiansen et al. 1999)
p43 I.58M0M (42) (Moroz et al. 2000)
IGFBP-3 1.09MoM (9) (Chu et al. 1998)
Ca 125 1.14MoM (34) O.94M0M (81) (Wald et al. 1997b)
PLGF I.26M0M (45) 0.67MoM (24) (Debieve et al. 2001; Spencer 
et al. 2001a)
Table 1.3,7 Summary o f  other suggested maternal serum markers o f  DS in first and 
second trimesters o f  pregnancy. URNAP=urea resistant neutrophil alkaline 
phosphatase SP-l=schwangerschafts protein 1, Pro MBP=pro eosinophil major basic 
protein, p43=placental isoferritin p43 component, IGFBP-3=insulin like growth factor 
binding protein-3, Ca 125=cancer antigen 125, PLGF=placental growth factor. 
Number o f  DS pregnancies on which M oM  values are based is indicated in parentheses. 
Where possible M oM  values are those reported in meta analyses.
1.3.8 W hy are M aternal Serum  M arker L evels A ltered?
Despite the work carried out to determine the degree of variation in maternal serum and 
maternal urine marker levels between normal and DS pregnancies, little is understood 
about why these levels are altered. These alterations and the reasons behind them have 
provoked some interest (Canick et al. 1988; Chard, 1991a; Waller et al. 1993; Knofler, 
1999; Goshen, 1999) and some studies o f the mechanisms that control the synthesis and 
release of these markers have been carried out to try and further understand normal 
production as well as the reasons behind the altered marker levels in abnormal 
pregnancies. These studies have mainly focused on differences in placental function in 
chromosomally abnormal pregnancies when compared to controls.
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1 .4  P la c e n ta
1.4.1 P lacen ta l d evelop m en t and  fu n ction
The human placenta is a unique organ that regulates the transfer o f nutrients, hormones, 
waste products, oxygen and other soluble factors between the mother and fetus. The 
placenta produces many protein and steroid hormones, including hCG, progesterone, 
human placental lactogen (hPL), chorionic thyrotrophin, human chorionic follicle 
stimulating hormone, human uterotropic placental hormone and chorionic 
corticotrophin. The placenta also produces estrogens with assistance from the fetal 
adrenal gland and liver (Osathanondh and Tulchinsky, 1980).
The placenta is formed of maternal and fetal components. The maternal component is 
derived from the decidua, while the fetal part arises from the villous chorion. Five days 
after fertilisation, the cell mass changes to a hollow structure called the blastocyst. The 
blastocyst consists o f an inner cell mass, which will later form the fetus, and an outer 
shell called the chorion. The chorion is composed of trophoblast cells and will later 
form part of the placenta. Seven to twelve days following fertilisation, the blastocyst 
implants in the endometrium during which time the chorion becomes a thick double­
layered structure. The inner cell layer is composed of cytotrophoblast cells, which are 
enclosed in the outer syncytial layer. The cytotrophoblast cells rapidly proliferate 
causing the formation of finger like projections of trophoblast cells called primary villi 
that project into the intervillous space. The formation of villi begins at around four 
weeks of gestation, with primaiy villi consisting of only cytotrophoblast cells clothed in 
an outer syncytial layer. During the following week of gestation, the villi begin to 
develop a mesenchymal core and become branched. They are now termed secondary 
villi. At the end of the fifth week of gestation tertiary villi, which are so called because 
of the presence of vasculature, can be found. As pregnancy proceeds tertiary villi 
predominate, with the formation of branched villi continuing until term (Moore and 
Persaud, 1998; Kingdom and Kaufmann, 2000).
Initially, the villi form in a hypoxic environment and receive nutrients from uterine 
glandular secretions and plasma filtrate in the intervillous space rather than the maternal 
circulation. It is thought that this oxygen poor environment minimises damage to the 
developing fetus by oxidative stress (Jaffe et al. 1997; Burton et al. 1999). The onset of 
maternal circulation into the intervillous space is thought to occur at around ten to
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twelve weeks of gestation. This event greatly increases the oxygen tension from 
<20mmHg at eight to ten weeks to >50mmHg at 12 weeks. The fetus now receives 
nutrients and oxygen from the maternal circulation (Rodesch et al. 1992). The fetal 
circulation (poorly oxygenated and low in nutrients) enters the formed placenta via the 
umbilical arteries and continues into the branched villi where exchange of nutrients, 
waste, oxygen and carbon dioxide occurs across the trophoblastic layer. The 
syncytiotrophoblast is bathed in maternal blood (rich in oxygen and nutrients), which 
enters the intervillous space via the endometrial spiral arteries and then drains back into 
the maternal circulation via the endometrial veins after an exchange of oxygen and 
nutrients through the trophoblast cells, has occurred with the fetal circulation. The 
oxygenated fetal blood then circulates from the villi back to the developing fetus via the 
umbilical vein (see figure 1.4.1) (Moore and Persaud, 1998). To meet the increased 
demand for maternal blood to the placenta, maternal endometrial spiral arteries must 
undergo physiological remodelling which involves removal o f the spiral artery smooth 
muscle. This enlarges the hlood vessels and diminishes their sensitivity to 
vasoconstrictors thereby allowing increased blood flow. This process is mediated by the 
invasion of extravillous cytotrophoblasts (EVT).
1.4.2 T rophob last Cells
All maternal-fetal exchange occurs over the trophoblastic layer making these cells of 
particular interest when studying placental physiology. They are also the site of 
production o f most pregnancy associated hormones and proteins including hCG. This 
layer consists of the inner cytotrophoblast cells, which differentiate to form the outer 
continual syncytial layer (Boyd and Hamilton, 1970).
1.4.2.1 C yto troph oblast cells
The imier cytotrophoblast layer consists of cells with a uniform oval shape, a clear 
cytoplasm and a large, single, hyperchromatic nucleus. They have distinct cell 
membranes and have the general appearance of epithelial cells (Boyd and Hamilton, 
1970; Mazur and Kurman, 1989). Cytotrophoblast cells are the precursor cells that 
differentiate to form the syncytiotrophoblast layer (Carter, 1964). In the early placenta 
an almost continual layer of these cells can be observed below the syncytiotrophoblast 
while by term very few residual cytotrophoblast cells remain. Many factors influence 
the differentiation of cytotrophoblast cells including growth factors and cytokines. The
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process of syncytialisation has been associated with the production of various placental 
factors including hCG and hPL both of which have been used as in vitro markers of the 
presence of viable trophoblast cells (Kliman and Feinberg, 1992).
During early pregnancy, cytotrophoblast cells also break through the syncytial layer and 
form cell columns that penetrate the uterine lining. Villi that have cell columns at the tip 
are called anchoring villi because they form a physical connection between the placenta 
and the decidualised endometrium, cytotrophoblast cells, derived from cell columns, 
invade the spiral aiteries and are thought to induce physiological remodelling. These 
EVT can invade the lumen of spiral arteries directly and migrate deeper into the 
endometrium. As they migrate the EVT replace the endothelial cells of the spiral 
arteries causing the remodelling required for increased blood flow. This process is likely 
to begin as early as four to six weeks of gestation. EVT also invade the decidua and 
progress into inner third of the myometrium where they cluster around the spiral 
arteries. EVT can also fuse to form multinucleated giant cells (Lyall and Robson, 2000).
1.4.2.2 S yn cytio troph ob last
The syncytiotrophoblast forms the outer surface of the placenta, which is bathed in 
maternal blood. It is a continual cellular layer with no membranes separating cells and 
has dense, pyknotic nuclei. Electron microscopy has revealed that the 
syncytiotrophoblast has many microvilli that increase the surface area where exchange 
between mother and fetus occurs. In the third trimester, nuclei in the 
syncytiotrophoblast aggregate to form bud like structures called syncytial knots that 
protrude from the syncytium. These knots detach from the villi and enter the maternal 
circulation (Boyd and Hamilton, 1970). Placental alkaline phosphatase (FLAP) is 
produced by the syncytium and can be used as an in vitro marker of the presence of 
syncytium.
1.4.3 V illous M orphology
When studied microscopically, different cell types that form the villous structure can be 
identified. This morphology alters as pregnancy progresses (see figure 1.4.3). Early in 
pregnancy, the villi ai'e smaller and the fetal blood vessels are small and centrally 
located. There is also a clear layer of individual cytotrophoblast cells underlying the 
continual syncytial layer. As pregnancy proceeds, the villi increase in size and the
45
endothelium can often be separated from the maternal circulation only by the syncytial 
layer. The number of cytotrophoblast cells becomes fewer as pregnancy proceeds and 
fibrinoid deposits are visible in areas of trophoblastic damage. The villous stroma or 
core is mainly a loose network of fibroblast cells with Hofbauer cells (fetal 
macrophages) also found within this area (Boyd and Hamilton, 1970; Moore and 
Persaud, 1998).
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Figure 1.4.1 Diagrammatic representation of a term placental cross section. This 
illustrates the interaction between the maternal (decidua & myometrium) and feta l 
(villous chorion) .sections o f  the placenta. Arrows indicate the direction o f  maternal and 
fe ta l blood flow, with oxygenated blood shown in red and oxygen-poor hlood shown in 
blue. Reproduced from  Moore and Fer.saud (I99S) in Before We Are Born with kind 
permission from WB Saunders Company.
47
1.4.4 P lacental M orphology in  A bnorm al P regnancy
Several groups have studied placental size and morphology in trisomie pregnancies, as 
well as the proliferation and apoptosis of placental cells. This has uncovered several 
abnormalities in the placental structure of these pregnancies.
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Figure 1.4.3 Diagram o f  viUous cross section in first trimester (A) and term (B) 
placentae. Reproduced from  Moore and Fer.saud (1998) in Before We Are Born with 
kind permission from  WB Saunders Company.
1.4.4.1 Placental & Fetal Size in DS
Early studies (Mac A tee et al. 1970; Kucera, 1971) measured the weight and size o f a 
large number of DS placentae and fetuses and found no significant difference from the 
normal gestational average. Two smaller studies found evidence of either normal or 
slightly heavier placentae in DS pregnancies (Arizawa and Nakayama, 1992; Qureshi et 
al. 1997). Ultrasound studies of the crown-rump length and biparietal diameter of DS 
fetuses have also shown them to be of the appropriate gestational size (Wald et al. 
1993; Kuhn et al. 1995).
1.4.4.2 Placental M orphology in DS
Several studies have noted considerable morphological abnormalities in trisomie 
placentae when studied at a microscopic level. Table 1.4.4.2 outlines these 
abnormalities and the different studies that have noted them. These morphological 
abnormalities could potentially play a role in the altered levels of hCG secreted into 
maternal serum during DS pregnancies. Analysis of placental cells from trisomie 
pregnancies by flow cytometry found no significant difference in the number of 
apoptotic cells in second trimester trisomie placentae when compared with gestation 
matched controls (Halperin et al. 2000).
48
Histological Anomaly Abnormality References
Trophoblast Hypoplasia
Stromal Oedema
Reduced Vascularisation
T2TT18
T21,T18
T21,T18,T13
Irregular Villous Maturation T21, T18, T13
Immature Villi
Loose Stroma
T2LT18, T13
T21,T18,T13
Persistence of Haufbauer Cells T21, T18, T13
Reduced Syncytialisation T21, T18, T13
Persistence of cytotrophoblast T21 
cells
(Rochelson et al. 1990; Jauniaux and
Hustin, 1998)
(Rochelson et al. 1990; Jauniaux and
Hustin, 1998)
(Oberweis et al. 1983; Rochelson et al. 
1990; Qureshi et al. 1997; Jauniaux and 
Hustin, 1998; Roberts et al. 2000) 
(Obeiweis et al. 1983; Rochelson et al. 
1990; Qureshi et al. 1997)
(Oberweis et al. 1983; Rochelson et al. 
1990; Arizawa and Nakayama, 1992; 
Roberts et al. 2000)
(Oberweis et al. 1983; Qureshi et al. 1997; 
Jauniaux and Hustin, 1998)
(Oberweis et al. 1983)
(Oberweis et al. 1983)
(Roberts et al. 2000)
Table 1,4.4,2, Histological anomalies noted in trisomie pregnancies by various studies. 
T21=trisomy 21, T18=trisomy 18, T13=trisomyl3.
i*4*4*3 P lacental Tissue Levels ofD S Serum  M arkers
A  study by Newby et al (1997) looked at levels of various maternal serum markers of 
DS in placental tissue extracts obtained from 2""^  trimester pregnancies. Both ihCG and 
fp-hCG were significantly elevated in placentae from DS pregnancies, mirroring the 
increase observed in maternal serum. In contrast, placental AFP levels were 
significantly increased in placentae from DS pregnancies, the opposite of the reduction 
in AFP levels observed in maternal serum. This group also studied the reason behind 
decreased UE3 levels in maternal serum of DS pregnancies. It was found that UE3 was 
significantly reduced in the placenta, as were levels o f the precursor 
dehydroepianrosterone sulphate (DHEAS). This suggested that reduced serum levels of 
UE3 could be due to reduced synthesis in the placenta because of a diminished supply of 
the precursor DHEAS (Newby et al. 2000).
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A study, which supports previous findings on increased (5-hCG subunit protein 
concentration in DS placentae, also reported increased LH/hCG receptor expression in 
DS placentae from 12-16 weeks of gestation. This was carried out by comparing 
immunohistochemical and in situ hybridisation staining intensity between DS and 
control placental sections. LH/hCG receptors and receptor mRNA were primarily 
localised to the syncytiotrophoblast layer with weaker staining of the cytotrophoblast 
cells. This study did not find a significant difference in free a  or ihCG in DS placentae, 
although there was a trend towards increased ihCG (Jauniaux et al. 2000). A study of 
first trimester and early second trimester placental mRNA from control and DS 
placentae, by northern blot analysis, revealed no significant difference in either a-hCG 
or P-hCG mRNA levels between the groups (Brizot et al. 1995). One group reported 
reduced mRNA expression of the syncytialisation markers hPL, hCGa, hCGp, placental 
growth hormone and leptin in DS placental mRNA extracts (Frendo et al. 2000; Evain- 
Brion et al. 2000). They suggested that in vivo formation of syncytiotrophoblast is 
defective in DS pregnancies.
1.4,5 T rophoblast ce ll cu lture
To further understand the mechanisms behind increased maternal serum hCG in DS 
pregnancies, it would be useful to use an in vitro model to study placental production of 
this hormone. Since the placental trophoblast cells are the major site of hCG synthesis, 
culturing these cells would be o f particular use for studying placental production of 
hCG in either normal or pathological pregnancies.
1.4.3.1 Trophoblast Isolation
Several groups have developed techniques to culture placental trophoblast cells in vitro 
(Kliman et al. 1986; Bax et al. 1989; Bloxam, 1991; Bloxam et al. 1997a; Bloxam et 
al. 1997b). The culture methods used by these groups employ different methods of 
isolating mono-nuclear cytotrophoblast cells and culturing these in vitro to allow them 
to differentiate into a continual syncytial layer. The Kliman method (Kliman et al. 
1986) involves the dissection and mincing of healthy villous tissue from a fresh 
placenta. The tissue is then serially digested using trypsin and deoxyribonucease 
(DNase) whilst shaking to release the cytotrophoblast cells. The supernatant containing 
the cytotrophoblast cells is collected and the trypsin inactivated by spinning the cells 
through calf serum. The cells are then centrifuged through a Percoll gradient to isolate
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the mononuclear cytotrophoblast cells. The Bax method (Bax et al. 1989) involves the 
dissection of villous tissue, which is digested using dispase and pancreatin to loosen 
trophoblast cells. The tissue is transfeiTed to a different tube containing buffered saline 
and agitated to dislodge the cytotrophoblast cells. Fragments of villous tissue in the 
resulting cell solution are strained from the cells using layers o f gauze. The cells are 
then spun thi'ough a Percoll gradient to isolate the mononuclear cytotrophoblast cells. 
Both o f these methods are routinely employed to isolate placental cytotrophoblast cells.
I.4.5.2 Trophoblast Purification and Q uality Control
First trimester placental trophoblasts require further purification due to the high level of 
contamination in these isolations. Term trophoblast isolations may also require further 
purification, depending on experimental requirements, because the 90-95% purity of 
cells obtained after Percoll gradient purification may not be adequate. Further 
immunopurification protocols have been employed by various groups using different 
antibodies to remove contaminating cells from trophoblast preparations. One method is 
to use magnetic beads coated with anti-HLA class I antibody. Villous trophoblast cells 
do not express the HLA-Class I major histocompatibility antigens, while other placental 
and maternal cell types express these antigens. This makes using anti-HLA class I 
antibodies a good method o f removing contaminating cells from trophoblast isolations 
(Kawata et al. 1984; Butterworth and Loke, 1985). One group (Morrish et al. 1991b), 
who observed that all placental cells except trophoblasts express the CD9 antigen used 
magnetic beads coated with anti CD9 antibodies to remove contaminating cells.
Regardless of the method o f isolation and purification, it is vital to ensure that the 
correct cells have been isolated. This can be achieved by analysing the isolated cells by 
immunocytochemistry using a panel of antibodies specific for various contaminating 
cells and confirming the presence o f cytotrophoblast cells using cytokeratin antibodies. 
Cytokeratin is a well established marker of epithelial cells. It is a filamentous protein 
found in the cell membrane usually associated with desmosomes and hemidesmosomes, 
and gives structural support to epithelial cells. Recently it was shown that cytokeratin 7 
in particular is the best trophoblast specific marker because other non-trophoblastic 
placental cells have been shown to express other forms of cytokeratin (Haigh et al.
1999), Trophoblast cells do not express vimentin, another filamentous protein that is 
typically expressed by mesenchymal and endothelial cells. Consequently, most 
contaminating cells found in trophoblast preparations show positive reactivity with
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antibodies targeted against vimentin. Other antibodies targeted against specific cells that 
could potentially contaminate trophoblast cultures may be used to assess the primary 
contaminants of a particular isolation protocol (table 1.4.5.2).
Antigen Clone Reactivity in Placenta Reference
CD 9 Pl/33/2 Fibroblasts, EVT, 
maternal leukocytes, 
endothelial cells
(Morrish et al. 1991b; 
Blaschitz et al. 2000)
CD 45 2B11 &PD7/26 Maternal leukocytes; 
fetal leukocytes & 
Hofbauer cells weak
(Blaschitz et al. 2000)
CD163 Ber-MAC 3 Hofbauer cells (Blaschitz et al. 2000)
Cytokeratin 7 OV-TL 12/30 All trophoblast cells (Haigh et al. 1999; 
Blaschitz et al. 2000)
Fibroblast specific A S02 Fibroblasts, endothelial (Blaschitz et al. 2000)
antigen (FSA) cells
HLA Class I W6/32 All cells except villous 
trophoblast
(Kawata et al. 1984; 
Butterworth and Loke, 
1985)
Vimentin V9 Maternal & fetal 
leukocytes, fibroblasts, 
endothelial cells, 
Hofbauer cells
(Blaschitz et al. 2000)
Table 1.4.5,2 Reactivity o f  each antibody used fo r  screening placental trophoblast cell 
isolations and the reference citing the use o f  the antibody.
1.4.5.3 Trophoblast Cell Lines
There have been many studies using trophoblast cell lines as a model of normal 
trophoblast function. These cell lines are more convenient to use than primary cultures 
because they do not require a lengthy isolation protocol and the number of cells is 
unlimited unlike the limited yield obtained from an isolation o f primary cells from a 
single placenta. Cell lines are usually much easier to culture than primary cells making 
them an attractive alternative to primary cell cultures. The most commonly used cell
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lines are BeWo, JEG and JAR, which are all derived from choriocarcinomas, however 
there are many other cell lines that have arisen by viral transformation or fusion of 
normal cytotrophoblast cells with choriocarcinoma cells (reviewed by King et al 
(2000)). Workshops at the European Placental Group conference in Schladming (1999) 
(King et al. 2000) and at the Rochester Trophoblast Conference (2000) (Shiverick et al. 
2001) have outlined criteria for evaluation of these cell lines. It was suggested that 
villous trophoblast cell lines should be positive for cytokeratin 7 and be negative for 
HLA-class I and CD9, while extravillous cell lines should be positive for cytokeratin 7, 
HLA-G and CD9 (King et al. 2000; Shiverick et al. 2001). The excretion of hCG and 
hPL from cultures is also used as an indication of trophoblast cell origin. The suitability 
of this and HLA-G and cytokeratin 7 as trophoblast markers has been called into 
question because tumour cells also express these markers and can excrete hCG and hPL. 
It was therefore concluded that a broad panel of markers, similar to those used for 
characterisation of primary cytotrophoblast preparations, be employed when evaluating 
the validity of trophoblast cell lines.
Recently there has been some doubt as to the validity of these cell lines, in particular if 
they are suitable models of normal trophoblast cells. A clear illustration of the 
importance of rigorous characterisation of trophoblast cell lines is the recent case of the 
widely used ED27 trophoblast cell line. This cell line was isolated from non-malignant 
first trimester chorionic villi. It exhibited many traits of trophoblast cells including 
PLAP, hPL, HLA-G and cytokeratin expression and the ability to synthesise estrogens 
and a degree of syncytialisation. In contrast to the situation in primary trophoblast 
cultures ED27 cells do not secrete hCG during the first days of culture and HLA-Class I 
antigens are expressed on the cell surface. Due to these discrepancies and differences in 
experimental results obtained using ED27 cells and primary trophoblast cultures, the 
validity of this cell line was further investigated and it was discovered that it displayed 
molecular markers of HeLa and WISH cell lines. It was therefore suggested that ED27 
cells had, at some point, been contaminated with these cell types (Kniss et al. 2001). 
This discovery means that published work using ED27 cell lines, and possibly other cell 
lines which have not undergone such rigorous characterisation, as a model of normal 
trophoblast function have to be interpreted with caution.
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i ,4*5'4 Culture o f  Trophoblast Cells fro m  DS Placentae
Most culture systems have studied the growth and function o f normal trophoblastic 
cells, although two groups have studied isolated trophoblast cells from DS pregnancies 
(Eldar-Geva et al. 1995; Frendo et al. 2000; Evain-Brion et al. 2000; Frendo et al. 
2001). The first group studied four normal and thiee DS trophoblast cultures from 2"  ^
trimester terminated pregnancies. The release of hCG into the culture medium was 
measured and morphological changes in the cells were monitored by light microscopy. 
The hCG mRNA levels were also studied in one DS and one control culture at 24h after 
plating. The quantity of hCG secreted from the cells, taken as a ratio of protein content, 
was significantly higher in the DS cultures, as was the quantity of hCG mRNA levels 
isolated from the single culture. It was obseiwed that the quantity of hCG secreted from 
DS cultures from 2"^ trimester placentae resembled the hCG secretion levels from 
normal trimester cultures. The DS cultures did, however, appear to syncytialise less 
efficiently than the control cultures, and the number of cells adhering to the culture 
surface was also less in the DS cultures as measured by total protein content of lysed 
cells remaining on the culture surface.
The second group has studied various aspects of DS trophoblast function in culture. It 
was found in both reports by the group that these cells failed to syncytialise as control 
trophoblast cells did, and less hCG was produced by DS cultures (Frendo et al. 2000; 
Evain-Brion et al. 2000). These results were based, in the former report, on 8 control 
and 8 DS placentae collected from second trimester terminations (Evain-Brion et al.
2000). The second report was based on 10 control and 15 DS placentae collected from 
both the second and third trimesters (Frendo et al. 2000). They suggested these in vitro 
observations supported the report of persistence of cytotrophoblast cells observed in 
sections o f chorionic villi collected from DS placentae (Roberts et al. 2000).
The same group suggested that this failure to syncytialise was due to overexpression of 
the chromosome 21 product, copper zinc superoxide dismutase (SOD-1) (Evain-Brion 
et al. 2000; Frendo et al. 2001). Both reports indicated that DS placentae expressed 
higher levels of SOD-1 than gestation matched controls. They also transfected normal 
term trophoblast cells with a plasmid containing the SOD-1 gene that caused increased 
SOD-1 expression similar to that in DS cells. It was observed that the transfected cells 
showed a similar inhibition in syncytialisation and hCG secretion as DS trophoblasts 
did. They also found that levels of hPL, hCGa, hCGp and placental growth hormone
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but not leptin mRNA were significantly lower in the SOD-1 transfected cells. This was 
similar to the reduction in the concentration o f these proteins observed in DS placentae. 
Because transfection of cells with SOD-1 expressing vector was not entirely effective, 
the second study tagged SOD-1 with green fluorescent protein (GFP) to allow 
visualisation of the transfected protein in the cultured trophoblast cells. They noted that 
the cells that showed positive GFP-SOD-1 reactivity did not syncytialise while cells in 
the same culture dish that did not express the GFP-SOD-1 fused to form syncytium. 
This study suggested that the defects in syncytialisation observed in DS placental cells 
may well be attributed, at least in part, to the over expression of SOD-1 (Evain-Brion et 
al, 2000; Frendo et al. 2001).
1.5  F a c to r s  A f fe c t in g  hC G  P r o d u c t io n  & R e le a s e
In vitro studies have revealed many factors that alter the rate of synthesis and release of 
hCG from the placenta. Among these factors are cytokines such as inhibin and activin, 
and growth factors such as epidermal growth factor (EGF) and transforming growth 
factor beta 1 (TGFPi). The control mechanisms, in which these factors are involved, are 
complex and highly inter-related.
Inhibin has been shown to inhibit hCG release from placental cytrophoblasts as they 
syncytialise (Petraglia, 1997), while activin stimulates its production (Steele et al. 
1993; Song et al. 1996; Petraglia, 1997). Conversely, hCG can act to increase the 
production of inliibin and decrease the production of activin, thereby acting in a self- 
regulatory manner. It remains unclear whether these factors affect hCG production or 
release directly, or act via gonadotrophin releasing hormone (GnRH). TGFpi has been 
found to suppress hCG secretion from placental cells, as well as suppress placental cell 
differentiation (Morrish et al. 1991a). TGFpi may act synergistically with activin-A to 
suppress inliibin-A secretion from placental cells, however TGFPi alone shows no 
affect on inhibin-A secretion and activin-A alone shows only a slight reduction in 
inliibin-A release. Activin-A may also inhibit hCG induced inhibin-A production. It has 
also been observed that EGF acts synergistically with testosterone to significantly 
increase inhibin-A release (Qu and Thomas, 1993) (fig 1.5).
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1 .5.1 In h ib ins and Act!v in s
Both inhibins and activins are members o f the transforming growth factor beta (TGF-P) 
superfamily which includes many hormones, growth factors and cytokines (Kingsley, 
1994; Knight, 1996a). Their physiological functions are diverse, including regulation of 
cell growth, proliferation, adhesion, apoptosis and immunoregulation (Vale et al. 1988). 
All members of the family are structurally related, and most exert their actions at type I 
and type II serine/threonine kinase receptors.
TGF-P
Inhibin-A synergistic decrease'
Activin-Aincrease
block"
decrease
hCGL— decrease ^ increase
EGF
decrease
t
synergistic
increase
Testosterone
Figure 1.5 Summary o f  the inter-relationships between hCXi, FGb', TCib'pi, activin-A, 
inhibin-A and testosterone as shown by in vitro cell culture systems, 'ihe words 
"increase ” and "decrease " are used to indicate where one factor increases or 
decreases either the production or release o f  another factor from  placental cells.
Structure and Localisation  
Inhibin
Mature inhibin is a 31-32 kDa heterodimeric glycoprotein composed of an alpha and 
either a beta A (|3a ), beta B (Pn) or beta C (Pc) subunit, which are linked by disulphide 
bonds. These arise from longer precursor molecules, which undergo post-translational 
modification to form the mature subunits. Inhibin-A has the structure aPA, while 
inhibin-B is of the form aPi^, and inhibin-C has the structure aPc (Robertson et al.
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1985; Vale et al. 1986). Free subunit forms of inhibin can also be found in different 
tissues (fig 1.5.1.1). Inliibin was first discovered in male and female gonads, but was 
later shown to he present in many tissues throughout the body (Bilezikjian and Vale,
1992). In women, the main biologically active form of inhibin is inhibin-A. During 
early pregnancy the corpus luteum secretes inliibin-A, however the principal source of 
inhibin-A during pregnancy is thought to he the placenta. In vitro studies have localised 
inliibin-A production and secretion in the placenta to trophoblast cells, which were 
shown to store inhibin in small vesicles within the cytoplasm prior to secretion (Qu et 
al. 1992).
A ctivin
Activin is a 24kDa homodimer o f the beta subunits, which like the alpha and beta 
subunits of inliibin, are linked by disulphide bonds. Activin may be one of three 
different forms: activin-A, which has the structure PaPa, activhi-B which is comprised 
of two pB subunits, or activin-AB which is of the form PaPb (fig 1.5.1.1). Activins 
containing the Pc subunit have not been isolated, despite the theoretical fact that the pc 
subunit is able to bind to the other p subunit forms. The most predominant form of 
circulating activin in females during both the normal menstrual cycle and pregnancy 
was found to be activin-A. The primary source of activin-A during pregnancy is thought 
to be the placenta (Petraglia et al. 1987; Petraglia et al. 1993; Petraglia et al. 1994a). 
Activin-B was found to be essentially absent from maternal serum, however it was 
found to be abundant in the AF and fetal cord serum prior to parturition (Petraglia et al.
1993).
1.5.1.2 Subunit L ocalisation
Several studies have looked at the localisation of the subunits of inhibin and activin by 
immunohistochemistry (Petraglia et al. 1991; Petraglia et al. 1992; Minami et al. 
1992; McCluggage et al. 1998). These studies have, however, given slightly different 
localisations for the a  and Pa subunits. The study by Petraglia et al (1992) found that 
both the a  and Pa subunits could be localised to all trophoblastic cells, while an earlier 
study by the same group (Petraglia et al. 1991) found that the Pa subunits were widely 
distributed but the a  subunits were confined to the cytotrophoblast cells. In contrast, 
two different studies found the a  subunits to be confined to the syncytial cells (Minami 
et al. 1992; McCluggage et al. 1998), with one of these studies concluding that Pa
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subunits were also found only in the syncytial layer (Minami et al. 1992). The reason 
for the variations in these results could be the different sources of the antibodies used in 
the immunohistochemical localisation experiments of the different groups. Only 
McCluggage et al (1998) used monoclonal antibodies that were proven to be highly 
specific for the different inhibin subunits (Groome et al. 1990; G room e and Lawrence, 
1991). A UK company (Serotec) also manufactures immunoassays for the detection of 
inhibins and activins in biological fluids using these new antibodies (section 1.5 .1.4).
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Figure 1.5.1.1 Structure and approximate molecular weights o f  t he forms o f  inhibin and 
activin and free subunits isolated in humans.
Î.5.1.3 Activin and Inhibin Binding Proteins
Inhibin and activin have been found complexed with the 725kDa protein alpha 2 
macroglobulin (a2M). This binding protein does not seem to alter the biological activity
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of either inhibin or activin. It is known that a2M  circulates in the blood at levels in 
excess of those observed for activin and inhibin, thereby providing ample opportunity 
for the formation of a2M  complexes. The biological relevance of the formation of 
complexes with a2M  remains unclear, however it is thought it may play a role in the 
clearance or delivery of inhibin and activin (Vaughan and Vale, 1993; Ki’ummen et al.
1993). In contrast to a2M , the 30-40kDa binding protein called follistatin renders 
activin biologically and immunologically inactive. Follistatin binds to one o f the p 
subunits with approximately equal affinity to the binding of activin with its receptor. It 
has been suggested, therefore, that follistatin plays an important role in limiting the 
activities of activin on target cells. Follistatin has also been shown to bind to the inhibin 
p subunit, although the effect of this binding on the activity o f inhibin has yet to he 
elucidated (Shimonaka et al. 1991; Nakamura et al. 1991; Krummen et al. 1993; 
Schneyer et al. 1994; Mathews, 1994; Petraglia et al. 1994b). The serum level of 
follistatin has been shown to he elevated during pregnancy when compared with the 
non-pregnant state. The follistatin level continues to rise throughout gestation, until 
parturition, although this elevation does not match the degree of elevation in activin 
levels observed towards the end of pregnancy (Wakatsuki et al. 1996).
1,5.1,4 A ssayin g  Inhibin and A ctiv in
The dimer structure of both activin and inhibin can complicate the matter of assaying 
the concentration of specific isoforms of inhibin and activin in biological fluids or 
tissues. Some assays were found to cross react with either different isoforms of the 
glycoprotein being measured, or with free subunits such as proaC. An example of such 
an assay is the Monash radioimmunoassay (McLachlan et al. 1986), which was unable 
to distinguish between dimeric inliibin and the free alpha subunit (Robertson et al. 
1989; Schneyer et al. 1990). Newer assays have now been developed that are specific 
for the dimeric forms of inliibins and activins (Groome, 1991; Groome and O’Brien,
1993)
The inliibin/activin binding proteins a2M  and follistatin can also cause interference in 
assays by masking the epitopes recognised by the immunoassay. These complications 
mean that early experiments using older, less specific assays often show conflicting 
results to those carried out more recently using the more sensitive assays (Groome and 
O'Brien, 1993; Groome et al. 1994; Muttukrishna et al. 1996; Knight et al. 1996b).
58
i .5-i<5 Physiological A ctions o f  Inhibin and A ctivin
Activins and inhibins have many important physiological functions including roles in 
the control of embryogenesis, osteogenesis, haematopoiesis and reproduction. In the 
female reproductive system, both inhibin and activin are involved in the control of the 
menstrual cycle and pregnancy. Ovarian inhibin has a negative feedback mechanism on 
the production of FSH by the anterior pituitary, with inhibin suppressing FSH secretion, 
and FSH increasing the production of inhibin. Activin has also been shown to alter the 
secretion of pituitary hormones such as LH, adrenocorticotrophic hormone (ACTH), 
growth hormone (GH) and FSH. Activin can act antagonistically to inliibin, increasing 
the secretion of FSH from the pituitary (Muttukiishna and Knight, 1991). In vitro 
studies have shown that inliibin, activin and follistatin also have local 
autocrine/paracrine actions on the follicle, oocytes, corpus luteum and ovary. They have 
been shown by several studies to modulate hormone production, cell differentiation and 
maturation in these tissues (Knight, 1996a).
1.5.1,6 Inhibins and A ctivins During Pregnancy
The levels of both inhihin-A and activin-A are greatly elevated in the serum of pregnant 
women when compared with the levels observed in the serum of non-pregnant 
individuals (Qu et al. 1991; Tovanabutra et al. 1993; Muttukrislina et al. 1995; 
Muttulaislma et al. 1996). One function of elevated circulating inliibin-A may be to 
suppress FSH secretion from the pituitary, which would augment the actions o f estradiol 
and progesterone to prevent follicular development during pregnancy. Although the 
corpus luteum produces significant quantities of inhibin during pregnancy, it is thought 
that the placenta is the major source of inhibin and activin, particularly towards the 
latter stages of pregnancy. In vitro studies have shown that activin can induce GnRH 
induced hCG release, while inhibin suppresses hCG secretion from placental cells (Qu 
and Thomas, 1993; Steele et al. 1993; Song et al. 1996).
Like inliibin-A and activin-A, the level of circulating follistatin is elevated in the serum 
of pregnant women, when compared with non-pregnant individuals. In the final 
trimester of pregnancy, the circulating levels of activin-A increase such that they exceed 
the levels of follistatin. Consequently, free activin-A is available to act in an endocrine 
manner at target cells (Woodruff et al. 1997). It is likely that there are still many
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autocrine/paracrine roles for activin, follistatin and inhibin in the fetoplacental unit, 
which are yet to be elucidated.
1,5,1,7 Inhibin-A and Activin-A  in DS Pregnancies 
Inhibin-A
As mentioned in section 1.3.4 maternal serum levels of inhibin-A are significantly 
elevated in DS pregnancies, and it has been suggested that this marker could improve 
the detection rate of DS pregnancies achieved using the current hCG, AFP screening 
strategy. In contrast, AF levels of inhihin-A are significantly lower in DS pregnancies. 
The placental levels of inhibin and the inhibin subunit mRNA have been studied in DS 
placentae (Dehiève et al. 2001). This study found no significant change in placental 
levels of inhibin-A or inhibin pro aC  although there was a trend towards increased 
levels in the DS samples. The median inhibin-A level was 1.29MoM and inhibin pro aC  
level was 2 .66M0M. Inhibin subunit mRNA levels were not significantly altered in DS 
placental samples. This study was based on only 6 DS samples, which were collected 
from 15 to 32 weeks gestation. A different study looked at placental inhibin subunit 
mRNA levels in 6 DS placentae and found significantly elevated a  subunit mRNA in 
DS placentae. No significant difference in pA subunit mRNA levels was found although 
there was a trend towards a slight reduction (Lambert-Messerlian et al. 1998).
Activin-A
There have been fewer studies carried out on the differences in activin-A levels between 
DS and unaffected pregnancies. Lambert-Messerlian et al. have carried out three studies 
each looking at activin-A levels in the maternal serum of DS and control pregnancies. In 
1996, they reported a small but statistically insignificant increase in the DS levels of 
activin-A to 1.16 MoM using an immunoassay that detected only free activin (Lambert- 
Messerlian et al. 1996a). Later that year' the same group repeated this study when a 
different assay became available which could measure both free activin-A, and activin- 
A that had been bound follistatin, (Lambert-Messerlian et al. 1996b). Again they 
reported a slight increase in activin-A levels from affected pregnancies (to 1.25 MoM), 
hut on this occasion the increase was statistically significant. The latest study carried out 
by this group has reported a small, but statistically insignificant decrease in the maternal 
serum levels o f activin-A from DS pregnancies (Lambert-Messerlian et al. 1998). In 
this latest study, the mRNA levels o f activin/inhibin subunits in placental tissues were 
examined. In accordance with the activin-A results, Pa subunit mRNA showed slightly
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lower levels of expression in DS placental tissues, however this difference was not 
statistically significant. Dehiève et al (2001) noted a non-significant increase in 
placental activin-A levels in DS placentae to 1.45MoM. As mentioned before this study 
found no difference in the activin-A subunit mRNA in DS placentae. Activin-A and 
follistatin levels have been studied in maternal serum from DS pregnancies with a view 
to determining their usefulness as maternal serum screening markers (Cuckle et ah 
1999). Activin-A levels were significantly elevated to 1.19MoM in the 30 DS cases 
studied hut follistatin levels were not significantly altered (0.93MoM). Despite finding a 
significant elevation in activin-A levels, it was concluded that due to the large overlap 
in control and DS levels, this would not make a useful screening marker.
1.5.2 T ransform ing G row th Factor B eta (TGF-(3)
1,5,2,! S tructure and Localisation
Transforming growth factor beta (TGF-P) is a member of a larger family of factors -  the 
transforming growth factor beta superfamily. TGF-P is a polypeptide growth factor 
which can he released by most cell types throughout the human body, including the 
reproductive organs and placenta (Dungy et al. 1991). In humans, three subtypes of 
TGF-p have been isolated: TGF-pi, TGF-p2, and TGF-Ps. All are synthesised as large 
precursor proteins (pre-pro TGF-p), which contain an N-terminal signal peptide, a pro­
segment Icnown as latency associated peptide (LAP) and the C-terminal polypeptide, 
which is the mature TGF-p monomer. The active form of TGF-p has a dimeric structure 
usually composed of two identical disulphide linked subunits, although heterodimers of 
TGF-p 1 and TGF-P2 subunits have been isolated. It is thought that LAP prevents the 
interaction of the mature TGF-p with receptors thereby rendering the factor inactive (fig 
1.5.2.2) (Derynck and Choy, 1998). In vivo, activation of TGF-p is thought to be 
mediated by proteolytic cleavage of the pro form to yield the bioactive factor. In vitro, 
TGF-P can be processed to the bioactive form by acid, alkali or heat treatment (Cui and 
Ackhurst, 1996). TGF-p has many other associated binding proteins, which inhibit the 
activities of the growth factor. One example is latent TGF-p binding protein (LTBP), 
which binds to LAP by a disulphide bond. Another of these proteins is a2M , which also 
forms complexes with inhibin and activin, hut unlike the situation with inhibin and 
activin, a2M  sequesters the activity of TGF-p. Two secreted proteoglycans, namely 
decorin and biglycan also bind TGF-p with high affinity (Derynck and Choy, 1998).
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Decorin has been localised to similar locations in the placenta as TGF-p (Lysiak et al. 
1995). Several collagens, thrombospondin and fibronectin also bind TGF-P with high 
affinity, which illustrates that the availability o f  bioactive TGF-P is controlled at many 
levels. It is thought that TGF-P is only activated when it is in close proximity to the 
membrane receptors it complexes with.
TGF-beta 1
—  C O O H
Disulphide Bonds
—  C O O H
Figure 1.5.2.1 Diagram of pre-pro TGF-pi dimer including the signal peptide, LAP and 
the mature TGL'-p] segments.
TGF-P is present in several ovarian tissues during both the normal menstrual cycle, and 
pregnancy (Chegini and Williams, 1992). TGF-Pi 2+3 mRNA expression has been noted 
in villous and decidual tissues throughout gestation (Dungy et al. 1991; Lysiak et al. 
1995; Ando et al. 1998; Caniggia et al. 1999; Schilling and Yeh, 2000; Simpson et al. 
2001). This mRNA expression has been primarily localised to the syncytiotrophoblast, 
decidual and stromal cells with variable reports on cytotrophoblast reactivity (Lysiak et 
al. 1995; Ando et al. 1998; Caniggia et al. 1999). Protein Immunolocalisation, largely 
carried out on paraffin wax embedded tissues, largely followed the reports on mRNA 
localisation. The most widely studied isotypes are TGF-p 1+2 often using an antibody 
that reacts with both subtypes although more recent studies employ isotype specific 
antibodies. TGF-p, 2+3 have principally been localised to the villous syncytium 
throughout gestation (Dungy et al. 1991 ; Minami et al. 1992; Chegini and Williams, 
1992; Graham et al. 1992; Vuckovic et al. 1992; Lysiak et al. 1995; Caniggia et al. 
1999; Schilling and Yeh, 2000) although two studies by the same group, which unlike 
the other studies used unfixed frozen tissue, found no syncytial staining in either first or 
third trimester placentae (Simpson et al. 2001; Lyall et al. 2001). In contrast villous 
cytotrophoblast cells have generally shown no TGFp reactivity (Vuckovic et al. 1992; 
Lysiak et al. 1995; Simpson et al. 2001; Lyall et al. 2001) although one study found 
TGF-P 1/2 staining in cytotrophoblast cells (Ando et al. 1998) and one reported
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cytotrophoblast TGF-Ps staining (Caniggia et al. 1999). TGFp 1,2+3 have been localised 
to EVT (Lysiak et al. 1995; Schilling and Yeh, 2000; Simpson et al. 2001; Lyall et al. 
2001) although the reports by Lyall et al (2001) failed to find any TGFPi 
immunostaining. The decidua has been noted as a site of intense TGFp 1+2 reactivity 
particularly during early pregnancy (Graham et al. 1992; Lysiak et ai. 1995; Ando et 
al. 1998; Simpson et al. 2001; Lyall et al. 2001). At term Lyall et al (2001) found no 
decidual TGF-Pi expression. One study noted in vitro secretion of TGFpi from a 
number of decidual cell types, first trimester cytotrophoblast and the JEG-3 
choriocarcinoma cell line (Jokhi et al. 1997). TGF-p type I and II receptors have been 
localised to EVT, syncytium, cytotrophoblast, decidua and myometrium indicating an 
endocrine/paracrine role for the TGF-p family in placental development (Hatthachote et 
al. 1998; Ando et al. 1998; Schilling and Yeh, 2000).
1.5.2.2 P hysio logical A ctions o f  T G F -p
Depending on the tissue and subtype, TGF-P seems able to both stimulate and suppress 
proliferation of cells. The ability of TGF-p 1 to suppress cellular proliferation has been 
of particular interest as a tumour suppressor drug. Its in vivo performance was, however, 
discovered to be less favourable than had been observed in vitro (Robinson and Rose, 
1992). TGF-P has been implicated in many biological functions including 
embryogenesis, reproductive function, growth and development, inflammation and 
repair, as well as host immunity (Shull and Doetschman, 1994; Clark and Coker, 1998). 
TGF-P2 has been shown to inlhhit the in vitro proliferation of first trimester and term 
placental trophoblasts, (Graham et al. 1992). A study using cultured human 
trophoblasts has shown that exogenous TGF-p 1 has an inhibitory action on the 
production of hCG and aromatase activity (estrogen production) (M omsh et al. 1991a; 
Song et al. 1996). The reason for this inhibition remains unclear. It could either he due 
to a direct inhibition in the production of these hormones, or it could be because TGF-p 1 
inhibits the differentiation o f cytotrophoblast cells to syncytiotrophohlasts, an 
occunence which has been associated with the increased production of hCG (Morrish et 
al. 1991a). TGF-Pi and activin-A synergistically inhibited inhibin secretion from 
cultured human placental cells, however TGF-p 1 alone showed no effect on inhibin-A 
secretion (Qu and Thomas, 1993).
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1,5*^ *3 TGF-p Levels in  Pregnancy
One study looking at the changing expression of TGF-p i in the placenta noted peak 
expression at around seventeen weeks with a second smaller peak observed in the latter 
stages of pregnancy at around 34 weeks (Dungy et al. 1991). Caniggia et al (1999) 
reported a peak in TGFPs expression at eight weeks of gestation but could find no 
alteration in either TGF-p 1+2 expression during this period. No gestational differences in 
expression or protein concentration o f any of the TGF-p isoforms with gestation were 
noted in first trimester and term studies (Simpson et al. 2001; Lyall et al. 2001). The 
levels of TGF-P type I and type II receptor expression was shown to be elevated in the 
human myometrium during pregnancy, when compared with the non-pregnant levels. 
The level of receptor expression in the myometrium drops at parturition, while the 
concentration o f TGF-p 1 remains elevated when compared to the non pregnant state 
(Hatthachote et al. 1998). Lawton et al (1997) isolated a novel form of TGF-p 
expressed in the placenta, which they named placental transforming growth factor-p 
(PTGFB). Although detectable in other adult tissues, PTGFB was expressed at much 
higher concentrations in the placenta.
TGF-p Levels in A bnorm al Pregnancy
Few studies have been carried out on TGFPi levels in abnormal pregnancies. One study 
has noted that maternal plasma levels of hioactive TGFPi were significantly higher in 
pre-eclampsia when compared with normotensive pregnancies (Djurovic et al. 1997). 
In contrast no difference was found in the second trimester AF concentration o f TGF-p 1 
in pregnancies that subsequently went on to develop preeclampsia (Heikkinen et al. 
2001). No difference was reported in placental expression o f any of the TGF-p 
isoforms, studied by immunohistochemistry and ELISA and RT-PCR analysis of 
placental extracts, in either first trimester or term pregnancies complicated with 
preeclampsia (Simpson et al. 2001; Lyall et al. 2001). In contrast Caniggia et al (1999) 
reported a significant elevation in placental TGF-Ps in third trimester preeclamptic 
placentae. Significantly higher plasma hioactive TGFPi has been noted in pregnant 
women suffering miscaiTiage and non-pregnant women with a history o f recurrent 
miscaiTiage (Ogasawara et al. 2000). DS AF levels of total TGFp measured by bioassay 
were found to be significantly elevated when compared to normal pregnancy (Bromage 
et al. 2000).
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1.5.3 S erin e  T h reon in e K inase R eceptors
Activin and TGF-p have been shown to exert their actions via serine/thieonine kinase 
receptors. Activation of these receptors is achieved when the ligand forms a heteromeric 
complex of the type I and II receptors. In humans, there are two different type II activin 
receptors known as activin receptor type II (ActRII) and activin receptor type IIb 
(ActRIIe), both of which are present in human placental plasma membranes, as well as 
many other tissues in humans (Peng et al. 1993; Petraglia et al. 1994a). There are two 
forms o f the type I receptor, known as ActRI and ActRIe, both of which are unable to 
bind activin directly but either can form a heteromeric complex with the ActRJI and 
activin, or the ActRIlB and activin (Attisano et al. 1993; Matsuzaki et al. 1993; ten 
Dijke et al. 1993). Only one type I and one type II TGF-P receptor has heen isolated in 
humans, known as TpR-I and TpR-II. The type II receptors are constitutively 
phosphorylated, while the type I receptors are phosphorylated only upon formation of 
the type I / type II receptor ligand complex (Mathews and Vale, 1993; Wrana et al.
1994). Receptor phosphorylation triggers a signal cascade, initiated hy phosphorylation 
of the intracellular signalling molecule Smad2. This associates with Smad4 and the 
complex moves to the nucleus. Target genes are induced hy binding of the Smad 
complexes directly to the promoter or by the Smad complex associating with other 
DNA binding proteins like FAST-1 (fig 1.5.3). Type III TGFp receptors have heen 
isolated, and are thought to act as ligand presenting receptors, however an equivalent 
activin receptor has yet to be discovered (McCarthy and Bicknell, 1993).
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Figure 1.5.3 Represent at ion o f  activin receptor activation and signal transduction from 
the receptor to the nucleus. Upon ligand binding, the type I and 11 receptors associate 
triggering the phosphorylation o f  Smad2. Sm adl then joins with Smad4, entering the 
nucleus where they trigger target gene transcription either alone or in association with 
other DNA binding proteins like F  AST-1.
The search for the inhibin receptor has proven difficult and little is known about inhibin 
receptors. It was first discovered that despite having an affinity for activin receptors, 
inhibin also bound to cell surface receptors separate from activin receptors. (Woodruff 
et al. 1992). Further studies isolated a l20kDa protein from bovine pituitary extracts, 
which bound inhibin A. The peptide sequence was elucidated and the protein was 
named p i 20. A matching human cDNA sequence was found to match the p i 20 peptide 
sequence and expression o f  pi 20 mRNA was noted in rat pituitary and liver, and human 
and rat testis. Immunolocalisation o f  pi 20 in the rat testis indicated that it was primarily 
localised to Leydig cells, which are known to be a major target cell o f  inhibin and have 
been shown to bind inhibin on their surface (Chong et al. 2000). To date p i 20 is the 
most likely candidate to be an inhibin receptor.
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1.5*4 E piderm al G rowth Factor (EGF)
1.5.4.1 S tructure and Localisation
Epidermal growth factor (EGF) is a 6.4kDa globular protein. It is synthesised as a 
longer pre-pro protein from which the mature form o f EGF is released by proteolytic 
cleavage. The precursor consists o f  an N-tenninal signal peptide, a pro-segment 
containing several EGF like repeats and a sequence, which shows homology to the LDL 
receptor (fig 1.5.4.1). The pro-segment also has a transmembrane hydrophobic domain, 
which suggests that the pro form o f  EGF may be membrane associated. The sequence of 
EGF is highly conserved between species, and shows homology to other factors like 
transforming growth factor alpha (Fisher and Lakashmanan, 1990).
N H , - |
Signal EGF Lil:e R qieats EGF TM
C O O H
LDL receptor homology
Figure 1.5.4.1 Diagram o f  pre-pro EGF including the signal peptide, EGF like repeats, 
the area o f  LDL receptor homology and the hydrophobic transmembrane (LM) region.
EGF can be found in most body fluids, for example urine, plasma, milk and saliva. Cells 
in many organs can synthesise this factor including the brain, kidney, stomach and 
salivary gland (Fisher and Lakashmanan, 1990). Both EGF and its receptors have been 
localised to cytotrophoblast cells and syncytium of the placenta (Ladines-Llave et al. 
1991 ; Maruo et al. 1995).
1.5.4.2 Physiological Actions o f  EGF
EGF is involved in many functions during embryonic development including promoting 
the development o f  teeth and lungs. In adults, it inhibits the secretion o f  gastric acids 
and controls hormone secretion from tumours. It also has effects on the central nervous 
system. EGF in part mediates wound healing along with other factors. EGF stimulates 
the proliferation o f  many types o f  epidermal and epithelial cells and also embryonic 
cells. The proliferation o f  some cells is however inhibited by EGF and EGF can also 
induce the differentiation o f  some cell types (Fisher and Lakashmanan, 1990). Studies 
on the effects o f  EGF on term trophoblast cell cultures have shown that it promotes 
syncytialisation and hCG and hPL secretion from these cells (Morrish et al. 1987). hCG
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and hPL secretion from first trimester explants is also stimulated by EGF (Barnea et al. 
1990; Maruo et al. 1995). EGF also acts as an anti-apoptotic factor in trophoblast 
cultures (Ho et al. 1999). It has also been shown to increase invasion of  trophoblast 
cells in first trimester explants and isolated cytotrophoblast cells (Barnea et al. 1990; 
Bass et al. 1994; Maruo et al. 1995).
1.5.4.3 E G F  Receptors
EGF receptors (EGFR) are expressed on the cell surface o f  most tissues. It is a l70kDa 
glycoprotein with intracellular tyrosine kinase activity, which may also be activated by 
TGF-a. Binding o f  ligand to the receptor causes activation o f  the kinase activity, which 
initiates a cellular signalling cascade (fig 1.5.4.3). EGF binds to the extracellular 
domain o f  the EGFR, forming an EGF-EGFR dimer. This induces two receptors to 
come together forming a dimer complex. ATP then binds the cytoplasmic kinase 
domain o f  either o f  the two EGF-EGFR dimers in the complex. The ATP-bound dimer 
complex interacts with another (EGF-EGFR) dimer complex, phosphorylating one of 
the four EGFR cytoplasmic tails on tyrosine 1068. This phosphorylation causes the 
binding o f  Grb2-Sosl, which is the first step o f  the EGF signalling cascade (Carpenter, 
2000; Bogdan and Klambt, 2001 ; Gschwind et al. 2001 ).
EGFR EGFR EGFR EGFR
Figure 1.5.4.3 Representation o f  the activation o f  the hXiFR i4pon I X jF  hindmg. 1. I X jL' 
hinds to the FCjL'R. 2. Two /CGh' bound receptors form and TXjF-TJGFR dimer complex. 
3. One o f  the kinase domains in the dimer complex binds AT!^ and phosphorylates 
tyrosine 1068 on the cytoplasmic domain o f  the FGFR. 4. Pho.sphoryiation o f  the 
tyrosine causes binding o f  the Grb2-Sosl complex.
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1 .5 .4  4  E G F  i n  P r e g n a n c y
Maternal urine concentrations o f EGF are slightly higher in the second trimester of 
pregnancy than levels in non-pregnant urine, though urinary levels in early pregnancy 
and at term are not significantly different from the non-pregnant concentration. The 
concentration increases between 6 and 20 weeks o f gestation, and then declines towards 
the non-pregnant level at term (Hofmann et al. 1988; Watanabe, 1990; Moharam et al. 
1992). In contrast, AF levels of EGF are higher towards term, correlating with 
gestational age (Watanabe, 1990; Varner et al. 1996). No correlation between maternal 
urine and AF levels of EGF can be observed indicating different sources o f EGF in each 
compartment (Hofmann and Abramowicz, 1990; Moharam et al. 1992). Labouring 
women have the highest plasma levels o f EGF and a function for EGF in the release of 
prostaglandins involved in the induction of labour has been suggested (Hofmann et al. 
1988; Watanabe, 1990). EGFR have also been localised to cytotrophoblast cells and 
syncytium of the placenta indicating a role for EGF in placental development. EGF has 
been indicated as a stimulator of endometrial stromal cell proliferation (Ladines-Llave 
et al. 1991; Hofmann et al. 1991; Amemiya et al. 1994).
1 .5 .4 .5  E G F  L e v e l s  i n  A b n o r m a l  P r e g n a n c y
Few studies have been carried out on the concentrations o f EGF in abnormal 
pregnancies. Low maternal urine and AF EGF levels have been noted in pregnancies 
affected by intrauterine growth retardation (lUGR) (Hofmann et al. 1988; Watanabe, 
1990; Varner et al. 1996; Lindqvist et al. 1999). One study failed to find this reduction 
in AF or urinary levels o f EGF in women delivering small for gestational age babies 
(Moharam et al. 1992). EGF levels have not previously been studied in DS 
pregnancies.
1 .6  C h r o m o s o m e  21: P o te n t ia l  F a c to r s  R e s p o n s ib le  
f o r  M a te r n a l S e r u m  M a r k e r  C h a n g e s  in  D S
1.6.1 DS C ritical R egion
The majority of the transcribed genes on chromosome 21 are situated on the long arm 
(q). Many studies have proposed that a region within the area 21q22 when present in 
triplicate is the minimum required to produce the DS phenotype. This has been termed 
the “DS critical region”. There have, however, been many different reported “critical” 
regions (Shapiro, 1999) which suggests that it would be more appropriate to consider all
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of the transcribed genes on chromosome 2 1  when trying to elucidate the mechanisms 
behind the phenotypic alterations observed in DS. Figure 1.6.1 illustrates the position of 
some genes o f  interest, which may be relevant to the biochemical and endocrinological 
changes noted in DS pregnancies.
22 12 
22 13
STCH
1FN-R2
IFN-Rl
SODl
IFNGR2
Figure 1.6.1
Diagram o f  Chromosome 21 indicating the relative positions 
o f  some genes o f  interest.
STCH=Stress 70 protein chaperone (21ql I), IFN-R2=Type 2 
interferon receptor (2lq22.1l), IFN-Rl =Type 1 interferon 
receptor (21q22.11), SODl=Superoxide dismutase 
(21q22.11), IFNGR2=lnterferon gamma receptor 2 
(21q22.11).
"Down's Syndrome Critical Region ” lies within 21q22.
1.6.2 In terferon  a/P R eceptor (IFN -R i & IFN-R2)
1.6.2.1 R eceptor S tructure
IFN a /p  receptors are constitutively expressed on the surface o f  both IFN responsive 
and IFN insensitive cells. The interferon a /p  receptor is composed of  two subunits, the 
type 1 receptor (1 lOkDa) and type 2 receptor (95-lOOkDa). Both subunits are required 
for cellular response to interferon (De Maeyer and De Maeyer-Guignard, 1998). The 
1FN-R2 is the ligand-binding component which, after IFN binding, complexes with the 
IFN-Rl (fig 1.6.2.1). Formation o f  the IFN-R2, IFN, IFN-Rl ternary complex then 
triggers an intracellular signalling cascade, namely the Jak/Stat pathway, which initiates 
the biological response to IFN stimulation of  the cell (De Maeyer and De Maeyer- 
Guignard, 1998). Increased receptor expression has been noted in cells from DS patients 
as would be expected for a gene localised to chromosome 21 (Gerdes et al. 1993). The 
effects o f  this overexpression in placental development in DS pregnancies have not been 
studied.
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IFN -R 2 I F N - R l
Intermediate Ternary complex
Figure 1.6.2.1 Interaction of II^'Na or IT'NP with its receptor. Ih'N first forms an 
intermediate complex with IJ^'N-R2, the ligand-hinding subunit o f  the receptor. This 
complex then binds the ITN-RI to form  a ternary complex.
Modified from  ' "The Structure o f X ytokine Receptors and their Signalling ”
Rubstein, M  et al ! http: bioinfo.weizmann.ac.il /.
1.6.2.2 Ja k /S ta t Signalling P ath w ay
The binding o f  interferon to its receptor initiates the Jak/Stat signalling cascade. Jak is 
an abbreviation for Janus kinase, which is a family of protein tyrosine kinases, and Stat 
is an acronym for Signal Transducer and Activator o f  Transcription (Darnell, 1997). 
The first event in this pathway is activation o f  the kinases Jak I and Tyk2 by 
phosphorylation. These kinases then phosphorylate either Stat I (91, 84kDa) or Stat2 
( I lSkD a) respectively on tyrosine residues causing the formation o f  Statl-Stat2 
heterodimers or Stat I-Stat I homodimers. The heterodimer moves to the nucleus where 
it complexes with the DNA binding protein p48. This complex then binds the interferon 
stimulated response element (ISRE), which is found in the promoter region of various 
IFN stimulated genes, initiating gene transcription. The Stat I homodimer can bind 
directly to the IFNy activation site (GAS) initiating gene transcription (Darnell et al. 
1994; Darnell, 1997; De Maeyer and De Maeyer-Guignard, 1998). Figure 1.6.2.2 
summarises this pathway.
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JAK1 B r
STAT2
DNA /
p U ï m .  m . f n i r  i n *
Figure 1.6.2.2
Summary o f  the Jak Stat 
intracellular signalling 
cascade initiated by the 
binding o f  Ib'Na to cell 
surface receptors.
Modified from  f http://www.grt.kyushu-u.ac.jp spad pathway ifn alpha.html j.
1.6.2.3 Biological Responses to IF N  a &  p  
IF N a
There are many different variants o f  IFNa, which have masses o f  l9-26kDa, all coded 
for by genes on chromosome 9. Monocytes, macrophages, lymphoblasts, fibroblasts and 
other cells produce IFNa following stimulation by viruses, hormones or nucleic acids 
The main biological activities o f  IFNa are its potent antiviral actions and inhibition of 
the growth o f  some tumours. It has been shown to alter cytokine expression in some cell 
types (De Maeyer and De Maeyer-Guignard, 1998). IFNa and its receptors have been 
localised to the human placenta (Howatson et al. 1988; Paulesu et al. 1991; Paulesu et 
al. 1997; Bennett et al. 1999), and the role o f  IFNa in human reproductive physiology 
has been studied (Chard et al. 1986; Chard, 1989; Chard, 1991b). IFNa also inhibits 
hCG secretion from hCG secreting bladder carcinoma cells (lies and Chard, 1989). 
Increased dosage o f  IFN-Rl & 1FN-R2 in DS placentae may therefore have a role in the 
biological changes noted in maternal serum of these pregnancies.
IF N P
IFNp is a 20kDa glycoprotein coded for by genes on chromosome 9. It is synthesised 
mainly by fibroblasts and epithelial cells, and the production can be induced by viruses, 
double stranded RNA and invading pathogens. Some cytokines, for example tumour 
necrosis factor and interleukin I also induce its production. IFNp plays an important
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role in non-specific anti-viral responses. It stimulates the activity o f  NK-ceils and the 
expression o f  HLA class 1 antigens, while blocking the expression o f  HLA class 11 
antigens. The serum levels o f  beta-2-microglobulin and the synthesis o f  low affinity IgE 
receptors are also enhanced by IFNp. Like IFNa, it inhibits the growth of some cells 
derived from solid tumours (De Maeyer and De Maeyer-Guignard, 1998).
1 .6 .3  In terferon  G am m a R eceptor 2 (IFNGR2)
1.6.3.1 Receptor S tructure
In order for IFNy to exert a biological response, the heterodimeric IFNGRI (gene on 
chromosome 6 ) and 1FNGR2 (gene on chromosome 21 ) must both be present on the cell 
surface (Soh et al. 1994; Hemmi et al. 1994). INFy binds the receptor as a dimer, with 
each subunit o f  the dimer associating with one IFNGRI subunit and one 1FNGR2 (fig
1.6.3.1 ). As with the IFN-RI and 1FN-R2, this initiates a Jak/Stat signalling cascade (De 
Maeyer and De Maeyer-Guignard, 1998).
IFNGR1
a
r  ,
Gam n^jj
V /
IFNGR2
Figure 1.6.3.1 Interaction o f  IFNy with its receptor. IFNy hinds as a dimer the 
Ih'NCiRI, which consists o f  an a  and a P  subunit. An accessory factor (I!^NGR2) is 
required for this binding to occur.
Modified from "The Structure o f  Cytokine Receptors and their Signalling"
Rubstein, M et al f  http://bioinfo.weizmann.ac.il/f
1.6.3.2 Jak /S ta t Signalling P athw ay
The binding o f  IFNy to its receptor initiates the Jak/Stat signalling cascade. The first 
event in this pathway is activation o f  the kinases Jakl and Jak2 by phosphorylation. The 
activated kinases then phosphorylate Stat I a  ( 9 1 kDa) inducing the formation of  Stat 1 a
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homodimers. The homodimers translocate to the nucleus where they can bind directly to 
the GAS response element initiating transcription o f  IFNy responsive genes (Darnel! et 
al. 1994; Darnell, 1997; De Maeyer and De Maeyer-Guignard, 1998). Figure 1.6.3.2 
summarises this pathway.
FN-y
(jAKi y JAK2
STAT
nucleus
Figure 1.6.3.2
Summary o f  the Jak Stat 
intracellular signalling 
cascade initiated by the 
binding o f  IFNy to cell 
surface receptors.
Modified from  jhttp: www.grt.kyushu-u.ac.jp spad pathway ifn gamma.html j.
1.6.3.3 Biological Responses to IFN y
IFNy is a dimeric protein with each subunit having a molecular mass o f  20 or 25kDa. 
The gene for IFNy maps to chromosome 12. It is synthesised mainly by T-cells and NK- 
cells when induced by antigens or mitogens. It is also produced by lymphocytes that 
express CD4 and CD8 antigens. B-cells can also produce IFNy. IFNy has both antiviral 
and antiparasitic actions. It influences cell-mediated cytotoxicity and T-cell growth and 
also controls the expression o f  MHC class 2 genes. The anti-proliferative activities of 
IFNy on many cell types, are the most pronounced o f  the IFN family (De Maeyer and 
De Maeyer-Guignard, 1998). IFNy was shown by one study to inhibit hCG secretion 
from term trophoblast cultures without increasing the incidence o f  cell necrosis (Marth 
et al. 1989). This and another study (Yanushpolsky et al. 1993) investigated the effect 
o f  IFNy administration to JAR cells. One study found no significant effects o f  IFNy on
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JAR cell function (Marth et al. 1989) while the other reported inhibition of growth and 
protein production but no differences in hCG release (Yanushpolsky et al. 1993).
1.6.4 S tress 70 P rote in  C haperone (STCH)
Stress 70 Protein Chaperone (STCH) is a 60kDa microsomal associated protein. It is a 
member of the heat shock protein 70 (HSP 70) family and is constitutively expressed in 
all tissues (Ulrich, 1996). Although located outside the “Down’s syndrome critical 
region” o f chromosome 21, it has been show that expression is increased in tissues from 
DS patients (Tassone et al. 1999; Yoo et al. 1999). The sequence of the HSP 70 family 
of genes is highly conserved among species. The main functions of this family of 
proteins are to assist folding, assembly or disassembly o f proteins; transport of proteins 
around the cell; degradation of unstable proteins and protein complexes; and to assist in 
the refolding of incoiTectly folded proteins. One of the HSP70 proteins binds to 
hydrophobic amino acids of unfolded proteins thereby preventing them from forming 
inappropriate structures either within themselves or with other proteins. This binding 
event triggers ATPase activity in HSP 70 and the resulting energy is thought to be used 
to fold the protein (Ulrich, 1996).
1.7  S u m m a r y  a n d  A im s
1.7.1 Sum m ary
As outlined above, there are many biochemical changes associated with DS 
pregnancies. O f particular interest are the altered maternal serum concentrations of 
hCG, AFP, U E 3 and inhibin-A because o f their use as serum screening markers o f DS 
pregnancies. The pathophysiological basis of these alterations has received limited 
study over recent years, often yielding conflicting results (sections 1.4.4 and 1.4 .5.4). 
Further understanding o f factors influencing the production and secretion of these 
markers could provide an insight into placental function in DS pregnancies. Advances 
in loiowledge of placental function and standardisation of culture methods for in vitro 
analysis o f placental trophoblast cells provide a platform for the investigation of 
biochemical alterations in DS pregnancies and the effects of increased expression of 
genes on chromosome 21. The aims of this study encompass these areas of interest.
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1.7.2 A im s
1.7.2.1 Inhibin-A and Activin-A
• To compare the concentration of inhibin-A in maternal serum and placentae 
from control and DS pregnancies, to discover the basis o f the elevation in the 
maternal serum concentration of this protein.
• To compare the concentration of activin-A in maternal serum and placentae 
from control and DS pregnancies to determine if there was any difference in 
the production or secretion of this protein in DS pregnancies.
• To correlate the inhibin-A and activin-A results with previously reported 
hCG concentrations in the same tissues.
• To localise the subunits o f inhibin-A and activin-A in placental sections 
using immunohistochemistry to compare the localisation and relative 
staining intensities of the subunits between control and DS placentae.
1.7.2.2 G row th Factors A ssocia ted  w ith  P lacental Function
• To compare the concentrations of EGF and TGF|3i in maternal serum, 
placentae, AF and maternal urine from DS and control pregnancies to gain 
an insight into placental/foetal grovrth in DS.
• To correlate these results with hCG concentrations previously measured in 
these pregnancies.
1.7.2.5 M easurem ent ofhCG mRNA Isola ted  fro m  P lacental Tissues
• To assess the sensitivity and practicality of northern blot analysis.
• To develop and validate an ELISA based method of mRNA quantification.
• To compare the ELISA method to a real time PCR method of mRNA 
quantification.
i . 7.2.4 P lacental Trophoblast Culture
• To optimise a standardised protocol for placental trophoblast isolation in a 
department where this work had not previously been carried out.
• To fully characterise the purity of isolated cells and monitor their behaviour 
in culture using standardised protocols.
• To study the effects o f cryopreservation on trophoblast viability.
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1.7 -2 .5  Effects oflF N a on P lacental hCG Production
• To localise IFN-Rl and IFNGR2 in control and DS placentae using 
immunohistochemistry and compare staining intensity between both groups.
• To analyse the potential effect o f IFN-Rl over expression on hCG secretion 
from DS placentae by analysing the effect of IFN a administration on hCG 
secretion from normal term trophoblast cultures.
• To determine effect of IFN a administration on hCG secretion and hCG 
mRNA production by term placental trophoblast cultures.
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Section 2
Materials and Methods
m
2.1  S a m p le  C o lle c t io n
2.1.1 P lacen ta l S am p les
Pieces of placenta that were previously snap frozen in liquid nitrogen were retrieved 
from storage at -70°C, and thawed. Control samples were collected between 1992 and 
1996 following termination of pregnancy (TOP) for psychosocial reasons, and for the 
Down’s syndrome (DS) cases between 1992 and 1998 following therapeutic TOP. TOP 
was by induction o f labour using Mifepristone/RU486. Use of placental tissue was 
approved by the Yorkhill NHS trust ethics committee. Details o f the gestations as 
determined from the date of last menstrual period, or if  the dates were uncertain from 
ultrasound scan, are outlined in table 2.1.1.
Gestation (weeks) Control Samples Down’s Samples
14 9 3
15 3 1
16 11 3
17 7 9
18 5 9
19 6 13
20 2 12
21 0 4
22 0 4
23 0 2
Total 43 60
Table 2.1.1 Number o f  control and DS placental samples available at each gestation.
The cytogenetic profile o f all DS foetuses was determined from either amniotic fluid 
samples or chorionic villus samples. Four o f the women were referred for cytogenetic 
profiling following an abnormal ultrasound scan, three were referred because of 
advanced maternal age, with the remainder detected by routine AFP/hCG biochemical 
screening.
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Placental extracts were prepared as previously described (Newby et al. 1997). A cross 
section of tissue of approximately 0.2g was washed in phosphate buffered saline (0.0 IM 
phosphate buffer, 0.0027M potassium chloride and 0.137M sodium chloride, pH 7.4, 
PBS), blotted on absorbent tissue, and homogenised in a Potter-Elvehjem homogeniser 
with 1ml o f extraction buffer (0.1% Triton-X-100 in PBS). The homogenate was then 
transferred to a 1.5ml micro centrifuge tube and sonicated on ice (2 x fifteen seconds at 
4pm). The resulting homogenate was spun for fifteen minutes at 10,000g, and the 
supernatant transfeiTed into a clean micro centrifuge tube. The placental extracts were 
stored at -40°C until the marker assays were performed.
2.1.2 W h ole P lacen tae for  Cell Iso la tion
Normal term placentae were collected within 30min of delivery by caesarean section. In 
all cases, informed parental consent was obtained following approval of the use of 
placental tissue by the Yorkhill NHS Trust ethics committee.
2.1.3 M aternal Serum  Sam p les
Clotted blood samples were collected from pregnant women having routine second 
trimester screening for DS and neural tube defects, and the serum separated by 
centrifugation. Half was used for the routine hCG/AFP screening, with the remainder 
stored at -20°C. Serum samples that were collected and stored by the Institute of 
Medical Genetics between 1992 and 1998 were retrieved from frozen storage and used 
in this study. The gestational range of the serum samples used in this study is outlined in 
table 2.1.3.
2.1.4 A m n iotic  F lu id  Sam p les
Amniotic fluid samples from which large cellular material had been removed by 
centrifugation for foetal chromosome analysis, were retrieved from frozen storage. The 
DS amniotic fluid samples were collected from the same cases from which placental 
samples were obtained. A random selection of 53 samples from unaffected pregnancies, 
matched for gestation and time of collection with the DS cases were used as a control 
group. The gestational range of all amniotic fluid samples is summarised in table 2.1.4.
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Gestation (weeks) Control Samples Down’s Samples
15 20 21
16 20 22
17 10 9
18 10 2
19 10 0
20 10 1
Total 80 55
Table 2.1.3 Number o f  control and DS maternal serum 
gestation.
samples available at each
Gestation (weeks) Control Samples Down’s Samples
15 6 3
16 11 10
17 9 20
18 10 13
19 11 3
20 6 1
Total 53 50
Table 2.1.4 Number o f  control and DS amniotic flu id  samples available at each 
gestation.
2.1.5 M aternal U rin e Sam ples
Control and DS maternal urine samples, from first and second trimesters o f pregnancy, 
were retrieved from frozen storage for use in this study. They were collected between 
1994 and 2000 and spun to remove particulate material before storage at -20°C. Some of 
the second trimester DS samples also had matched serum and placental samples. Table
2.1.5 outlines the number of urine samples available at each gestation.
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Gestation (weeks) Control Samples Down’s Samples
7 0 1
8 0 1
9 0 0
10 10 1
11 10 4
12 10 7
13 10 9
14 10 0
15 10 2
16 9 3
17 7 6
18 10 9
19 10 6
20 6 3
21 1 2
22 0 2
Total 103 56
Table 2,1,5 Number o f  control and DS maternal urine samples available at each 
gestation.
2 .2  C e ll C u ltu r e  M e th o d s
2.2.1 C ytotrophoblast Cell Iso la tion
The following buffer was prepared using Milli-Q RG ultrapure water and sterilised by 
filtering through a 0.22pm bottle top filter (Millipore). Culture medium was prepared 
using sterile supplies (Gibco BRL).
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Ix Hank’s Balanced Salts Solution (HBSS) pH7.4 (Sigma)
5.36mM potassium chloride
0.44mM potassium phosphate monobasic
136.89mM sodium chloride
0.34mM sodium phosphate dibasic
5.55mM D-Glucose
4.17mM sodium bicarbonate
Supplemented Medium 199 (M199)
Medium 199
10% heat inactivated foetal bovine serum (FBS)
1 OOU/ml penicillin G 
lOOpg/ml streptomycin sulphate 
0.25pg/ml amphotericin B
Placental trophoblast cell isolation was carried out using a method modified from that of 
Kliman et al (1986). The following method was scaled up or down accordingly if more 
or less tissue was used,
2 ,2 ,t , l  P lacental D issection
A  placenta was obtained as soon as possible following caesarean section. In a lamina 
flow cabinet, using sterile instruments, the placenta was cut into cubes (approx. 4cm) 
avoiding the edges, the point o f cord attachment or calcified areas, and placed into 
warm, sterile 0.9% saline. The cubes were washed 3-5 times in fresh warm saline to 
remove excess blood, leaving the tissue in the final wash o f saline. The cubes were 
removed one at a time from the saline and healthy villous tissue dissected and placed in 
fresh saline until 3 0-3 5g tissue was collected. The villous tissue was drained thi’ough 
gauze and crudely minced before being washed again through gauze to remove traces of 
blood.
2 ,2 ,1,2 E nzym atic D igestion
The tissue was transferred to a 11 conical flask to which 150ml sterile HBSS was added 
followed by 15ml sterile 2.5% trypsin solution in Ca^VMg^^ free PBS (Roche
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Diagnostics Ltd.) and 30mg type IV deoxyribonuclease I (DNase) from bovine pancreas 
(Sigma). The flask was covered and incubated at 37°C, shaking gently in an orbital 
shaking incubator, for 30min. Following incubation, the flask was placed horizontally in 
the flow cabinet to allow the tissue to settle before approximately 100ml of supernatant 
was removed to a clean sterile beaker. A further 100ml HBSS, 10ml trypsin and 20mg 
DNase was added to the tissues and the flask returned to the shaking incubator for a 
fui*ther 30min. During this incubation period, the 100ml of supernatant that was 
removed from the flask was layered in 25ml aliquots on top of 5ml newborn calf serum 
(NCS, Gibco BRL) in 30ml tubes and spun at l,000g for lOmin. The supernatant was 
aspirated from the tubes and the cell pellet suspended in M l99 and stored refrigerated 
until all cells could be pooled. Following the 30min incubation period, the placental 
tissue was allowed to settle as before and the supernatant removed and treated as 
described. Initially, a third digestion step was carried out however this was found to 
cause the villous tissue to break up leading to contamination of the trophoblast cells 
with villous fragments. All cells were pooled and spun at l,000g for lOmin to pellet 
them before suspending in 6ml M l99.
2 .2 ,1,3 T rophoblast Enrichm ent by  D ensity G radient 
C entrifugation
Two discontinuous percoll (Pharmacia) gradients were prepared by layering the stock 
concentrations into two 30ml glass corex tubes as described in figure 2.2.1.3 Suspended 
cells were layered on top of the percoll gradients (3 ml per gradient) and were spun at 
l,600g for 30min with the centrifuge brake switched off. Following centrifugation, 
several bands o f cells were visible. The four bands between the marks on the tube 
(1.048-1.062g/ml), containing mononuclear cells were collected, pooled in a 50ml tube, 
topped up with M l99 and spun at l,000g to pellet the cells. The supernatant was poured 
from the cell pellet, which was re-suspended in 2ml M l 99 for counting. Cells were 
counted at a 1 in 100 dilution using 1 part M l99, 1 part trypan blue solution (0.4% 
trypan blue in 0.81% sodium chloride and 0.06% potassium phosphate dibasic, Sigma) 
in an improved Neubauer haemocytometer. Cells were then seeded at the appropriate 
density (see table 2.2.3) or further purified by immunodepletion.
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2m 1 10%
2m 1 20% 
4m 1 30%
2m I 35%jjyo j
2ml 45%
Percoll cone. (%) Percoll (ml) Sterile H2O (ml) lOxHBSS (ml)
10 5 40 5
20 10 35 5
30 30 60 10
35 17.5 27.5 5
40 20 25 5
45 22.5 22.5 5
50 25 20 5
55 27.5 17.5 5
60 30 15 5
70 52.5 15 7.5
Figure 2.2.1.3 Preparation o f  discontinuous percoll gradients. Table describes how 
each percoll solution was prepared using stock percoll, sterile water and lOx HBSS. 
Diagram illustrates the quantity o f  each percoll concentration layered to construct 
gradient. The tube was marked at arrows.
2 .2 .2  P u rification  o f  C ytotrophoblast Cells by  
Im m u n od ep letion
Contaminating cells were removed from isolated cytotrophoblasts using magnetic beads 
(Dynal UK Ltd.) coated with monoclonal mouse anti-HLA Class I antibody (Harlan 
Sera-Lab Ltd. UK). This has been shown to be an efficient way of purifying 
cytotrophoblasts because HLA Class I antigen is expressed on all contaminating cells 
but not trophoblasts (Kawata et al. 1984). Firstly, lOOpl (4x10’) Dynabeads Pan Mouse 
IgG were washed by suspending in 1ml of HBSS + 0.1% bovine serum albumin (BSA), 
then aspirating the wash buffer when the tube was in a magnetic holder. The beads were 
re-suspended in lOOpl of wash buffer to which 4pl (2pg) anti-HLA antibody was added, 
and then incubated at 4°C on a roller mixer for approximately Ih to allow the beads to 
be coated with antibody. The beads were washed 3 times as before and re-suspended in
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lOOpl of wash buffer. Cells were purified by addition of 50|li1 o f coated beads for up to a 
maximum of 50x10^ cells recovered from percoll separation, in a total volume of 1ml. If 
more cells were purified, the number of beads was increased proportionally. The 
cell/bead suspension was incubated at 4°C on a roller mixer for 30 min to allow 
contaminating cells to bind to the beads. Following incubation, the now pure cells were 
removed from the beads, which were held in the tube using a magnetic stand, and plated 
at the appropriate density (table 2.2.3).
2 .2 .3  Culture o f  Iso la ted  C ytotrophoblast Cells
Following isolation, cells were plated on culture treated dishes (Sterelin) at the densities 
outlined in table 2.2.3. Cells were cultured at 37°C, 5% CO2, in M l99. The cells were 
cultured for 24h to allow them to adhere to the culture surface, before the medium was 
removed and the cells washed using HBSS to remove any loose cells. The culture 
medium was replaced and subsequently changed at 24h intervals. Aspirated medium 
was stored at -40°C for further analysis.
Well Diameter Culture Area Wells/Plate No. of Cells Medium/Well
35mm 9.5cm^ 6 4x10" 4ml
22.1mm 3.8mm^ 12 2x10" 2ml
15.6mm 1.9mm^ 24 1x10" 1ml
Table 2.2.3 Trophoblast plating density in each size o f  culture dish, and the quantity o f  
M l 99 used.
To estimate plating efficiency, the number of cells that had failed to adhere to the 
culture surface after 24h was counted using an improved Neubauer haemocytometer. 
Culture medium was transferred directly to the counting chamber without further 
dilution. As a different method of estimation of cell number, cells were scraped into 
PBS/0.1% triton-X-100 (100ml per 10*" cells) and stored at -40°C until a protein or DNA 
assay was carried out on the lysates.
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2 .2 .4  A dd ition  o f  In terferon  to  T rophoblast Cell C ultures
Ceils were seeded on 12-well culture dishes at the appropriate density (table 2.2.3) and 
cultured in M199 for 24h to allow the cells to adhere to the culture surface. Culture 
medium was changed and replaced with M l99 containing 1, 10 or 1 OOU/ml IFN a  
(Serotec, UK). IFNa had previously been reconstituted in HBSS/0.1% BSA solution at 
a 100 times final concentration to allow 20pl of this solution to be added to the 2ml of 
M l99 in each culture well. Some cells also received diluent only or no addition to act as 
controls. All additions were made to triplicate wells. At 24h periods, culture medium 
was collected and stored at -40°C, and replaced with new medium with the appropriate 
addition. At each time point, cells were pooled from the triplicate wells in tri-reagent 
(Sigma) and stored at -70®C until RNA, DNA and protein could be extracted (section 
2.5.1).
2.2 .5  Cell F reezin g
Cells were cryopreserved according to the method described by Yui et al (1994). 
Immediately following isolation, cytotrophoblast cells were suspended (10’ cells/ml) in 
FBS with 10% dimethyl sulphoxide (DMSO) and transferred to 1.8ml cryovials (Nunc). 
Tubes were wrapped in several layers o f bubble wi’ap and placed in a -70°C freezer for 
24h. The cells were then transferred to liquid nitrogen for long-term storage. Cells were 
recovered by thawing in a 37°C water bath, suspending in approximately 45ml M l99 
and centrifuging to pellet. The cells, now washed free of DMSO, were re-suspended in 
M l 99 at the appropriate density and seeded into culture dishes as outlined previously 
(section 2.2.3).
2 .3  I m m u n o c y to c h e m is tr y  & 
I m m u n o h is to c h e m is t r y
2.3.1 P reparation  o f  frozen  tissu e  sec tio n s
Pieces of placental tissue, previously collected and snap frozen in liquid nitrogen, were 
retrieved from storage at -70°C and sections (6pm) cut using a Leica cryostat at -20°C. 
Sections were adhered to superfrost plus slides (BDH) and allowed to air dry for 20min
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before fixing in acetone (BDH) for 20min, followed by air-drying for a further 20min. 
Sections were stored sealed at -20°C until required.
2 .3 .2  P reparation  o f  C ytospins
Wet fixed cytospins were prepared using a Shandon Cytospin® cytocentrifuge system. 
Freshly isolated trophoblast cell suspension was pipetted into a sample chamber (1x10^ 
cells in 0.5ml PBS) to which 6 drops o f CytoFixx™ cytological fixative (Cell Path, UK) 
were added. The cells were cy to spun at 1500rpm for 3 min to allow the cells to adhere to 
superfrost plus slides. After removal from the cytocentrifuge, a further 2 drops of 
CytoFixx’'^ *'^  were dropped onto the circle of cells on each slide. Cytospins were stored 
sealed at -20°C until required.
2 .3 .3  F ixation  o f  T rophob last ce lls in  C ulture D ish es
Trophoblast cells growing in culture were fixed to allow immunostaining of cells at 
various stages of differentiation. Cultuie medium was removed from the cells, which 
were then washed using PBS. Ice-cold methanol (BDH) was added to the culture dish, 
and placed in a -20°C freezer for 20min. Following fixation, the cells were washed 3 
times using PBS, and were stored refrigerated in PBS until required.
2 .3 .4  A v id in /B io tin  Im m u n op erox id ase S ta in in g  o n  
F rozen  S ection s
Frozen tissue sections were allowed to return to room temperature, loaded into a 
Sequenza staining chamber (Shandon, UK) and washed using PBS. Non-specific 
staining was blocked by incubating the sections for lOmin at room temperature in lOOpl 
normal goat serum (SAPU, NGS) diluted 1:4 using PBS. Appropriately diluted primary 
antibody (see table 2.3) was added to each section (lOOp.1) and incubated for Ih. The 
sections were washed for 5min using PBST (PBS + 0.3% Triton-X-100) before lOOpl 
solution 1 (biotinylated goat anti-mouse and anti-rabbit secondary antibody in PBS) of 
the duet staining system (Dako Ltd., UK) was added to each slide and incubated at room 
temperature for 35min. The sections were washed as before, then 100pi of solution 2 
(biotinylated horse radish peroxidase + avidin) of the duet system was added to each
section. This was incubated for 35min before being washed as before, then removed 
from the Sequenza and washed for 5min in water. Antibody binding was visualised by 
incubating for 2-lOmin in a diaminobenzidine (DAB), hydrogen peroxide solution 
(KEMENTECH, Denmark). Once the desired strength of colour was reached, sections 
were washed for 5min in water. Sections were counterstained in haematoxylin, 
differentiated in acid alcohol (0.25% conc. hydrochloric acid in methylated spirits) and 
rinsed in Scotts tap water (0.04M sodium bicarbonate, 0.16M magnesium sulphate in 
water) to intensify the blue staining. The sections were dehydrated through methylated 
spirits, 2 changes o f ethanol, 2 changes of histoclear (National Diagnostics) and 
mounted using synthetic resin (Ralmount, BDH). Slides were viewed using an Olympus 
light microscope. Matched control and DS sections were stained in the same batch. Each 
batch included a negative control, either omitting the primary antibody or replacing the 
primaiy antibody with control mouse immunoglobulin fraction.
2 .3 .5  A v id in /B io tin  Im m u n op erox id ase  S ta in in g  on  F ixed  
Cells in  C ulture
PBS was removed from the culture dish and non-specific staining was blocked by 
incubating the cells for 30min at room temperature in a covering of NGS (1:50 using 
PBS). The serum was poured off and enough of the appropriately diluted antibody (see 
table 2.3) was added to cover the culture surface. This was incubated at room 
temperature for 45min before being washed (3x5min) using PBS. The duet staining 
system was used as previously described, followed by visualisation using DAB. Dishes 
were filled with PBS and viewed using an Olympus CK2 inverted light microscope.
2 .3 .6  F lu orescen t Im m u n oh istoch em istry  & 
Im m u n ocytoch em istry  o n  Frozen  sec tio n s  & 
C ytospins
Tissue sections or cytospins were allowed to return to room temperature before being 
loaded into the Sequenza staining system as described before. Non-specific staining was 
blocked by incubating the sections for 20min at room temperature with lOOpl NGS (1:9 
using PBS). Antibody was diluted (see table 2.3) in PBS + 0.1% BSA, added to the
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slides and incubated at room temperature for Ih. Slides were washed for 15min using 
PBS 4- 0.1% Triton-X-100. Fluorescein isothiocyanate (FITC) conjugated goat anti­
mouse secondary antibody (Dako Ltd., UK), diluted 1:20 in PBS/BSA, was added to 
each slide and incubated, shielded from light, for Ih. All subsequent steps were carried 
out in the dark. The slides were washed as before and mounted in fluorescent mounting 
medium (Dako Ltd., UK) containing 0.75pM propidium iodide. When complexed with 
DNA, propidium iodide absorbs light at 493nm, and fluoresces red (630nm). This 
allows nuclei to be visualised by microscopy. Slides were viewed using an Olympus 
fluorescence microscope and images were eaptured using an Olympus camera and IP 
Lab software.
2 .3 .7  F lu orescen t Im m u n ocytoch em istry  on  F ixed  Cells in  
C ulture
The protocol outlined for avidin/biotin immunocytochemistry (section 2.3.5) was 
followed until the wash step following incubation with the primary antibody. FITC 
conjugated secondary antibody was added to the dishes and incubated at room 
temperature for 45min. The dishes were washed as described before, then drained. The 
cells were mounted with a round coverslip, using two drops of fluorescent mounting 
medium containing 0.75pM propidium iodide. Cells were visualised using the 
fluorescence microscope described previously.
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Antigen
Inhibin a  subunit 
Inhibin/activin subunit 
CD 45 
Vimentin
Cytokeratin 7
CD 9 
CD 163
Fibroblast specific antigen 
(FSA)
HLA Class I
Placental alkaline 
phosphatase (PLAP) 
Desmoplakin 1&2
Interferon a /p  receptor 
(rabbit polyclonal) 
Interferon y receptor p 
(rabbit polyclonal) 
Cytokeratin 5/6/18
Goat F(ab’)2 anti mouse 
immunoglobulin FITC conj.
Clone
_
E4
2B11 &PD7/26 
V9
LP5K
Pl/33/2 
Ber-MAC 3 
A S02
W6/32
8B6
DP2.15
C18
N20
LP34
Supplier Dilution
Serotec Ltd. UK 1:50
Serotec Ltd. UK 1:75
Dako Ltd. UK 1:100
Novo Castra 1:100
Laboratories Ltd. UK 
Autogen Bioclear 1:20
UK Ltd.
Dako Ltd. UK 1:20
Dako Ltd. UK 1:20
Oncogene Research 1:20
Products, USA 
Harlan Sera-Lab Ltd., 1:20 
UK.
Autogen Bioclear 1:50
UK Ltd.
Autogen Bioclear 1:50
UK Ltd.
Santa Cruz 1:100
Biotechnology, UK
Santa Cruz 1:100
Biotechnology, UK
Novo Castra 1:20
Laboratories Ltd. UK
Dako Ltd. UK 1:20
Table 2.3 Suppliers o f  antibodies, and dilutions used in immunocytochemistry and 
immunohistochemistry. All antibodies are mouse monoclonal unless otherwise stated.
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2 .3 .8  C om parison  o f  Im m u n oh istoch em istry  S ta in in g  
In ten sities
The difference in relative staining intensities between gestation matched control and DS 
placental sections was compared using a semi-quantitative method. Two independent 
scorers assessed the staining intensity, blinded to the identity of the section, using the 
criteria outlined in table 2.3.8. One scorer gave two sets o f independent scores for each 
section, while the other scorer gave one score for each section. The average score was 
then calculated for each section. In some cases different areas o f the section were scored 
separately i.e. stroma and trophoblast layer scored separately.
Score Degree of Staining
No staining
+/- Light and patchy staining not on all villi
+ Light staining on the majority of villi
++ Medium to strong staining
++H- Strong to very strong staining
Table 2.3.8 Criteria fo r  scoring the intensity o f  immunohistochemical staining o f  
placental sections.
2 .4  A s s a y s
2.4.1 P rotein  A ssay
The protein level of each placental sample was determined to standardise all further 
measurements against, using a method modified from that of Lowry et a/ (1951). This 
assay involves the pre-treatment of the samples with an alkaline copper solution to 
which a solution of sodium tungstate, molybdate and phosphate (Folin-Ciocalteau 
reagent) is added. The copper-amino acid complex (primarily involving tyrosine and 
tryptophan) reduces the Folin-Ciocalteau reagent producing a blue colour, which 
absorbs light at 690nm.
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Prior to commencing the assay, three solutions were prepared: A (2% sodium carbonate 
in O.IM sodium hydroxide), B, (1% copper sulphate in distilled water) and Bj (2% 
sodium potassium tartrate in distilled water). Next, freeze dried BSA was reconstituted 
in distilled water to give a 500p.g/ml stock solution. From this stock solution, dilutions 
were carried out to give a series of 7 standards with concentrations ranging from 0 to 
500pg/ml. Before the commencement of each assay, a solution A /B /B j (98% /l% /l%  
respectively) was prepared. Placental samples were diluted either 1 in 5 or 1 in 10, using 
distilled water and protein isolated from cultured trophoblasts were diluted 1 in 10.
Firstly, 20pl of diluted sample or BSA standard was pipetted in duplicate into wells of a 
microtitre plate, to which 200pl of the prepared A/B/B^ solution was added. The 
microtitre plate was shaken gently before covering and incubating at room temperature 
for 15 min. Following incubation, 20pl of Folin-Ciocalteau phenol reagent (BDH), 
diluted 1:1 with distilled water, was added to each well o f the microtitre plate. This 
addition was made while the plate was shaking to ensure immediate, thorough mixing. 
The plate was incubated at room temperature, in the dark, for 45 min. Finally, the 
absorbance of each well was read at 690nm on a Labsystems Multiskan® Bichromatic 
plate reader, and the protein concentration of each sample determined from the BSA 
standard curve (using Genesis software).
2 .4 .2  Inhib in-A  Im m u n oassay
The concentration of inhibin-A present in the placental homogenates was determined 
using a medium sensitivity inhibin-A dimer assay kit (Serotec Ltd., UK). This is a solid 
phase enzyme linked immunosorbent sandwich assay, which has a pre-treatment step to 
improve the specificity and affinity of the assay, and allow haemolysed samples to be 
assayed. The antibodies used in this assay make it highly specific for inhibin-A, and it 
therefore does not cross-react with other species of inhibin, or free alpha subunits 
(Groome, 1991; Groome and O'Brien, 1993).
The protocol supplied with the assay was followed for the previously prepared samples 
of placental homogenate, which were diluted (either 1 in 10 or 1 in 20) in the supplied 
foetal calf serum. The inhibin-A standards were also diluted using foetal calf serum 
giving a range of 0-2000pg/ml.
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The basic steps of the protocol firstly involved 50 pi of sodium dodecyl sulphate (SDS) 
being added to lOOpl of sample or standard in micro centrifuge tubes, which were then 
capped and placed in a boiling water bath for 3min. After cooling, lOOpl of assay 
diluent, and 50pl o f 6% hydrogen peroxide were added to each sample, and incubated at 
room temperature for 30min. Following incubation, 80pl of treated sample was added, 
in duplicate to the wells o f the antibody coated microtitre plate, which was then covered 
and incubated for 2h at room temperature. The plates were then washed 4 times using 
the supplied wash buffer and drained on absorbent paper before 50pl o f the alkaline 
phosphatase conjugated anti inhibin-A a  subunit antibody was added to each well. The 
plate was covered and incubated at room temperature for 30min. After incubation, the 
plate was thoroughly washed 8 times, as described above, leaving the final wash 
solution to soak in the wells for 15min. The plate was then washed a further 3 times, 
before draining the plate, and adding 50pl of substrate solution to each well. The plate 
was covered and incubated at room temperature for 30 min to allow the reaction to 
proceed. Each well of the plate then received 50pl of amplifier solution and was mixed 
by gentle agitation. The plate was covered and incubated at room temperature for 
approximately 40 min, until the absorbance of the 2000pg/ml standaid at 490nm 
reached 2.0. Once the desired absorbance was achieved, 50pl o f stop solution (0.46M 
sulphuric acid) was added to each well and the absorbance values for each well were 
determined at 490nm, referenced at 620nm. The standard curve was plotted using four- 
parameter logistic software (4-PL), and the values of the samples extrapolated from this.
2 .4 .3  A ctivin-A  Im m u n oassay
The concentration of activin-A present in the placental homogenates was determined 
using an ultrasensitive activin-A dimer assay kit (Serotec Ltd., UK). This assay has 
similar properties to the inhibin-A assay, making it highly specific and allowing the 
total activin-A concentration of each sample to be determined (Groome, 1991; Groome 
and O'Brien, 1993). The protocol supplied with the assay was followed for the 
previously prepared samples o f placental homogenate which were diluted (either 1 in 50 
or 1 in 100) in the supplied 5% BSA in PBS. The supplied activin-A standards were also 
diluted using BSA in PBS giving a range of 0-5000pg/ml.
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The basic steps o f the protocol firstly involved the addition of 125 pi of SDS to 125pi of 
sample or standard in micro centrifuge tubes, which were then capped and placed in a 
boiling water bath for 3 min. After cooling, 20pl of 30% hydrogen peroxide was added 
to each sample, and incubated at room temperature for 30min. Meanwhile, 25 pi o f assay 
diluent was pipetted into each well of the supplied antibody coated microtitre plate. 
Following incubation, lOOpl of treated sample was added, in duplicate to the wells of 
the microtitre plate. To this 25pi of reconstituted biotinylated anti inhibin-A (3^  subunit 
antibody was added, and the plate was covered and incubated at room temperature 
overnight on a plate shaker. On the following day, the plates were washed 4 times using 
the supplied wash buffer, allowing the buffer to soak in the wells for 15sec between 
each wash. The plate was allowed to drain on absorbent paper before 50pl of diluted 
streptavidin alkaline phosphatase solution was added to each well o f the microtitre plate. 
The plate was then covered and incubated at room temperature for Ih. After incubation, 
the plate was thoroughly washed 8 times, as described before, leaving the final wash 
solution to soak in the wells for 15 min. The plate was then washed a further 3 times, by 
immersing the plate in fresh wash buffer. After draining the plate, and adding 50pl of 
substrate solution to each well, the plate was covered and incubated at room temperature 
for 2h to allow the reaction to proceed. Each well of the plate then received 50pl of 
amplifier solution and was mixed by gentle agitation. The plate was covered and 
incubated at room temperature for approximately 20 min, until the absorbance o f the 
5000pg/ml standard at 490nm reached 1.7 absorbance units. Once the desired 
absorbance was achieved, 50pl of stop solution was added to each well and the 
absorbance values for each well were determined at 490nm, referenced at 620nm. The 
standard curve was plotted using 4-PL software, and the values of the samples 
extrapolated from this.
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2 .4*4 T ran sform in g G row th Factor B eta i (TGFpi) 
Im m u n oassay
The TGF p, ELISA (Promega, UK) is specific for bioactive TGF p„ showing less than 
2% cross reactivity with either TGFP2 or TGFp; (Promega data sheet). The following 
buffers were prepared for use in this assay using distilled deionised water:
DPBS (pH 7.35) Carbonate Coating buffer
2.7mM potassium chloride 25mM sodium carbonate
140mM sodium chloride 25mM sodium bicarbonate
1.47mM potassium phosphate monobasic TBST Wash Buffer
S.lmM  sodium phosphate dibasic 20mM Tris-HCl (pH 7.6)
0.9mM calcium chloride 2 hydrate 150mM sodium chloride
0.49mM magnesium chloride 6 hydrate 0.05% v/v Tween 20
To allow measurement of total levels of this growth factor, samples were firstly acid 
pre-treated to process the latent form of TGFp, to the bioactive form of the protein. 
Prior to acid treatment, serum placental and amniotic fluid samples were diluted 1 in 5 
using DPBS. Samples were acidified by adding lOpl IN  hydrochloric acid to lOOpl 
diluted sample, incubating for 15 min, and then neutralising by addition of lOpl IN 
sodium hydroxide. Placental and serum samples were further diluted 1 in 20 (final 
dilution 1 in 100) using the supplied diluent, while amniotic fluid samples were not 
further diluted. All samples were assayed in duplicate following the protocol supplied 
with the kit.
Prior to the commencement of the assay, 96 well microtitre plates (Nunc MaxiSorp) 
were coated with monoclonal antibody by adding 100pi diluted antibody (lOpl antibody 
in 10ml carbonate coating buffer) to each well and incubating overnight for 17h at 4°C. 
The antibody solution was flicked from the plate and 270pl of supplied block buffer 
(diluted 1 in 5 with water) was added to each well of the plate and incubated at 37°C for 
35 min. This solution was removed from the wells, and the plate washed once using
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TBST wash buffer. Each well o f the coated plate received lOOpl o f prepared sample or 
standard (O-lOOOpg/ml), was sealed and then incubated at room temperature shaking for 
90min. The samples were removed from the plate, which was washed 5 times using 
TBST. Anti TGFp, polyclonal antibody (diluted 1:1,000) was added to each well o f the 
plate (lOOpl per well) and incubated at room temperature shaking for 2h. The plate was 
washed 5 times before lOOpl horseradish peroxidase (HRP) conjugated secondary 
antibody, diluted 1:2,000, was added to each well of the plate and incubated for 2h. 
During this incubation time, the enzyme substrate solution was prepared by adding 5ml 
tetramethylbenzidine (TMB) solution to 5ml peroxidase substrate, which was mixed and 
stored shielded from light until required. Following incubation, the plate was washed a 
final 5 times using TBST before addition of lOOpl of prepared substrate solution. This 
was incubated at room temperature for 15 min to allow development of a blue colour. 
The reaction was stopped by addition o f lOOpl IM phosphoric acid, which changed the 
colour to yellow. The absorbance was read at 450nm and the sample results calculated 
from a standard curve plotted using 4-PL software.
2 .4 .5  E piderm al G row th Factor (EGF) Im m u n oassay
The EGF assay (R&D Systems, UK) is a highly specific ELISA with a limit of detection 
of less than 0.7pg/ml. Amniotic fluid samples were assayed undiluted, and urine 
samples were assayed at a 1 in 300 or 500 dilution in supplied urine sample diluent, 
both according to the manufacturer’s recommended protocol for urine samples. Serum 
samples were assayed at a 1 in 20 dilution in supplied serum sample diluent following 
the serum protocol. The standards (n=7) used to assay the serum and urine samples 
ranged from 3.9-250 pg/ml, while the amniotic fluid samples were assayed against a 7- 
point standard curve ranging from 0.97-62.5 pg/ml each constructed using the 
appropriate diluent. Each sample and standard was added in duplicate, 200pl per well, 
and the plate was sealed and incubated at room temperature for 2h. Samples were 
flicked from the plate, which was washed 3 times using the supplied wash buffer, before 
200pl HRP conjugated anti EGF polyclonal antibody was added to each well of the 
plate. For the urine protocol the plate was incubated at room temperature for Ih while 
for the serum protocol this incubation was 2h. Following incubation, the plate was 
washed 3 times as before. To each well, 200pl substrate solution (TMB) was added and
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incubated at room temperature for 20 min until a blue colour formed. The reaction was 
stopped by addition of 50pl o f stop solution (2N sulphuric acid), which produced a 
yellow colour. The absorbance was read at 450nm corrected at 540nm and the values of 
the samples extrapolated from the standard curve which was plotted using 4-PL 
software.
2 .4 .6  H um an C horion ic G onadotroph in  (hCG) 
Im m u n orad iom etr ic  A ssay
The quantity o f hCG secreted into culture medium by trophoblasts was measured using 
the MAI A clone '^"^ magnetic solid phase immunoradiometric assay (BioChem 
ImmunoSystems UK Ltd.). Culture medium was assayed neat or diluted 1 in 2, 5 or 10 
using fresh culture medium. The first step o f the assay was addition of 25pi sample or 
standard (0-500mIU/ml) in duplicate, to 5ml plastic assay tubes, to which 250pl ‘’"I 
anti-hCG Reagent ( ‘^ "l and fluorescein labelled anti-hCG monoclonal antibody solution) 
was added. The tubes were vortex mixed and incubated at 37°C for 15min. Next, lOOpl 
Separation Reagent (sheep anti-fluorescein coated magnetic beads) was added to each 
tube and vortex mixed. The tubes were incubated at room temperature for 5min and then 
the rack of tubes were attached to a magnetic separator base and allowed to settle for 
2min. While still in the separator, the supernatant was poured from the tubes, which 
were then inverted on paper towels and tapped to dislodge any drops o f liquid in the 
tubes. The tubes each received 500pi of wash buffer, were vortex mixed and returned to 
the magnetic separator for 2min before the supernatant was removed as described 
before. The tubes and separator were left inverted on paper towels for 5 min to ensure 
removal of all drops of liquid. Each tube was counted for 2min in a Packard Cobra 5010 
gamma counter. Log,o concentration o f standards was plotted against counts per minute 
and a spline curve fit was carried out, from which the values o f each sample were 
calculated. Positive and negative control samples were included in each assay.
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2 .4*7 P lacen ta l A lkaline P h osp h atase (PLAP) 
Im m u n oassay
The concentration o f PLAP released into the culture medium by trophoblasts was 
determined using the Innotesf^'^ hPLAP immunoassay (Autogen Bioclear UK, Ltd.). 
Previously collected culture medium was assayed undiluted by adding lOOpl of sample 
in duplicate to the wells of the supplied mouse monoclonal anti-hPLAP coated 
microplate strips, followed by lOOpl assay buffer. Supplied standards (0-1000 mU/1) 
were also added in duplicate to the strips (200pl per well) before the plate was mixed, 
sealed and incubated for 3h at 37°C to allow the PLAP to bind to the immobilised 
antibody. The plate was washed 3 times using the supplied wash buffer and drained. 
Prepared substrate (p-nitrophenyl phosphate/ N-ethylaminoethanol solution) was added 
to each well (200|l l 1) and mixed. The plate was incubated for 2h in the dark at 37°C to 
allow the immobilised PLAP to produce a yellow coloured product from the substrate. 
The absorbance o f each well was measured at 405nm and the value of each sample 
calculated from the standards by linear regression. Controls supplied with the kit were 
included in each assay.
2 .5  W e s te r n  B lo t t in g
The following buffers were prepared for use in western blotting:
Gel Buffer A (pH 8.8) Gel Buffer B (pH 6.8)
l.SM Tris 0.5M Tris
0.4% SDS 0.4% SDS
RIPA Buffer PBST
1% Igepal CA-630 (Sigma) 2.5% Tween-20 in PBS
0.5% sodium deoxycholate
0.1% SDS Running Buffer (pH 8.3)
in PBS 125mM Tris
IM glycine 
0.5% SDS
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Loading Buffer (5x) Transfer Buffer
500mM Tris-HCl (pH 6.8) 25mM Tris
50% glycerol 0.2M glycine
10%SDS 0.5% SDS
5% mercaptoethanol in 20% methanol
0.5% bromophenol blue
2.5.1 D en atu rin g  Gel E lectrop h oresis an d  P rotein  
T ransfer
A 12% resolving gel was prepared using 28.8ml 30% acrylamide (acrylamide;bis- 
acrylamide 37.5:1), 4.8ml 50% glycerol, 18ml buffer A, 20ml water, 360pl 10% 
ammonium persulphate (APS), 36pl TEMED. This was poured into the gel former and 
the air excluded using a layer of isopropanol. The stacker gel was prepared using 2.7ml 
30% acrylamide, 5ml buffer B, 12.2ml water, lOOpl 10% APS, 20pl TEMED. The 
isopropanol was washed from the resolving gel before the stacker gel was poured and 
combs carefully positioned to form the wells for sample loading. Samples that had 
previously been homogenised in RIPA buffer, 0.1 mg/ml PMSF, aprotinin, ImM sodium 
oithovanadate were diluted and mixed with the appropriate quantity of 2x loading buffer 
to allow addition o f 20-100pg protein per lane. The samples were boiled for 5min then 
put on ice before loading into the gel. After the stacker gel was set, combs were 
removed and the gel transferred to the tank and top and bottom reservoirs were filled 
with running buffer. Samples and pre-stained SDS-page protein markers were loaded in 
the wells ensuring the same quantity of protein was added to each well. The gels were 
run at 15mAmps, 400volts for approximately 2h until separation o f the marker bands 
was visible. Nitrocellulose (Hybond, Amersham Pharmacia) and filter paper were cut to 
the same size as the gel and soaked in transfer buffer. Sponges from the transfer 
equipment were also soaked in buffer. The stacker gel was trimmed from the top of the 
gel and the transfer sandwich was carefully assembled under transfer buffer. The protein 
was transfened to the membrane by electrotransfer (30volts, 250Amps) at 5°C, 
overnight.
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2 .5 .2  Im m u n ob lottin g
The membrane was removed from the transfer apparatus and trimmed. Successful 
transfer o f protein could be confirmed at this point by staining the membrane with 0.1 /b 
Ponceau S in 5% acetic acid (Sigma). This stains major protein bands red and is 
reversible by washing membrane in O.IM sodium hydroxide for Imin. Non specific 
antibody binding was blocked by incubating the membrane in 5% powdered milk in 
PBST for Ih at room temperature. The primary antibody was diluted to the appropriate 
concentration (table 2.5.3) in 3% milk in PBST and incubated with the blot for Ih  at 
room temperature. The membrane was washed twice for 5min in PBST before addition 
of secondary antibody (HRP labelled goat anti rabbit or goat anti-mouse, Amersham 
Pharmacia Biotech) at a 1:1000 dilution in PBST containing 3% powdered milk. This 
was incubated at room temperature for Ih before the membrane was washed three times 
for at least lOmin each wash. The membrane was covered in a layer of luminol detection 
reagent (ECL western blotting detection reagent, Amersham Pharmacia Biotech) and 
incubated at room temperature for Imin. The blot was placed between plastic and 
exposed to film (Hyperfilm ECL, Amersham Pharmacia Biotech) in a light proof 
cassette containing intensifying screens and exposed at room temperature for up to Ih. 
Film was developed in a Fuji RGII x-ray film processor.
Antigen Clone Supplier Diln.
IFN a/p  receptor (rabbit polyclonal) C l8 Santa Cruz Biotechnology, UK 1:100
pSTATl (mouse monoclonal) A-2 Santa Cruz Biotechnology, UK 1:100
Table 2 .53  Suppliers o f  antibodies, and dilutions used in western blotting.
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2 .6  M o le c u la r  M e th o d s
The following buffers were purchased for use during molecular methods:
MESA Buffer (pH 8.3) (Sigma)
40mM 3-(N"Morpholino) propane sulphonic 
acid (MOPS)
ImM Ethylenediaminetetra-acetic acid (EDTA)
lOmM sodium acetate
DNA Loading Buffer (Promega, UK)
0.005% ethidium bromide 
15% Ficoll 400 
0.03% bromophenol blue 
0.03% xylene cyanol FF 
0.4% orange G 
lOmM Tris-HCL (pH7.5)
50mM EDTA
RNA Loading Buffer (Sigma)
62.5% deionised formamide 
1.14M formaldehyde 
1.25x MESA buffer 
0.02% bromophenol blue 
0.02% xylene cyanol 
TAE Buffer (CP Labs)
40mM Tris-acetate (pH8.3)
ImM EDTA
TE Buffer (pH 8) (Sigma)
lOmM Tris 
ImM EDTA
20x SSC Buffer (pH 7) (Sigma)
0.3M sodium citrate 
3M sodium chloride
2.6.1 RNA, DNA and  P rotein  Iso la tion
2.6.1.1 RNA Isola tion
Total RNA was extracted from placental tissue and cultured trophoblast cells using Tri 
Reagent (Sigma), which is based on the single step method previously reported 
(Chomczynski and Sacchi, 1987; Chomczynski, 1993). All steps were carried out in 
certified RNase free micro centrifuge tubes (Anachem Ltd., UK), using RNase free 
reagents dispensed from RNase free aerosol resistant pipette tips (BDH).
Tissue chunks were ground to a fine powder under liquid nitrogen then added to the Tri 
Reagent (1ml per lOOmg tissue) and further homogenised using a Polytron homogeniser 
(Kinematica, Switzerland). The resulting solution was spun at 12,000g for lOmin at 4°C 
to remove insoluble material, and the supernatant transferred to a fresh 2ml micro 
centrifuge tube. Cells were lysed directly on the culture surface using 1ml tri reagent per
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8x10^ cells, and the solution transfened to a 2ml micro centrifuge tube. The procedure 
for both tissue chunks and cultured cells was identical from this point. Once the cells 
had been allowed to stand in 1ml Tri Reagent for 5min at room temperature, 0.2ml 
chloroform (BDH) was added to the tube, which was shaken vigorously for 15sec and 
allowed to stand at room temperature for approximately lOmin. The resulting mixture 
was spun at 12,000g for 15min at 4°C, which caused the formation of thiee layers. The 
upper aqueous phase containing the RNA was transferred to a fresh tube while the lower 
red coloured organic layer and the white interphase were retained for DNA and protein 
isolation. Isopropanol (0.5ml) (BDH) was added to the aqueous phase, mixed and 
incubated at room temperature for 5-lOmin to allow the RNA to precipitate. This was 
spun at 12,000g for lOmin at 4°C to allow the RNA precipitate to form a pellet. The 
RNA pellet was washed using 1ml 75% ethanol, briefly air dried, and resuspended in 
diethylpyrocarbonate (DEPC, Sigma) treated water. To confirm the purity and estimate 
the quantity of RNA isolated, the absorbance of the RNA solution was checked, 
suspended in TE buffer, at 260nm and 280nm using a Gene Quant II spectrophotometer 
(Pharmacia Biotech). The 260nm/280nm ratio was generally between 1.8 and 2.2, 
indicating pure RNA. The quantity of RNA isolated was estimated by multiplying the 
absorbance reading at 260nm by 40 to give the concentration of RNA in the cuvette in 
pg/ml. Denaturing gel electrophoresis was used to determine the integrity of isolated 
RNA. A small sample of RNA mixed 1:2 in RNA loading buffer was heated to 65°C for 
lOmin then loaded onto a 1.2% agarose, denaturing formaldehyde (0.6M) gel in MESA 
buffer. An RNA marker (0.2-10Kb) was also included on the same gel to determine if 
the two visible rRNA 28s and 18s bands were of the correct size (5333b and 2366b 
respectively). A representative gel is illustrated in figure 2.6.1.1. Isolated RNA was 
stored at -70°C, precipitated in 70% ethanol, 0.083M sodium acetate (pH5.2).
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Figure 2.6.1.1 Representative RNA check gel with 9 different RNA samples extracted 
from  term placental trophoblast cultures. L=RNA ladder. 28s and 18s bands are clearly 
visible and are o f  the correct size.
2.6.1.2 DNA Extraction
DNA was precipitated from the lower organic phase and interphase, retained from the 
RNA isolation procedure, by addition of 0.3ml absolute ethanol per 1ml tri reagent 
used. This was mixed and allowed to stand at room temperature for 2-3min before 
centrifugation at 2,000g for 5min at 4°C. The supernatant was removed and retained for 
subsequent protein isolation. The DNA pellet was washed twice in O.IM sodium citrate, 
10% ethanol solution, allowing the DNA to stand in this solution for 30min for each 
wash. The pellet was then suspended in 75% ethanol and allowed to stand for 10-20min 
at room temperature before freeze drying under a vacuum for 1 Omin and dissolving in 
8mM sodium hydroxide.
2.6.1.3 Protein  Isolation
Protein was precipitated from the phenol-ethanol supernatant retained from the DNA 
isolation procedure by addition of 1.5ml isopropanol per 1ml tri-reagent used. The tubes 
were incubated at room temperature for lOmin before centrifugation at 12,000g. The 
supernatant was discarded and the protein pellet washed 3 times in 0.3M guanidine 
hydrochloride/95% ethanol. The pellet was allowed to stand in this solution for at least 
20min for each wash step. The protein pellet was suspended in absolute ethanol and 
allowed to stand at room temperature for 20min before centrifuging at 7,500g for 5min 
at 4°C. The pellet was then freeze dried under vacuum for lOmin and dissolved in 1% 
SDS solution. The pellet obtained from cultured trophoblasts was suspended in 200pl 
1% SDS solution and stored at -40°C until being assayed for total protein content 
(section 2.4.1).
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2 .6 .2  D evelop m en t o f  hCG m RNA A ssay
In order to quantify the amount of hCG mRNA in either cultured trophoblasts or 
placental tissue chunks, a method was developed based on the Quantikine® mRNA 
assay kit (R&D Systems Europe Ltd.). This is a microplate-based assay that quantifies 
specific mRNA at much lower levels than required for northern blotting and was first 
described as a method of quantifying specific ribosomal RNA from bacterial cells 
(Wicks et al. 1998). The outline of the method is illustrated in figure 2.6.2. Specific 
probes for GAPDH were available from R&D Systems, however specific probes for 
hCG had to be designed and the assay system optimised for their use.
2,6,2.1 D esign o f  Target Specific Probes
From the Genbank mRNA sequence of the hCG pg subunit, two probes were designed to 
hybridise with either end of the mRNA (fig 2.6.2.1).
The first, directed against the 5’ end of the mRNA was 34 bases in length and had the 
sequence:
5’ CAT CTC CAT CCT TGG TGC GTC CCC TGC CTT GTC T 3 \
The second, directed against the 3’ end of the mRNA was 39 bases long and had the 
sequence:
5’ GCG GAT TGA GAA GCC TTT ATT GTG GGA GGA TCG GGG TGT 3’.
The 34 base probe was 5’biotin labelled, while the other was 5’digoxigenin labelled, 
and were both obtained from VH Bio Ltd. (UK). PCR was used to determine the 
specificity of the probes, which meant a complementary probe was required to act as a 
primer, which had the sequence:
5’ AGA CAA GGC AGG GGA CGC ACC A AG GAT GGA GAT G 3’.
This probe was 5’biotin labelled and was also used as a control to exclude the presence 
o f contaminating DNA, To check for the formation of secondary structures within or 
between probes, the sequences were analysed using Net Primer 
(www.premierbiosoft.com). Cross reactivity of the probes with other genes was 
excluded by carrying out a BLAST search (www.ncbi.nlm.nih.gov/blast/) for each 
probe.
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1. Total RNA and target specific 
labelled probes are hybridised at 
65/70°C for I h.
AT
3. Plate is washed and alkaline 
phosphatase labelled anti-digoxigenin 
antibody is added to plate and 
incubated at room temperature for Ih.
2. Hybridisation mixture is transferred 
to a streptavidin coated microtitre plate 
and incubated at room temperature for 
Ih.
4. Plate is washed and substrate is 
added to plate and incubated at room 
temperature for 30min until colour 
develops.
Figure 2.6.2 Basis of plate based hCXi mRNA quantification method. The first well is 
that o f  a standard microtitre plate; while the following three depict one well o f  a 
streptavidin coated capture plate that will bind biotin. Digoxigenin (DIG) labelled 
probe is shown in red and biotin labelled probe is shown in green. Alkaline 
phosphatase (AP) labelled anti DIG antibody is coloured purple.
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AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG AGGGCTGCTGC  
TGTTGCTGCTG CTGAGCATGG GCGGGACATG GGCATCCAAG GAGCCGCTTC
GGCCACGGTG CCGCCCCATC AATGCCACCC TGGCTGTGGA GAAGGAGGGC
TGCCCCGTGT GCATCACCG TCAACACCAC CATCTGTGCC GGCTACTGCC
CCACCATGAAC CCGCGTGCTG CAGGGGGTCC TGCCGGCCCT GCCTCAGGTG 
GTGTGCAACT ACCGCGATGT GCGCTTCGAG TCCATCCGGC TCCCTGGCTG
CCCGCGCGGC GTGAACCCCG TGGTCTCCTA CGCCGTGGCT CTCAGVCTGTC  
AATGTGCACT CTGCCGCCGC AGCACCACTG ACTGCGGGGG TCCCAAGGAC
CACCCCTTGA CCTGTGATGA CCCCCGCTTC CAGGACTCCT CTTCCTCAAA
GGCCCCTTCC CCCAGCCTTC CAAGTCCATC CCGACTCCCG GGGCCCTCGG
ACACCCCGAT CCTCCCACAA TAAAGGCTTC TCAATCCGC
Figure 2.6.2.1 hCG mRNA sequence with forward and reverse probes primers 
indicated by green and red arrows. Intron exon boundaries are indicated by A  and 
Alul restriction enzyme cleavage site by ▼.
2 ,6.2.2 Reverse Transcriptase Polym erase Chain Reaction (Oligo 
DT M ethod)
Reverse transcriptase polymerase chain reaction (RT-PCR) was carried out using the
TrueSprinterT"^ RT-PCR kit (Hybaid UK) on total RNA isolated from three different
placentae. This method involves the use o f  oligo DT primers and was chosen because
this is particularly good for amplifying long mRNA transcripts. The buffers supplied
with the kit had the following composition:
lOx R T - B u f f e r  lOx P C R - B u f f e r
500mM Tris/HCl (pH8.3) 500mM Tris/HCl (pH9 . 1 )
750mM potassium chloride 140mM ammonium sulphate
30mM Magnesium chloride 17.5mM magnesium chloride
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For each RT reaction, Ip l RNA (5|ug, denatured at 70°C for 5min), 0.5|al RNase 
inhibitor (40U/|ul), ljul oligo d(T)i5 primer (20jliM), 2pl lOx RT-Buffer, 4pi 
dithiothreitol (DTT, 50mM), 0.4pl deoxynucleoside triphosphate mix (dNTP-mix, 
40mM), 10.1 pi DEPC treated water and Ipl reverse transcriptase (50U/pl) were 
assembled in a microcentrifuge tube, on ice. The tube was then incubated at 42°C for 
45min, then 70°C for 1 Omin. The resulting cDNA was used in the PCR reaction using 
the hCGp5 primers. For each PCR reaction, 2pi cDNA, 5pi lOx PCR-buffer, 3pi 
forward primer (300nM), 3pi reverse primer (300nM), 1 pi dNTP-mix, 30.5pl water and 
0.5pl Taq/Pwo mix were assembled on ice. A negative control using water instead of 
cDNA was also included. The PCR reaction was carried out on a Hybaid Omni Gene 
thermal cycler with an initial dénaturation step o f 94°C for 5min, then 30 cycles of 
94°C Imin, 65°C Imin and 72°C Imin with a final 1 Omin 72°C elongation step. To 
confirm that the PCR reactions amplified the correct region o f cDNA, the PCR product 
was digested using Alu I restriction enzyme (recognition sequence 5’ AG’^ CT 3% 
Promega, UK) known to cut the 539bp product into two fragments o f 345bp and 194bp. 
For one digest, 15.45pl water, 3pi lOx buffer (60mM Tris-HCl (pH 7.5), 600mM 
sodium chloride, 60mM magnesium chloride and lOmM DTT), 0.3pi ESA (1 mg/ml), 
7.5pi PCR product and 3.75pl Alu 1 restriction enzyme (lOU/pl) were combined and 
incubated at 37°C for 3h. A negative control digest using no enzyme was included for 
each sample. The digest products (mixed with DNA loading buffer) were visualised by 
gel elctrophoresis on 1.5% agarose gel in TAE buffer containing 0.4pg/ml ethidium 
bromide. A DNA marker (pGEM, Promega, UK) was also included on the gels.
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2 ,6 ,2,3 hCG mRNA A ssa y  Procedure
A Quantikine® mRNA base kit was purchased from R&D systems, which included the 
following items:
A hybridisation 96 well microplate 
A streptavidin coated 96 well microplate
21ml each o f calibrator and sample diluent (buffered protein solutions)
21 ml anti-digoxigenin conjugate (alkaline phosphatase conjugated polyclonal 
anti-digoxigenin antibody solution)
100ml lOx wash buffer concentrate 
Substrate (NADPH) and 7ml buffered diluent
Amplifier (alcohol dehydrogenase and diaphorase) and 7ml amplifier diluent 
(ethanol and INT-violet)
6ml stop solution (2N sulphuric acid)
Plate sealers
Float collar (allows microplate to float in water bath)
Biotin and digoxigenin labelled probes were suspended in a diluent made up in DEPC 
treated water, so that once probes and sample were added to the wells of the 
hybridisation plate, probes were at a final concentration of 0.025pM in 2.5xDenhardt’s 
solution (0.05% solution o f BSA, ficoll and polyvinylpyrrolidine, made from 50x 
Denhardt’s, Sigma) with 0.125mg/ml sheared salmon sperm (CP Labs). This solution 
was derived from the original paper describing this method of RNA quantification 
(Wicks et al. 1998). An arbitrary standard curve of placental RNA was constructed by 
diluting total RNA, isolated in bulk from term placental chunks, in calibrator diluent. 
The eight point standard curve ranged from 0-30|ag RNA per well.
The hybridisation plate was washed twice using the supplied wash buffer, before 50|ul 
hCG specific probes were added to the wells of the plate. Next, 150p.l standard or 
appropriately diluted sample RNA was added in duplicate to the wells o f the plate, 
which was then sealed, placed in a float collar and incubated at 70^C in a water bath for 
60min. The streptavidin-coated plate was washed twice before 150 )l i 1 of the RNA probe 
mixture was transferred from the hybridisation plate to the streptavidin plate. This was 
incubated at room temperature for 60min on a plate shaker before washing 4 times with
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the supplied buffer. Next, 200 j l l 1 anti-digoxigenin conjugate was added to the wells, 
which were sealed and incubated at room temperature for 60min on a plate shaker. The 
plate was washed 6 times as before, then 50pl substrate solution was added to each 
well, and the plate incubated at room temperature for 60min on a plate shaker. An equal 
volume (50|al) o f amplifier solution was added to each well, and the plate incubated at 
room temperature for 3Omin on a plate shaker. Finally, 50pl stop solution was added to 
each well, and the absorbance determined at 492nm corrected at 690nm. The results 
were extrapolated by linear regression from the standard curve plotted on a log/log 
scale.
Probes specific for GAPDH were obtained from R&D Systems and these assay results 
used as a control against which the hCG results could be standardised. The protocol for 
this assay was the same as that outlined for the hCG assay except that probes were 
supplied in a diluent rather than being diluted in the Denhardt’s/salmon sperm diluent, 
and hybridisation was carried out at 65°C.
2 .6 .3  N orthern  B lotting
2,6,3,! Gel E lectrophoresis and Transferring RNA
RNA samples (1, 2, 5, 10 or 20pg) were mixed 1:2 with RNA loading buffer and loaded 
into the wells of a 1% agarose, denaturing formaldehyde (0.6M) gel in MESA buffer. 
An RNA marker (0.2-10Kb) was also included on the same gel to provide an indication 
of the size of the final bands. The gel was run at 80 volts for approximately Ih until 
good separation of the RNA marker could be seen. After running, the gel was washed in 
DEPC treated water to remove the formaldehyde and then soaked in 0.05M sodium 
hydroxide to partially hydrolyse the RNA. It was washed again in water before soaking 
for 45min in 20xSSC. The RNA was transferred to a nylon membrane (Hybond-N, 
Amersham Life Science, UK) by capillary blotting overnight using 20xSSC buffer. 
RNA transfer was confirmed by viewing the gel on a UV transluminator to ensure no 
RNA remained. The membrane was briefly washed, then baked at 80°C for 3!4h to fix 
the RNA to the membrane.
2,6,3,2 Probe P reparation
The following buffers were used during probe preparation;
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STET Buffer (pH 8) lOx Restriction Digest Buffer
8% sucrose lOOniM Tris-HCL (pH7.5),
5% triton-X-100 500iuM potassium chloride
50mM EDTA 70mM magnesium chloride
50mM Tris lOmMDTT
E.Coli containing a plasmid with beta-hCG5 DNA sequence (Talmadge et al. 1984) 
were obtained from the American Type Culture Collection and cultured for 24h in LB- 
broth (Gibco BRL) containing 50jug/ml ampicillin. The plasmid (pBR322) was 
extracted using the triton-lysis mini-prep method. The cells were suspended in 350jul 
ice cold STET buffer to which 25jul freshly prepared lysozyme (lOmg/ml) was added. 
This mixture was boiled for 90sec then spun at 2,500g for 15min. The supernatant was 
transferred to a fresh tube and the centrifugation/removal of supernatant procedure was 
repeated 8-10 times until as much supernatant as possible was collected. The DNA was 
extracted from the supernatant by addition of V2 volume phenol:chloroform mixture 
(1:1) then centrifuging at l,200g and collecting the supernatant. The DNA was 
precipitated from this solution by addition o f isopropanol and 3M sodium acetate than 
incubating in dry ice for 3Omin. The DNA pellet was washed with 95% ethanol and re­
suspended in water.
The resulting DNA was digested using Kpn I (recognition sequence 5’ G GTA'^CC 3 \  
Promega, UK) and Sma 1 (recognition sequence 5’ CCC^GGG 3% Promega, UK) 
restriction enzymes to elucidate the structure of the construct, and determine which 
section should be used as a probe. The digests comprised 15.75 j l i 1 water, 2 .5|l i 1 
lOxbuffer, 0.25pl BSA (1 mg/ml), 5|ul DNA, 3p,l enzyme. These were incubated for Ih 
at 37°C in the case of Kpn I and Ih at 25°C in the case of Sma I. The digest products 
were mixed with 5pi DNA loading buffer and visualised by gel electrophoresis (fig 
2.6.3.2a) on a 1% low melting temperature agarose gel (NuSieve GTG agarose, 
Flowgen) in TAE buffer. From these results the structure of the construct could be 
established (fig 2.6.3.2b) A large scale Sma I digest was carried out to produce enough 
of the probe to be excised from the gel and used in northern blotting. The excised piece 
o f gel was weighed and 3pi water added to it for each pg o f gel and boiled for 2min.
I l l
The probe was ’“P labelled using the RmT random primer labelling kit (Stratagene). 
Probe solution (42pl) was boiled for 5min before 5pi deoxycytidine-5’-triphosphate [a- 
'^P] (dCTP) and 3pl magenta DNA polymerase were added and incubated at 37°C for 
20min. Labelled probe was separated from unincorporated nucleotides using the 
MicroSpin G-50 Column (Amersham Parmacia Biotech). The column was pre-spun for 
Imin at 735g and transferred into a fresh supporting 1.5ml tube. The probe mixture was 
carefully layered on to the sephadex in the column before centrifugation at 735g for 
2min. The purified sample was collected in the supporting tube and used to probe the 
fixed membrane
Sma 1
Kpn I , , Sma I non
5U y(lbp
4<i7:bp
Vi.Mbp
2(0('bp
IMbbp
Figure 2.6.3.2a Results of digesting 
liC'C) plasmid with Kpn I, 
Smal (XKpnl, Sma I and undigested 
plasmid (non). A DNA marker was 
also run (L). Both photographs are 
o f the same gel, with the lower 
showing a higher magnification to 
allow visualisation o f  the 5()0hp 
fragment. Approximate fragment 
sizes generated by each combination 
were:
Kpn I - 2 at 4.2Kb;
KpnIdcSmal 4.2Kb, 2Kb, IKb, 2 at 
500bp;
Sma I 7Kb, IKb, 500bp.
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Sma I
1 kb
Sma I 2 kb
I n s e r t0.5 kb
Sma I P i 'o b e
0.5 kb
Kpn I Kpn I
4.2 kb
Figure 2.6.3.2b Graphical representation of pBR322 plasmid and insert, highlighting 
the area that was subsequently used as a northern blotting probe. This diagram was 
constructed using the results illustrated in fig  2.6.3.2a.
2.6,3.3 H ybrid isa tion
Following 3'/2h o f  baking, the membrane was soaked in DEPC treated water for 2min 
then placed in a sealing glass tube to which 5ml preheated QuikHyb hybridisation 
solution (Stratagene) was added. The membrane was pre-hybridised for 20min at 68°C 
in a rotating oven. Meanwhile, 150pl sheared salmon sperm DNA was added to the 
probe and boiled for 5min. This was added to 1ml QuikHyb, which was then added to 
the hybridisation tube. The membrane was hybridised for 2h at 68°C. Following 
hybridisation, the membrane was washed at room temperature in 2xSSC, 1%SDS then 
IxSSC, 1%SDS and O.lxSSC, 0.1% SDS. The membrane was then wrapped in plastic 
and placed on Kodak autoradiography film in a light proof cassette containing 
intensifying screens and exposed at -40°C for up to 96h. Film was developed in a Fuji 
RGII x-ray film processor.
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2 .6.4 DNA A ssay
To standardise RNA measmements in each sample, the total DNA content was 
measured to give an indication of cell number. This was carried out by a method 
modified from that of Labarca and Paigen (1980). The fluoroclii'ome Hoechst 33258 
(bisbenzimide) preferentially binds the minor groove of DNA (preferring A-T rich 
regions) under high salt conditions, allowing the concentration of DNA to be 
determined in the presence of proteins, RNA, nucleotides and buffer reagents. When 
bound to DNA, Hoechst 33258 dye has an excitation peak at 360nm and an emission 
peak at 460nm. Because Hoechst 33258 preferentially binds to A-T sequences, a 
standard curve should be constructed from DNA with a similar A-T content to the 
samples.
Before commencing the assay, DNA standards (1 mg/ml, lOOpg/ml and lOpg/ml) were 
prepared using DNA type XIII from human placenta (Sigma) in distilled deionised 
water. A 2pg/ml solution of Hoechst 33258 was prepared containing lOmM Tris, ImM 
EDTA and 2M sodium chloride in distilled deionised water. The DNA assay was carried 
out in black wall microtitre plates (Jencons, UK) suitable for fluorescence-based assays. 
Each well received 5 pi sample or the appropriate quantity of DNA standard (see table 
2.6.4) in duplicate. Next, 200pl Hoechst solution was added to each well, which was 
mixed thoroughly before the plate was transferred to a Wallac Victor^ 1420 fluorimeter 
(Perkin Elmer, Finland). The excitation filter was set to 355nm, and the emission filter 
was set to 460nm. The fluorescence emitted from each well was determined and the 
concentration of DNA in the samples extrapolated from the standard curve using 
Multi Calc software.
114
Total DNA per well DNA stock solution used Volume of DNA
1 mg/ml 2pl
Ifig lOOpg/ml lOpl
O.Spg 1OOpg/ml 5 pi
0.1 pg lOpg/ml lOpl
O.OSpg lOpg/ml 5 pi
0.02pg lOpg/ml 2pl
Table 2.6.4 Construction o f  DNA standard curve using previously prepared stock 
solutions.
2 .6 .5  Taq Man® R eal T im e PCR
Real time PCR allows the quantitative analysis of mRNA for specific genes using a 
small sample size. The RNA sample was firstly reverse transcribed using random 
primers. Real time PCR analysis was then earned out using the ABI Prism® 7700 
sequence detection system. Standard PCR primers are used in the reaction, along with 
target specific probes that contain a fluorophore (5’ TET or 5’ F AM) and a fluorogenic 
quencher (3’ TAMRA). As long as the fluorophore and quencher are both linlced to the 
probe, fluorescence is quenched. During the PCR amplification, the probe binds to the 
complementary cDNA strands and the exonuclease activity of the Taq polymerase 
cleaves the fluorophore from the probe. This means that the fluorophore is no longer 
quenched by TAMRA so the fluorescence can now be measured. The amount of 
fluorescence is directly proportional to the amount of target DNA accumulation during 
the PCR cycles and is recorded by the TaqMan® machine. After the PCR reactions have 
been completed amplification curves are created for each sample where the number of 
PCR cycles is plotted against the apparent amount of PCR product at that cycle (ARn 
value). These amplification plots can be compared for each sample and the gene of 
interest can be quantified relative to a housekeeping gene by comparing the number of 
cycles each sample requires to reach the threshold cycle (Ct) that is the point at which 
the amplification curve reaches a plateau.
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2, 6,5>i D esign o f  T arget Specific Prim ers and Probes
Primers and probes specific to hCGp mRNA and the mRNA for the housekeeping gene, 
cyclophilin A (PPIA) previously described by Frendo et al (2000) were obtained from 
VH Bio Ltd. (UK). The hCG probe was labelled with a 5’-FAM fluorescent label and 
the PPIA probe was labelled with 5’-TET. Both probes had a 3’ TAMRA fluorescence 
quencher label. The specificity of the probes was confirmed by carrying out a BLAST 
search (www.ncbi.nlm.nih.gov/blast/). To further confirm the specificity of the probes a 
negative control cDNA was used which was known not to express hCG mRNA, and a 
“no cDNA” control (water) was also included in each run. The sequences of probes and 
primers are detailed in table 2.6.5.1.
Gene Sequence
hCG p fwd primer 5’-GCTACTGCCCCACCATGACC-3 ’
hCG P rev primer 5’-ATGGACTCGAAGCGCACATC-3’
hCG p probe 5’-FAM-CCTGCCTCAGGTGGTGTGCAACTACC-TAMRA-3’
PPIA fwd primer 5 ’-GTCAACCCCACCGTGTTCTT-3 ’
PPIA rev primer 5 ’ -CTGCTGTCTTTGGGACCTTGT-3 ’
PPIA probe 5 ’-TET-AGCTCAAAGGAGACGGCCCA-TAMRA-3 ’
Table 2.6.5.1 Sequences o f  probes and primers used in TaqMan® real time PCR 
analysis.
2,6.5.2 Reverse Transcriptase Polym erase Chain R eaction
(Random  P rim er M ethod)
RT-PCR was carried out using the Reverse Transcription System (Promega) on total 
RNA isolated from placental trophoblast cultures. This method involves the use of 
random primers and was chosen because neither end of the mRNA transcripts is 
preferentially transcribed. The supplied RT buffer had the following composition: 
lOx RT-Buffer (pH9)
1 OOmM Tris-HCl 
500mM Potassium chloride 
1% Triton-X-100
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For each RT-PCR reaction, 2|al RNA (2pg, denatured at 70°C for 5min), 8pi 
magnesium chloride (25mM), Ipl RNasin RNase inhibitor (40U/pl), 2pi random 
primers (0.5pg/pl), 4pl lOx RT-Buffer, 4pl dNTP-mix (lOmM), 17.5pl nuclease free 
water and 1.5 pi reverse transcriptase (20U/pl) were assembled in a micro centrifuge 
tube, on ice. The tube was then incubated at room temperature for 1 Omin, 42°C for 
3Omin, and then 95°C for 5min. The resulting cDNA was stored at -40°C until used in 
TaqMan® analysis.
<2.6.5.3 Real Time PCR Procedure and O ptim isation
The real time PCR reaction was assembled in a 96 well PCR reaction plate with 
optically clear sealing strips. TaqMan® universal PCR master mix was obtained from 
Applied Biosystems (UK). This is a 2x reaction mix containing all of the components 
required for the PCR reaction, excluding primers and probes. Both primers and probes 
were diluted to a concentration of 5pmol/pg. Primer concentrations of 50, 300 and 
900nm were tested to find the optimum working concentration. Using this primer 
concentration, probe concentrations of 25, 50, 75, 100, 125, 150, 175 and 200nm were 
tested. The optimum primer or probe concentration is determined by finding which 
gives the lowest Ct value i.e. reaches the threshold cycle fastest, and the highest product 
yield as determined by the highest ARn value. This optimisation procedure was carried 
out for both the hCG and PPIA primers and probes. Tables 2.6.5.3a and 2.6.5.3b give 
the Ct and ARn values obtained for each primer and probe concentration that was 
studied. A compromise between the best ARn and Ct values usually has to be chosen, 
and also the practicality of which primer and probe concentrations are easiest to work 
with if two concentrations give similar results. Optimum primer concentrations for both 
hCG and PPIA was 300nM and optimum probe concentrations were both 225nM.
For each multiplex PCR reaction, 12.5p,l 2x universal PCR master mix, 1.74pl nuclease 
free water, 1.5 pi each fwd and rev primer (final concentration 300nM), 1.13pi each 
probe (final concentration 225nM) and 2.5pl cDNA was combined in the reaction tube 
to give a total volume of 25pi. All samples were studied in duplicate. This was 
transferred to the pre-heated TaqMan® machine and a standard real time PCR reaction 
was carried out with the following steps. The first step was 50°C for 2min then a
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dénaturation step of 95°C for lOmin, which also triggers the hot start Taq polymerase in 
the reaction mix. Then 40 cycles of 95°C for 15sec and 60°C for 60sec were carried out. 
This is a two-step PCR reaction that allows elongation to occur as the temperature in the 
tube is returning to the annealing temperatm*e.
Fwd primer (nM) Rev primer (nM) HCG PPIA
ARn Ct ARn Ct
50 50 2.0015 18.29 0.256825 22.05
50 300 2.5483 17.98 -0.014061 40
50 900 2.46465 17.945 0.192485 23.24
300 50 1.36035 17.13 0.32085 21.475
300 300 2.26395 16.585 0.40897 21.89
300 900 2.49335 16.625 0.41286 22.28
900 50 0.009726 40 0.191795 21.855
900 300 2.1004 16.45 0.465275 21.74
900 900 2.7973 16.345 0.461495 21.92
Table 2.6.5.3a Primer concentrations tested fo r  both hCG and PPIA primers and
resulting ARn and Ct values obtained. The primer concentrations that were chosen
use are highlighted in bold text.
Probe (nM) hCG PPIA
ARn Ct ARn Ct
25 1.2283 17.36 0.19911 23.38
50 1.42985 17.335 0.25467 22.99
75 1.97975 17.12 0.289475 22.665
100 2.01445 17.145 0.33488 22.6
125 2.5742 16.935 0.43974 22.205
150 2.6911 16.825 0.49993 21.655
175 2.44585 17.069 0.486405 21.92
200 2.7787 16.9 0.579745 21.985
225 2.94035 16.79 0.57775 21.54
Table 2.6.5.3b Probe concentrations tested fo r  both hCG and PPIA primers and the 
resulting ARn and Ct values obtained. The probe concentrations that were chosen for  
use are highlighted in bold text.
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2 .6 .5*4 TaqMan® D ata  A n alysis
In order to express the hCG mRNA results relative to both the standard calibrator 
sample and the quantity of housekeeping gene PPIA mRNA, results were expressed as
2-AAct ig calculated for each sample using the average Ct value from the duplicate 
reactions for both hCG and PPIA. Firstly the ACt value for each sample was calculated 
by taking the reference (PPIA) Ct away from the target (hCG) Ct (ACt=Ctiarget-Ckef). 
Next the AACt for each sample was calculated by taking the ACt value for the calibrator 
sample away from the ACt for each of the individual samples (AACt=AChampie- 
ACt^ aiii^ jator)- Filially the AACt value of each sample was used to calculate This is
the value that was used to represent the quantity of hCG mRNA present in the samples 
corrected against the housekeeping gene, and relative to the calibrator sample. For the 
calibrator sample, this value should be approximately 1.0.
2 .7  S ta t is t ic a l  M e th o d s
2.7.1 C oefficient o f  V ariation  (cv)
The coefficient of variation (CV) gives a measure of assay reproducibility and is the 
standaid deviation (SD) expressed as a percentage of the mean (X). The inter and intra 
assay CV was calculated using the equation:
( f )CV=100x X
2.7.2 R egression  A nalysis
This analysis gives an estimation of the relationship between a dependent variable 
(gestation) and an independent variable (marker level). Various models were used, the 
equations for which are outlined below. From the regression equation, median marker 
levels were determined at each week of gestation for use in calculation of MoM values.
Linear: y= a +bx
Quadratic: y=a+bx+cx^
Growth:
Inverse: y=a+(b^x)
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2 .7*3 M edians, M eans and  P ercen tiles
2 ,7 .3 .! M edians
The median is the middle value when cases are sorted in ascending order, also called the 
50th percentile. If  there is an even number of cases, the median is the average of the two 
middle cases when they are sorted in ascending or descending order. The median is a 
measure of central tendency and is not sensitive to outlying values and is therefore used 
when the data set is skewed.
2 .7 .3 .2  M eans
The mean gives the central value of a data set. It is calculated by dividing the sum of all 
cases by the number of cases. This measure is only used in sample groups with an even 
distribution.
■2.7.3.3 1 0 *^  ^and Percentiles
The 10“' and 90* percentiles are the values below which 10 and 90 percent o f cases fall.
2.7 .4  M ultip les o f  th e  M edian (M oM )
Control and DS marker levels were converted to multiples o f the control median (MoM) 
at the appropriate week of gestation. This allows for gestational variation in marker 
levels, and is calculated using the equation:
Marker Level
M o M = -------------------------------------------------------------------
Regresses Median Level at Appropriate Gestation
2.7.5 M easures o f  V ariable D isp ersion
2 .7 .5.1 S tandard  D eviation
The standard deviation (SD) is a measure of dispersion around the mean, and is 
described as the square root o f the variance. Standard deviation is calculated using the 
following equation where y=individual case values and N=number of cases.
(N-1)
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2 .7*5*2 Standard  E rror o f  M ean (sent)
The standard error of the mean (sem) gives a measure o f how much the value o f the 
mean may vary from sample to sample taken from the same distribution. It is calculated 
by dividing the standard deviation by the square root of the number of cases.
2.7 .6  A nalysis o f  V ariation  B etw een  Sam ple G roups
2 .7.6.1 M ann-W hitney U T est
This is a nonparametric test, which is equivalent to the parametric t-test. It tests whether 
two independent samples are from the same population. The distributions o f both groups 
are analysed by ranking values in ascending order, and the number of times a value in 
the first group precedes a value in the second group is calculated (U). If one group has a 
higher proportion of high ranks, then both groups are likely to have different 
distributions. This is deemed statistically significant if p<0.05.
2 .7.6.2 Sign Test
This is a nonparametric test used with two related samples to test the hypothesis that 
two variables have the same distribution. The differences between the two variables for 
all cases are computed and classified as either positive, negative, or tied. If the two 
variables are similarly distributed, the numbers of positive and negative differences will 
not be significantly different. If one group has more positive differences, then the 
variables are likely to have different distributions. This is deemed statistically 
significant if  p<0.05.
2 .7.6 .3  General L inear M odel U nivariate (GLM U nivariate)
This test uses regression analysis and analysis of variance (ANOVA) to determine the 
effect of various factors or variables on one dependant variable. The GLM Univariate 
tests null hypotheses about the effects of other variables on the means of various 
groupings of a single dependant variable. Interactions between factors as well as the 
effects of individual factors can also be studied. This test can be used on balanced (each 
cell has the same number of cases) or unbalanced models. If the overall F test has shown 
a significance (p<0.05), then differences between the means of individual groupings can 
be further investigated using a post hoc test.
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2 .7.6.4 One-W ay ANOVA
The One-Way ANOVA procedure produces a one-way analysis of variance of the effect 
of a dependent variable on a single factor (independent) variable. Analysis of variance is 
used to test the hypothesis that means are equal. This technique is an extension of the 
two-sample t-test.
2.7.6.5 P aired Sam ples T-Test
The Paired-Samples t-test compares the means o f two variables for a single group. 
Firstly it calculates the differences between values of the two variables for each case and 
then tests whether the average differs from 0. A difference is deemed significantly 
different if p<0.05.
2.7.6.6 W ilcoxon M atched P airs Signed Ranks Test
This is a nonparametric test, which is equivalent to the parametric paired t-test. This test 
is used to determine if two related variables have the same distribution. Unlike the Sign 
Test, information on the magnitude o f difference between the paired samples is taken 
into account and more weight is given to pairs that show large differences than to pairs 
that show small differences. The absolute differences between pairs are ranlced and 
information on the number of positive differences, negative difference and ties is 
reported. If there is a significant difference in the distribution of the pairs of variables, 
p<0.05.
2.7.7 P earson  C orrelation  C oefficient (r)
The degree of linear association between two variables was quantified using this test. 
Values of the correlation coefficient (r) range from -1 to 1, with a minus answer 
indicating a negative correlation and a positive answer indicating a positive correlation. 
The absolute value indicates the strength of correlation, with larger values indicating 
stronger relationships. If the significance level of the correlation is less than 0.05, then 
there is a significant association between these variables.
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Section 3
Results
3-1 L e v e ls  o f  I n h ib in s  a n d  G r o w th  F a c to r s  in  
T is s u e s  a n d  F lu id s
3.1.1 Inhib in-A  L evels
3.1.1.1 Placenta
Regressed median control levels of inhibin-A in placental tissue, expressed as pg/pg 
protein, were calculated using linear regression on logio transformed data, giving the 
equation y=0.001758-0.024194x (figure 3.1.1.1a). Actual and regressed control median 
values are outlined in table 3.1.1.1. All results were converted to MoMs using the 
regressed median value at the appropriate gestation. The median control MoM was 1.04, 
while the DS median MoM was significantly elevated to 1.46 (p=0.041). Individual 
cases are illustrated in figure 3.1.1.1b.
Gestation Inhibin-A Medians (pg/pg protein) 
(weelcs) Regressed Observed
Activin-A Medians (pg/pg protein) 
Regressed Observed
14 4.605 3.920 58.126 67.188
15 4.355 8.020 56.655 45.799
16 4.118 4.270 55.221 73.134
17 3.895 4.090 53.824 36.903
18 3.684 3.090 52.461 88.372
19 3.484 3.69 51.134 64.194
20 3.295 5.050 49.840 22.750
21 3.116 / 48.578 /
22 2.947 / 47.349 /
23 2.787 / 46.150 /
Table 3.1.1.1 Observed and regressed control placental median inhibin-A and activin-A 
levels at each week o f  gestation. Results are expressed as a ratio o f  protein 
concentration.
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Figure 3.1.1.1a Individual piaceniai inhihin-A control data points flog/o pg pg protein), 
with actual and regressed median and lO'^ ' and 90' '^ percentile lines plotted.
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Figure 3 .1.1.1b l)S  placental inhihin-A K4oMs.
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3 ^t,i.2 M aternal Serum
Regressed median control levels o f  inhibin-A in maternal serum, expressed as pg/ml, 
were calculated using a quadratic curve fit on logio transformed data resulting in the 
equation y=5.693234-0.38282x+0.010447x“ (figure 3.1.1.2a). Actual and regressed 
control median values are outlined in table 3.1.1.2.
♦  control values
 regressed median
 observed median
■ - - 10th percentile
■ - - 90th percentile
3.10
2 90
2.50OX)
v=5.6932.t4-0.38282\+0.010447x
2 30
OX)
.90
.70
Gestation (weeks)
Figure 3.1.1.2a lndividi4ul maternal serum inhihin-A control data points (logm pg ml), 
with actual and regressed median and  / (f' and 9(f' percentile lines plotted.
Gestation Inhibin-A Medians (pg/ml) Activin-A Medians (pg/ml) 
(weeks) Regressed Observed Regressed Observed
15
16
17
18
225.88
144.84
140.16
204.70
219.12
180.14
116.57
198.34
3593.5
3140.7
3740.7
5393.7
3575
3027.5
3907.5 
5010
Table 3.1.1.2 Observed and regressed control serum inhihin-A and activin-A levels at 
each week o f  gestation. Re.sults are expressed as pg ml.
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All results were converted to MoMs using the regressed median value at the appropriate 
gestation. The median control MoM was 1.03, while the DS median MoM was 
significantly elevated to 2.06 (p<0.0001). Individual cases are illustrated in figure 
3.1.1.2b.
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Figure 3.1.1.2b DS maternal serum mhibin-A MoMs
3.1.2 Activin-A  L evels
3 .1.2,1 Placenta
Regressed median control levels o f  activin-A in placental tissue, expressed as pg/pg 
protein were calculated using a growth curve fit on non-transformed data, resulting in 
the equation y=e'^ 1 3.1.2.1a). Actual and regressed control median
values are outlined in table 3 .1.1.1. All results were converted to MoMs using the 
regressed median value at the appropriate gestation. The median control MoM was 1.05, 
while the DS median MoM was significantly elevated to 1.62 (p=0.0098). Individual 
cases are illustrated in figure 3.1.2.1b.
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Figure 3.1.2.1a Individual piaceniai aciivin-A control data points (pg. pg protein), with
actual and regressed median and l(f^' and 90'" percentile lines plotted.
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Figure 3 .1.2.1b DS placental activin-A MoMs.
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3 -1-2 .2  M aternal Serum
Regressed median control levels o f  activin-A in maternal serum, expressed as pg/ml, 
were calculated using a quadratic curve fit on logio transformed data resulting in the 
equation y=2078.172036x-55.587912x“- l 5343.373248 (figure 3.1.2.2a). Actual and 
regressed control median values are outlined in table 3.1.1.2. All results were converted 
to MoMs using the regressed median value at the appropriate gestation. The median 
control MoM was 1.00, while the DS median MoM was significantly elevated to 1.26 
(p=0.01 ). Individual cases are illustrated in figure 3.1.2.2b.
♦  control values
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Figure 3.1.2.2a Individual maternal serum activin-A contra! data points (logio pg ml), 
with actual and regressed median and / / / '  and 90' '^ percentile lines plotted.
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3.1.3 P lacental E xpression  o f  Inh ib in /A ctiv in  Subunits
3 .1.3 ,!  Inhibin/Activin a  and f3\ Subunit Localisation
ImmunohistocheiTiistry shows that the inhibin-a and the inhibin/activin (3a subunits 
were mainly localised to the trophoblast layer o f  placental tissues, with both syncytium 
and cytotrophoblast showing positive reactivity (fig 3.1.3.1a & 3.1.3.1b). Syncytial 
knots showed positive staining for both subunits. Lighter staining was also noted on the 
endothelium of blood vessels, particularly in the case o f  (3a subunit staining. Stromal 
cells, some o f  which were characteristic o f  Hofbauer cells, also showed positive staining 
for both subunits. No staining was evident in negative control tissue sections (tig 
3.1.3.1c).
3 .1.3 .2  Com parison o f  S tain ing In tensity
Two different scorers assessed the staining intensity for both antibodies in the 
trophoblast layer and stroma o f placental villi from 20 matched pairs o f  DS and control 
sections. The staining for both antibodies tended to be stronger in the DS sections when 
compared with controls (fig 3.1.3.1a & 3.1.3.1b). The sign test showed this to be
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significantly different only in the case o f  (3a  subunit staining. Table 3 . 1. 3.2  shows 
scoring intensity for each pair o f  sections and summary is illustarated in fig 3 . 1. 3 .2 . 
Analysis o f  the effect o f  scorer on scoring level by one-way ANOVA revealed no 
significant difference between or within scorer (p=0.7).
Figure 3.1.3.1a Immunohistochemical localisation o f  inhihin a-suhunits in 
mid-trimester control (A) and DS (B) placental sections. k=syncytial knot, 
e endothelium, t trophoblast. Size bar in A =0.05mm, and in B=0.1 mm.
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Figure 3.1.3.1b Immunohistochemical localisation o f  inhibin/activin p\-suhunits in 
mid-trimester control (A) and DS (B) placental sections, k syncytial knot, 
e endothelium, t trophoblast. Size bar in A =0.05mm, and in B=0.1 mm.
Figure 3.1.3.1c
Negative control section (primary 
antibody was replaced with 
control immunoglobulin fraction) 
Size bar 0.1 mm.
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Alpha Subunit Beta A Subunit
Gestation (weelts) Trophoblast Stroma Trophoblast Stroma
14 +ve +ve +ve +ve
14 +ve +ve +ve +ve
14 +ve +ve tie tie
15 +ve +ve tie tie
16 +ve +ve +ve +ve
16 tie -ve tie H-ve
16 -ve tie +ve +ve
17 tie tie tie +ve
17 tie tie +ve +ve
17 +ve +ve +ve tie
17 +ve tie +ve tie
18 tie +ve tie -ve
18 +ve tie tie -ve
18 +ve tie +ve +ve
18 +ve -ve tie tie
19 tie tie +ve -ve
19 -ve +ve tie tie
19 -ve -ve -ve +ve
19 tie -ve tie tie
20 tie tie tie +ve
Total -ve 3 4 1 3
Total ties 7 8 10 7
Total +ve 10 8 9 10
p value from sign 0.0923 0.3877 0.0215 0.0923
Table 3.1.3.2 Ties and positive and negative differences shown in staining intensity
each matched pair o f  slides for staining with both subunits. Total number o f  pai
falling into each category is summarised at the foot o f  the table, with the p  value
determined by the sign test, also shown.
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Figure 3.1.3.2 Bar chart o f  negative differences, positive differences and ties in inhihin 
a  and Pa subunit staining intensity in paired tissue sections. * p<().05 according to sign 
test.
3.1.4 E piderm al G row th Factor (EOF) L evels
3 .1.4.1  Placenta
A preliminary study o f  the concentration o f  EG F in placental samples indicated that 
placental levels o f  this growth factor reflected only the amount o f  blood remaining in 
the placental extract. This was noted due to the large range of  concentrations between 
samples and also because samples that were particularly blood stained had the highest 
concentration o f  EOF. Consequently, placental levels could not be further studied due to 
the confounding effects o f  contaminating blood.
3 .1.4 .2  M aternal Serum
Regressed median control levels o f  EOF in maternal serum, expressed as pg/ml, were 
calculated using a quadratic curve fit on non transformed data resulting in the equation 
y=30641.263333-3680.136667x+l 13.833333x“ (figure 3.1.4.2a). Actual and regressed 
control median values are outlined in table 3.1.4.2. All results were converted to MoMs
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using the regressed median value at the appropriate gestation. Median levels o f  EGF in 
maternal serum from DS pregnancies did not differ significantly from the control group. 
Control median MoM was 0.968 while the median in DS pregnancies was 1.026MoM 
(p=0.639). Individual cases are illustrated in figure 3.1.4.2b. Maternal serum levels of 
EGF were compared with 10 non-pregnant serum samples (5 female and 5 male). 
Median pregnancy levels were found to be significantly higher (958.3pg/ml versus
382.5 pg/ml, p<0.001).
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Figure 3.1.4.2a Individual maternal serum FCIT' control data points (pgml), with
actual and regressed median and 10"' and 90' '^ percentile lines plotted.
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Figure 3 .1.4.2b DS maternai serum EGF MoMs.
Gestation EGF M edians (pg/ml) TGPPi M edians (pg/ml)
(weeks) Regressed Observed Regressed Observed
15 1051.71 1072.1 22894 30565
16 900.41 882.7 14081 15370
17 976.77 958.3 12397 11240
18 1280.80 1020.2 15625 12410
Table 3.1.4.2 Observed and regre.ssed control serum EGb' and TGb'pi levels at each 
week of gestation. Results are expressed as pg/ml.
3 .1.4 .3  M aternal Urine
Regressed median control levels of EGF in maternal urine, expressed as pg/mg 
creatinine, were calculated using an inverse curve fit on logio transformed data resulting 
in the equation y=4.693877+(1.7I7917-;-x) (figure 3.1.4.3a). Actual and regressed 
control median values are outlined in table 3 .1.4.3. All results were converted to MoMs 
using the regressed median value at the appropriate gestation. The median control MoM 
was 0.932, while the DS median MoM was significantly reduced to 0.726MoM 
(p=0.011 ). Individual cases are illustrated in figure 3.1.4.3b.
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Gestation (weeks) EGF M edians (pg/mg creatinine)
Regressed Observed
10 73395.6 39050.1
11 70802.7 108916.2
12 68713.2 41035.4
13 66991.5 76402.2
14 65552.6 54246.9
15 64329.5 681 13.5
16 63277.6 80188.6
17 62363.4 57883.8
18 61563.0 46146.2
19 60854.1 65952.1
20 60224.0 56206.8
21 59659.5 75442.8
Table 3.1.4.3 Observed and repressed control maternal urine EC lb' at each week o f  
gestation. Results are expressed as pg mg creatinine.
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Figure 3.1.4.3a Individual maternal urine EOb control data points (logm p g m g  
creatinine), with actual and regressed median and l ( f '  and 90''' percentile lines plotted.
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Figure 3 .1.4.3b DS maternal urine A(;/' MoMs.
3 .1.4 .4  Am niotic Fluid
Regressed median control levels o f  EGF in amniotic fluid, expressed as pg/ml, were 
calculated using an inverse curve fit on non transformed data resulting in the equation 
y=10.743525-(88.036156-^x) (figure 3.1.4.4a). Actual and regressed control median 
values are outlined in table 3.1.4.4. All results were converted to MoMs using the 
regressed median value at the appropriate gestation. The median control MoM was 
0.991, while the DS median MoM was significantly reduced to 0.499MoM (p<0.0001 ). 
Individual cases are illustrated in figure 3.1 4.4b.
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Gestation
(weeks)
15
16
17
18
19
20
EGF Medians (pg/ml) 
Regressed Observed
4.874
5.241
5.565
5.823
6.110
6.341
4.621
4.137
5.349 
7.321 
4.646
7.350
TGFpi Medians (pg/ml) 
Regressed Observed
432.707
403.586
376.425 
351.091 
327.463
305.425
391.80
390.65
480.65 
424.85 
335.30 
180.47
Table 3.1.4.4 Observed and repressed control amniotic fluid bXfb' and IXjI^'pi levels at 
each week o f  gestation. Results are expressed as pg ml.
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Figure 3.1.4.4a Individual amniotic fhdid EOF control data points (pg ml), with actual
and regressed median and 10'^ ' and 90''  ^percentile lines plotted.
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Figure 3 .1.4.4b DS amniotic fluid IXjF MoMs.
3.1.5 T ransform ing G rowth Factor Beta i  (TGFpi) L evels
3 .1.5.1 Placenta
Regressed median control levels o f  TGPPi in placental tissue, expressed as pg/pg 
protein were calculated using a quadratic curve fit on non-transformed data, resulting in 
the equation y = l0.309955-0.984298+0.028265x^ (figure 3.1.5.1a). Actual and regressed 
control median values are outlined in table 3.1.5.1. All results were converted to MoMs 
using the regressed median value at the appropriate gestation. The median control MoM 
was 1.02, while the DS median MoM was significantly reduced to 0.675 (p=0.002). 
Individual cases are illustrated in figure 3.1.5.1 b.
1 3 9
Gestation (weeks) TGFpi Medians (pg/pg protein)
Regressed Observed
14 2.070 2.089
15 1.905 1.550
16 1.797 2.139
17 1.745 1.731
18 1.750 1.616
19 1.812 1.560
20 1.930 2.254
Table 3.1.5.1 Observed and regressed control placental TGFPi at each week o f  
gestation. Results are expressed as pg/pgprotein.
3.1,5,2 M aternal Serum
Regressed median control levels o f TGFpi in maternal serum, expressed as pg/ml, were 
calculated using a quadratic curve fit on logio transformed data resulting in the equation 
y=26.2215-2.6259x-0.779x^ (figure 3.1.5.2a). Actual and regressed control median 
values are outlined in table 3.1.5.2a. All results were converted to MoMs using the 
regressed median value at the appropriate gestation. The median levels of TGFPi in 
maternal serum from DS pregnancies did not differ significantly from the control group. 
Control median MoM was 0.983 while in DS pregnancies it was 0.927MoM (p=0.720). 
Individual cases are illustrated in figure 3.1.5.2b. Maternal serum levels of TGFpi were 
compared with 10 non-pregnant serum samples (5 female and 5 male). No significant 
difference was found between groups in serum TGFPi concentrations (p>0.05).
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Figure 3.1.5.1a Individual placental TGh'pi control data points (pg pg protein), with 
actual and regressed median and I a n d  90' '^ percentile lines plotted.
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Figure 3.1.5. lb  DS placental TCiFpi MoMs.
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Figure 3.1.5.2a Individual maternai serum TGh' /?/ control data points (logio pgm l), 
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Figure 3 .1.5.2b DS maternal serum TGhpf MoMs.
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M aternal Urine
Urinary levels o f  TGFpi were below the limits o f  detection ( 15 pg/ml) o f  the assay used.
3 .1.5 .4  Am niotic Fluid
Regressed median control levels o f  TOpPi in amniotic fluid, expressed as pg/ml, were 
calculated using linear regression on logio transformed data resulting in the equation 
y=3.090064-0.0302x (figure 3.1.5.4a). Actual and regressed control median values are 
outlined in table 3.1.5.4. All results were converted to MoMs using the regressed 
median value at the appropriate gestation. The median control MoM was 1.088, while 
the DS median MoM was significantly reduced to 0.685MoM (p=0.0064). Individual 
cases are illustrated in figure 3.1 5.4b.
•  control values
 regressed median
 observed median
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• - - t)Oth percentile _
0000
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G e s ta t io n  ( w e e k s )
Figure 3.1.5.4a Individual amniotic fluid IG F  f3] control data points (log/n p g  ml), with 
actual and regressed median and  I ()''' and 9(f'' percentile  lines plotted.
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Figure 3.1.5.4b D S  am niotic  flu id  T G h p i  MoMs.
3.1.6 C orrelations B etw een  M arker Levels
Correlations between marker levels were calculated using Pearson's Pairwise 
correlation coefficient (r). Previously determined t]3-hCG and ihCG levels in the 
placental and serum samples (Newby et a l  1997) were used in these calculations.
3 .1.6 ,! Inhibin and activin
Correlations between serum  and p lacen tal levels
Using Pearson's bivariate pairwise correlation, maternal serum and placental inhibin-A 
and activin-A M oM 's were compared. Control placental inhibin-A and activin-A 
showed some correlation (r=0.4255, p=0.004). A weak association was found between 
the inhibin-A and activin-A MoMs in the DS placental samples with a correlation 
coefficient o f  0.2878 (p=0.025). These correlations are illustrated in fig 3.1.6.1. This 
situation was mirrored in DS maternal serum, with inhibin-A and activin-A MoMs 
showing a degree of correlation (r=0.3055, p^0.05). No significant correlation was 
observed between serum and placental levels o f  inhibin-A or activin-A in DS 
pregnancies. This lack o f  correlation between placental and maternal serum levels o f  
inhibin-A and activin-A was further explored by examining the levels in fifteen 
placental homogenates and corresponding serum samples collected at the time of 
termination. This eliminates the possibility that any change in analyte levels was due to
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the difference in time from obtaining the serum-screening sample (around 15-17 weeks 
gestation), and the time of  obtaining the placental sample at termination (approximately
2-3 weeks later). This produced a strong correlation between placental and serum levels 
o f  inhibin-A (r=0.7097, p=0.003), but not for activin-A (r=0 .189, p=0.507). A summary 
o f  all correlation coefficients can be found in table 3.1.6 . la.
Correlations betw een hCG and inhibin-A/activin-A in placen ta and  
m aternal serum
Placental and maternal serum levels o f  inhibin-A and activin-A found in the present 
study were compared with those o f  total hCG and free beta hCG previously reported by 
Newby e( a! (1997). Control placental levels o f  inhibin-A and free beta hCG show a 
significant correlation (r=0.4122, p=0.006) with a similar, but not statistically 
significant trend being seen between inhibin-A and total hCG. There appears to be little 
association between activin-A levels and total or free beta hCG levels in control 
placental samples. In DS placental samples, no correlation could be found between 
either activin-A or inhibin-A levels and total or free beta hCG levels. There was a 
significant correlation between DS maternal serum activin-A and both total and free 
beta hCG (r=0.6619, p=0.014 and r=0.6421, p=0.018 respectively). There was, 
however, no significant correlation between inhibin-A and either total or free beta hCG. 
All correlation coefficients are summarised in table 3.1.6 . lb.
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Figure 3.1.6.1 C'orrelafions between inhihin-A and activin-A in control (blue) and DS 
(red) placental samples. The correlation coefficient (r) and significance (p) is as 
calculated using Pearson \s bivariate pairwise correlation.
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MoM values compared DS Samples Control Samples
Placental inh-A/act-A r=0.2877, p=0.0025, (61) r^O.4255, p=0.004, (43)
Placental/serum act-A r=0.1982, p=0.220, (40) /
Placental/serum inh-A r=-0.2006, p=0.214, (40) /
Serum inh-A/act-A r=0.3055, p=0.05, (41) /
Placental/pre-TOP serum act-A r=0.1859, p=0.507 (15) /
Placental/pre-TOP serum inh“A r=0.7097, p=0.003 (15) /
Table 3.1.6.1a Summary o f  correlation coefficients (r) obtained using Pearson’s 
bivariate pairwise correlation on inhibin-A (inh-A) and activin-A (act-A) M oM  values. 
The number o f  samples on which the correlation was carried out is given in brackets, 
while the significance o f  the correlation is given as the p  value.
Control Placental DS placental DS serum
r-0.4122 I--0.0581 1-0.1221
p=0.006 (43) p-0.756 (31) p=0.694 (13)
r=0.2469 r^O.2848 1-0.3594
p-0.110(43) p-0.120 (31) p-0.228 (13)
r=-0.1005 r=-0.1357 1—0.6421
p-0.522 (43) p-0.467 (31) p-0 .018(13)
r-0.0831 r=-0.0108 1-0.6619
p=0.596 (43) p=0.954 (31) p-0 .014(13)
Inh-A/ f(3-hCG
Inh-A/ihCG
Act-A/fp-hCG
Act-A/ihCG
Table 3.1.6.1b Summary o f  correlation coefficients (r) obtained using Pearson’s 
bivariate pairwise correlation on inh-A and act-A M oM  values compared with 
previously reported hCG MoMs. The number o f  samples on which the correlation was 
carried out is given in brackets, while the significance o f  the correlation is given as the 
p  value.
3.1.6.2 G rowth Factors
Using Pearson’s bivariate pairwise correlation, amniotic fluid levels of EGF and TGFp] 
expressed as MoM, were compared to f[3-hCG and ihCG levels previously reported 
(Newby et al 1997). Little or no correlation was observed between the growth factor 
levels and both forms o f hCG (table 3.1.6.2). Correlation coefficients between DS
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placental and amniotic fluid TGFpi levels were also calculated in the same way. There 
was no significant association between these values 1—0.031, p^O.853, n=39.
MoMs Compared Amniotic Fluid
fP-hCG /EGF r=0.070p-0.813n=14
ihCG/EGF r=-0.259 p=0.370 n-14
EGF/TGFPi r=-0.087 p-0.548 n=50
fP-hCG /TGFpi 1-0.319 p-0.266 n=14
ihCG/TGFPi r=0.363 p=0.202 n-14
Table 3.1.6.2 Summary o f  correlation coefficients (r) obtained using Pearson's 
bivariate pairwise correlation on DS amniotic flu id  EGF and TG F fi M oM  values 
compared with previously reported hCG MoMs. The number o f  samples on which the 
correlation was carried out is indicated by the n value, while the significance o f  the 
correlation is given as the p  value.
3 .2  D e v e lo p m e n t  o f  E L IS A  B a s e d  h C G  p m R N A  
Q u a n t if ic a t io n  M e th o d
3.2.1 S pecificity  o f  A ssay
Before the hCG mRNA assay could be used to measure the quantity of mRNA present 
in test samples, the specificity of the assay had to be determined. This was firstly 
assessed using one of the probes, and a complementary probe as a primer pair for PGR 
(see section 2.5.2.1 for sequences). The specificity in assay format was confirmed by 
using samples known to contain no hCG mRNA and also by substituting one of the 
probes for the complementary probe which would only bind to DNA.
3.2.1.1 Confirm ation o f  Probe Specificity by PCR
Three different placental RNA samples were reverse transcribed and amplified by PCR 
following the method outlined in section 2.5.2.2. Figure 3.2.1.1a illustrates that a 
fragment of the correct size (539bp) was obtained in all samples. To further confirm the 
identity of the amplified region, Alul restriction digest was carried out, which was
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expected to produce bands of 345bp and 194bp. As can be seen from figure 3.2.1.1b 
bands of the correct size were obtained.
—  567bp 
^ 5 1 7 h p
Figure 3.2.1.1a Results o f  PCR amplification o f  three different placental cDNA samples 
(l,2dc3). A no DNA negative control sample (-ve) was loaded beside each PCR reaction 
sample along with a DNA marker (L). A band o f  539bp is clearly visible fo r  each 
reaction.
I 2 3 -ve
null digest nun digest nun digest
Figure 3.2.1. lb  Residts o f  A lu l digest o f  PCR product from  three different placental 
samples (1,2N3). An undigested control (non) and digested (digest) sample fo r  each 
placenta was loaded, along with a no DNA PCR negative control (-ve) and a DNA 
marker (L). A band o f  539bp is clearly visible fo r  each control reaction and two bands 
of345bp and I94bp are visible fo r  each digested sample.
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3 *2,1.2 Confirm ation o f  Specificity in A ssay  F orm at
Total RNA isolated from cultured fibroblast cells, which do not express hCG mRNA, 
was assayed using this method and produced a result close to zero. Substituting the 
biotin labelled probe with the complementary probe, which would only specifically bind 
to any contaminating DNA, gave a result close to zero. Together these experiments 
exclude the possibility that the hCG probes bind to other mRNA sequences or that the 
assay system gives spurious results because of non-specific binding of either probes or 
antibody at any step in the procedure.
3 ,2 .2  R eproducib ility  and  A ccuracy o f  A ssay
To check the reproducibility of the assay, two samples were used as controls each time 
an assay was performed to determine the inter assay variation. Samples were also run 
repeatedly on one plate to give the intra assay coefficient of variation (CV). One sample 
with an average concentration of 4.47 ai'bitrary units was assayed in 9 wells of one plate 
giving a CV of 13.3% and another sample was assayed in 23 wells giving an average 
concentration of 5.51 units with a CV of 17%. For research purposes, a sample was re­
assayed if the intra assay CV was >20%. In most cases, a good linear standard curve 
was obtained from the arbitrary set of placental RNA standards. Figure 3.2.2 illustrates 
a typical standai’d curve.
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Figure 3.2.2 Typical hCG RNA standard curve generated using Genesis software 
package.
3 .2 .3  C om parison  w ith  N orthern  B lotting
A northern blot was carried out using various quantities o f  a total placental RNA sample 
per lane ( 1 ,2 , 5 ,  10 or 20pg) to assess the sensitivity o f  this method in comparison to 
the RNA assay (fig 3.2.3). As can be seen, it was difficult to pick up anything less than 
a 5-fold difference in target mRNA concentration at the lower concentrations, and a 2- 
fold difference at higher concentrations. As well as being less sensitive at detennining 
differences between samples, more RNA is required to perform northern blots than is 
used in the plate based assay. From this blot using lOpg RNA per lane would be the 
minimum to allow accurate comparison o f  results.
5 *10 \
Figure 3.2.3 Autoradiograph o f  hCG northern blot using varying quantities o f  RNA 
(indicated above each lane in pg). RNA size marker is on right hand side o f  figure, with 
sizes o f  each band indicated in kb.
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3-2 .4  C om parison  w ith  Taq Man® Real T im e PCR
Typical amplification plots for hCG and PPIA mRNA are illustrated in fig 3.2.4a and 
3.2.4b respectively. The number o f  PCR cycles (x-axis) is plotted against the ARn 
value, which is an index o f  the quantity o f  PCR product (y-axis) for each individual 
reaction. This allows the rate o f  the PCR reaction for each sample to be visualised. 
These plots are used to set the threshold level from which the Ct value for each sample 
can be calculated The threshold value should be within the logarithmic phase o f  the 
reaction and the negative control sample should have a Ct close to 40 at this threshold 
value. This method requires by far the least amount o f  starting total RNA (2pg is 
sufficient for several PCR reactions). Each batch of  reactions can determine the quantity 
o f  both hCG and PPIA mRNA in 45 test samples, making this an extremely quick 
method o f  study a large quantity o f  samples.
l o r o -
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Figure 3.2.4a Typical hCG mRNA real time PCR amplification plot. The thre.shok! 
value (indicated by a black horizontal line) was set so that the PCR reactions had not 
yet reached a plateau and the negative control sample (dark blue and dark green lines) 
gave a (1 number dose to 40. Amplification plots are o f  24h-96h mRNA isolated from  
cultured trophoblast cells. 24h samples have very little hCG mRNA as indicated by the 
high Ct (magenta, blue, red and green lines).
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Figure 3.2.4b Typical PPIA mRNA real time PCR amplification plot. The thre.shold 
value (indicated by a black horizontal I me) wa.s set so that the PCR reactions had not 
yet reached a plateau and the negative control sample (dark blue and red lines) gave a 
Cl number dose to 40. Amplification lots are o f  24h-96h mRNA i.solated from cultured 
trophoblast cells.
3 .2 .5  C orrelation  B etw een  hCG mRNA A ssay and Real 
Tim e PCR M ethods
A selection o f  62 RNA samples collected for the IFNa study, the results o f  which are 
out outlined in section 3.4, were assayed using both the plate based hCG mRNA assay 
and the real time PCR method to compare the results each gave. The 2'^'^' values 
obtained from the real time PCR method were compared to the hCG results divided by 
the GAPDH results obtained from the plate based method using the Pearson pairwise 
correlation. A significant correlation was observed between both data sets (r=0.384, 
p=0.002). These results are illustrated in fig 3.2.5.
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Figure 3.2.5 Correlation between Rea! time PCR and piate based assay method o f  
mRNA quantification. The correlation coefficient (r) and significance (p) is as 
calculated using Pearson \s bivariate pairwise correlation
3  3  D e v e lo p m e n t  a n d  C h a r a c te r is a t io n  o f  C e ll 
C u ltu r e  M e th o d
3.3.1 V alidation  o f  In itia l C ultures and E ffects o f  
C ryopreservation
As an initial step in developing the trophoblast culture method the viability and purity 
o f  cells was assessed both before and after cryopreservation.
3 .3 .1.1 M orphology and Purity
Purity o f  pre and post cryopreservation cells was gauged by carrying out 
immunocytochemistry using vimentin V9 and cytokeratin 5/6/18 antibodies on fixed 
trophoblasts after 24h in culture. Cultures were generally >90% pure. The 
differentiation o f  cytotrophoblasts to syncytiotrophoblast in fresh cultures was 
monitored at 24h intervals by light microscopy. After 24h the cells were mainly
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mononuclear individual cells, and as the culture period progressed these cells fused into 
a continual syncytial layer (fig 3 .3 .1 . lb).
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Figure 3.3.1.1b Differentiation o f  trophoblasts over a 96h culture period. Photographs 
were taken at 24h intervals using phase contrast microscope. Arrows indicate areas 
with no cells from  which trophoblasts have migrated during syncytialisation. Size bars 
represent 0.1 mm.
3.3,1.2 hCG and PLAP Secretion
Function and viability o f  the cells was determined by measuring hCG secretion and 
PLAP secretion from cytotrophoblasts as they syncytialised. Figure 3.3.1.2a shows the 
hCG results o f  8  cultures, before and after freezing, taken as a ratio o f  total protein 
content o f  the cells in each well to account for variations in cell plating efficiency. As 
can be seen from this figure, very little hCG was produced in the first 24h o f  culture 
when the cytotrophoblasts were adhering to the culture surface. As the cells 
syncytialised the rate o f  hCG production increased to a peak at 72h, and then declined at 
96h when most cells had formed syncytium. It is also clear that the cells did not behave 
normally after freezing, with the rate o f  hCG production significantly lower (p=0.025) 
at the 72h time point. This reduction in hCG production was accompanied by cells 
which did not adhere to the culture surface and did not appear to differentiate as they 
had done as fresh cells.
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The rate o f  placental alkaline phosphatase (PLAP) secretion was at a peak at 24h, 
declined at 48h and then increased through the culture period (tig 3.3.1.2b) as the cells 
syncytialised. The peak at 24h is probably due to release o f  PLAP by syncytial 
fragments and other pieces o f  tissue, which are washed from the culture surface at the 
first medium change. In subsequent cultures the number o f  digests was decreased from 
3 to 2, which gave cleaner preparations due to sharper percoll bands, thereby decreasing 
this peak o f  PLAP. There was no significant difference in the rate o f  PLAP secretion 
between fresh and frozen cultures.
3-3-i»3 Q uantity o f  Cells
The effects o f  cryopreservation on the number o f  cells remaining in culture was 
investigated by measuring the total protein content and the DNA content o f  a cell lysate 
that had been scraped from duplicate wells o f  a 24 well culture dish at 24h time points. 
There was no significant difference in either the protein or DNA content in the wells at 
any time point when fresh cultures were compared to frozen cultures (p>0.05) using the 
Wilcoxon Matched pairs signed ranks test (fig 3.3.1 3a and fig 3.3.1.3b).
140
3O
€
"3
ouQ.
DX
E
O
U
120
■ fresh 
- -» - frozen100
80
60
40
20
0
24 48 72 96
H o u rs  in C u l tu re
Figure 3.3.1.2a Comparison o f  hCG secretion from  trophoblast cultures before and 
after cryopreservation. Results are expressed a mean o f  8 cultures ±sem  in IIJ HCG per 
mg protein per hour. *p<0.05 by Wilcoxon Signed Ranks Test.
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Figure 3.3.1.2b Comparison o f  PLAP secretion from  trophoblast cultures before and 
after cryopreservation. Results are expressed a mean o f  S cultures ±  sem in m il PLAP 
per g protein per hour.
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Figure 3.3.1.3a ( 'omparison o f  protein concentration in trophoblast cultures before and 
after cryopreservation. Results are expressed a mean o f  7 cultures ±sern in pg protein 
per ml cell lysate.
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Figure 3.3.1.3b Comparison o f  DNA concentration in trophoblast cultures before and 
after cryopreservation. Results are expressed a mean o f  7 cultures ±sem  in pg  DNA per 
ml cell lysate.
In addition to assessing the effect o f  cryopreservation on cell number using both 
methods, the accuracy o f  the DNA method and the protein method were assessed. The 
DNA and protein concentrations were compared using Pearson’s pairwise correlation to 
determine if  both methods o f  determining cell number were comparable. In both fresh 
and frozen cultures, a significant correlation was observed between both methods 
indicating that either would be an appropriate method of  determining the number of 
cells present in culture well. For the fresh cultures r=0.4495 (p=O.OI6 ) and for the 
frozen cultures r=0.4054 (p=0.032). These results are illustrated in figure 3.3.1.3c. Time 
in culture had no significant effect on either protein or DNA content o f  cells (p>0.05, 
GLM Univariate).
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Figure 3.3.1.3c Correlations between protein content and DNA content of cell lysates o f  
fresh (blue) and cryopreserved (pink) trophoblast cells. The correlation coefficient (r) 
and significance (p) is as calculated using Pearson \s bivariate pairwise correlation.
3 .3 .2  Im m u n op u rification  o f  T rophoblasts
3 .3 .2.1 Screening Purified Cells Using A n tibody Panel
Following isolation o f  trophoblasts from three different term placentae, cytospins were 
prepared using cells before and after immunopurification using FILA Class I coated 
magnetic beads (see section 2.2.2). Fluorescent immunocytochemistry was carried out 
on these cytospins using a panel o f  antibodies designed to detect and identify 
contaminating cells. Table 1.4.5.2 outlines the placental cell types each antibody reacts 
with. The reactivity o f  these antibodies was also tested on frozen term placental sections 
(figure 3.3.2. la). It can be seen from this figure that the cytokeratin 7 antibody picks up 
only trophoblast cells, while the HLA class I, FSA and vimentin antibodies reacted with 
all placental cells except the trophoblast layer. The CD9 antibody showed very variable 
staining o f  stroma and blood vessel endothelium, with decidual staining being most 
evident. The CD 163 antibody picked out specific stromal cells, which are likely to be 
hofbauer cells. The CD45 antibody failed to react with tissue sections probably because 
this is specific for blood leukocytes and there was very little blood on the frozen 
sections. The negative control sections showed no reactivity.
When used on cytospins, these antibodies showed that the contaminating cells were 
mainly blood leukocytes (CD45, HLA Class I and vimentin positive) with a minor
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contribution from hofbauer cells (CD 163, HLA Class 1 and vimentin positive) and other 
fibroblasts (HLA Class 1 and vimentin positive). Table 3.3.2.1b outlines the average 
result based on counting 4 fields of view on each cytospin from 3 pre and post 
purification cultures. These findings are also shown in figure 3.3.2.1b. Vimentin and 
cytokeratin antibodies were used to assess the purity of each subsequent cell isolation 
preparation.
Antibody Culture 1 Culture 2 Culture 3
Pre Post Pre Post Pre Post
Vimentin 7.25% 0.5% 7.5% 0 10.25% 0.5%
FILA Class I 8.25% 1% 6% 0 8.75% 0
CD9 0.5% 0 1.5% 0 1.25% 0.25%
CD45 8.25% 2% 5.75% 0 9.25% 0
CD 163 0.25% 0 0 0 2.25% 0
Table 3,3.2.1b Percentage positive staining o f  cytotrophoblast cytospins pt'e and post 
immunopurification using HLA Class I antibody coated beads.
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Figure 3.2.2.la  Fluorescent IHC on frozen term placental sections with panel oj 
antibodies used to assess trophoblast purity. Antibody staining is green and nuclei are 
counterstained red. Staining was carried out using antibodies against A-cytokeratin 7, B- 
vimentin, C-FSA, D-HLA Class I, E-CD9, F-CD9, C-CD163, FI-negative control. 
Trophoblast layer (t), stroma (s), blood vessels (bv), blood vessel endothelium (end) and 
decidua (d) are labelled. Size bar represents 200pm.
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Figure 3.2.2.1b
Fluorescent ICC  
on pre (column 1)  
and post (column2) 
purification 
cytospins o f  
isolated placental 
trophoblasts. 
Antibody reactivity 
is green coloured 
and nuclei are 
counterstained red. 
Size bar represents 
50pm.
A-cytokeratin 7, 
B-vimentin,
C-HLA Class I, 
D-CD163,
F-CD9,
F-CD45.
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3 >3 ‘2 .2  Effects o f  Im m unopurification on S yn cytia lisa tion
The effects o f  immunopunfication on hCG and PLAP production as well as 
morphological differentiation were studied. Figures 3.3.2.2a and 3.3.2.2b demonstrate 
that production o f  both proteins, and therefore syncytialisation, was not significantly 
altered by immunopurification (as tested by Wilcoxon Signed Ranks Test). This 
observation was also supported by no difference in morphological differentiation as 
observed in figures 3.3.2.2c and 3.3.2.2d which show the fusion o f  discrete cells into 
syncytial layers as marked by the disappearance o f  desmoplakin I&2 staining between 
nuclei, and increased production o f  PLAP as syncytialisation progressed.
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Figure 3.3.2.2a I\ffecls of immimopiirificution on the rate of hCG secretion. Results are 
expre.ssed as a mean of 3 cultures ±SI'JM in JIJ hCi'j per mg protein per hour.
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Figure 3.3.2.2b Effects of immimopurification on the rate of E lA E  secretion. Results 
are expressed as a mean o f 3 cultures ± SE M  in m il EJAE per mg protein per hour.
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Figure 3.2.2,2c Fluorescent ICC fo r  desmoplakin I&2 on pre (column A) and post 
(column B) purification placental trophoblasts, fixed  at 24h intervals over a 96h 
culture period. Over the culture period staining fo r desmoplakin disappeared between 
some nuclei, which indicates formation o f  syncytium. Antibody reactivity is green 
coloured and nuclei are counterstained red. Size bar represents 50pm.
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Figure 3.2.2.2d Fluorescent ICC fo r  FLAP on pre (column A) and post (column B) 
purification placental trophoblasts, fixed  at 24h intervals over a 96h culture period. 
Over the culture period staining fo r  PLAP increased, as syncytialisation proceeded. 
Antibody reactivity is green coloured and nuclei are counterstained red. Size bar 
represents 50pm.
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3 4 C h a lle n g in g  T r o p h o b la s t s  w it h  I n te r fe r o n  
A lp h a  (IF N a )
3.4 .1  C onfirm ation  o f  F u nction al In terferon  R eceptor  
(IFN-R)
3 .4 .1 ,! Localisation  oflFN- R i  &  R2  in P lacental Sections
IFNa/p receptors (IFN-R 1 & R2) were localised by immunohistochemistry on frozen 
sections from mid trimester control and DS placentae. Most placental cells expressed 
IFN-R in both term and mid trimester placentae (fig 3.4.1.1), although staining was 
most intense on trophoblast cells. Semi quantitative analysis o f staining intensity 
revealed no significant difference in IFN-R staining intensity between control and DS 
sections.
3 .4 .1 .2  Localisation  oflFN - R i  &  R2  in Iso la ted  Trophoblasts
Fluorescent immunocytochemistry was carried out on acetone fixed trophoblast 
cytospins to confirm the presence of IFN-R 1 & R2 on freshly isolated cells. Cells from 
four different placentae were investigated and all were found to express IFN-R on the 
cell surface (fig 3.4.1.2).
3 .4 *1 .3  Confirm ation ofSTATi A ctiva tion
The first event of IFNa/p receptor activation is phosphorylation of ST AT 1. Protein 
isolated from cultured trophoblasts at 24h time points treated or untreated with IFNa, 
was analysed by western blotting to confirm the presence of activated (phosphorylated) 
ST AT l a  and ST AT Ip. A positive control cell lysate (Santa Cruz) was also run on 
western blotting gels. Bands o f the expected sizes (84&911cDa) were observed in the 
positive control lane and the smaller (84kDa) band was present in the majority of cell 
lysates indicating the presence o f activated ST AT 1 (fig 3.4.1.3). Other non-specific 
bands of smaller proteins were observed in all lanes including the positive control.
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Figure 3.4.1.1
Fluorescent 
immunoh is toc hem ical 
localisation o f  IFN-Rl cî- 
R2 on term placental 
sections. Antibody 
f I reactivity is green
coloured and nuclei are 
counterstained red. 
Trophoblast layer is 
indicated by T and 
stroma by S.
A= IFN-Rl & R2 
localisation,
B=negative control,
Size bar =100pm.
■ M
Figure 3.4.1.2 Fluorescent ICC localisation o f  IFN-Rl fÇ- R2 on isolated trophoblast 
cells. Antibody reactivity is green coloured and nuclei are counterstained red. 
A=IFN-Rl & R2 localisation, B negative control. Size bar =50pm.
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Figure 3.4.1.3 Western blot for pSTA T I using cell lysates from  trophoblast cultures 
treated or untreated with IFNa. Cell lysates were collected at 24h periods and had been 
cultured in the presence o f  IhN a  at I, 10 or lOOU ml. Negative control cultures ((') 
received no IFNa. Approximate band sizes in kl)a are indicated as obtained from  a size 
marker. A positive control ( ' ve) was also included.
3 .4 .2  Effect o f  IFNa on  hCG P roduction  by Term  
T rophoblasts
3 .4 .2.1  hCG Secretion into Culture M edium
Trophoblasts isolated from six placentae were cultured in the presence and absence o f  
various concentrations if  IFNa. Culture medium was collected at 24h intervals and the 
quantity o f  hCG secreted (measured by immunoradiometric assay) was taken as a ratio 
o f  protein level o f  the cell extract from the appropriate wells. In all cases, the rate of 
hCG secretion increased to a peak at 72h after plating and declined until the end o f  the 
culture period. Addition o f  IFNa at different concentrations did not make a significant 
difference to the rate o f  hCG secretion at any time point (tig 3.4.2.1a). Addition of 
lOOU/ml did, however, seem to cause the cells to peel from the culture surface after 96h 
in culture which meant it was difficult to accurately assess the quantity o f  hCG secreted 
under these conditions. The cumulative total quantity o f  hCG released into the medium 
over the 96h culture period did not significantly differ between the treatments (fig 
3.4.2.1b).
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Figure 3.4.2.1 a Fffects of IFNa treatment on the rate o f  hC G secretion. Results are 
expressed as a mean o f  6 cultures in m ill hCXI per pg protein per 24h period  t SFM. 
Blank no addition, control carrier added.
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Figure 3.4.2.1b Fffects o f  IFN a treatment on the cumulative total amount o f  hC'G 
secreted in the 96h ci4lture period. Results are expressed as a mean o f  6 cultures in m ill  
hex I per pg protein. Error bars indicate SFM. Blank no addition, control carrier 
added.
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hCG in Trophoblast Cells
From the same cells cultured in the presence and absence o f  IFNa, total protein was 
extracted from the scraped cells. The hCG concentration was determined in these 
protein extract using an immunoradiometric assay and was expressed as a ratio o f  the 
total protein concentration. As with the rate o f  hCG secretion, no significant difference 
in rate o f  hCG production or the cumulative total amount o f  hCG present in the cells 
over the culture period was observed (fig 3.4.2.2a, fig 3.4.2.2b).
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Figure 3.4.2.2a I\ffecls o f  Ih'Na treatment on the quantity of hCii in trophoblast cells. 
Results are expressed as a mean o f  6 cultures in m ill hCXi per pg protein per 24h 
period  t SEM. Blank no addition, control carrier added.
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Figure 3.4.2.2h Effects o f  Ib'Na treatment on the cumulative total amount o f  hCX'j in 
trophoblast cells over the 96h culture period. Results are expressed as a mean o f  6 
cultures in m ill hCG per pg protein. Blank no addition, control carrier added.
3 .3 .2 .3  hCG mRNA Levels
From the same cells cultured in the presence and absence o f  IFNa, mRNA was 
extracted from the scraped cells. The quantity o f  hCG mRNA and PPIA mRNA in each 
sample was assessed using real time quantitative PCR. The rate o f  hCG mRNA 
production, corrected against the housekeeping gene PPIA and expressed relative to a 
calibrator sample, was determined for each treatment (expressed as There was
no significant difference in the rate o f  hCG mRNA production when the cells were 
treated with IFNa (fig 3.4.2.3).
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Figure 3.4.2.3 Effects o flE N a  treatment on the rate ofhC G  mRNA production. Results 
are expressed are the mean o f  6 cultures as 2'^‘^  ' which expresses hCG mRNA levels 
relative to PRIA levels per 24h period  i  SKK4. Blank no addition, control carrier 
added.
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Section 4
Discussion
m
4 .1  I n h ib in  a n d  A c t iv in
4.1.1. Inhib in-A
This study has demonstrated that both the maternal serum and placental levels of 
inliibin-A are elevated in DS pregnancies. These results are in agreement with previous 
studies on maternal serum which reported an elevation in the median DS inhibin-A level 
to between 1.6 and 3.65 MoM (Spencer et al. 1993; Cuckle et al. 1994; Cuckle et al. 
1995; Aitken et al. 1996; Wald et al. 1996; Wallace et al. 1996; Wallace et al. 1996; 
Lambert-Messerlian et al. 1996a; Lambert-Messerlian et al. 1998a; Debiève et al. 
2001). The results of the earlier studies (Spencer et al. 1993; Cuckle et al. 1994; 
Cuckle et al. 1995) were generated using an older inhibin-A assay that detected free 
subunits of inhibin-A as well as the intact dimer. It is therefore more appropriate to 
compare the cuiTent results with those using the dimeric inhibin-A assay (Groome, 
1991; Groome and O'Brien, 1993) as used in the present study. The DS median MoM of 
2.06 reported in the current study is towai’ds the higher end of the range of those 
previously reported. The reason for this observation may be that most of the serum 
samples used in this study had elevated hCG (Newby et al. 1997) because they were 
identified by prenatal screening. Serum hCG and inliibin-A show a degree of correlation 
(Aitken et al. 1996) therefore, a serum sample with high hCG levels would also be 
expected to have an elevated inliibin-A level.
The significant elevation in DS placental inhibin-A levels to 1.46MoM in the current 
study contrasts with the results recently reported by Debiève et al (2001). In the latter 
study, which was based on placental protein extracts from only 6 DS placentae collected 
between 15 and 32 weeks of gestation, no significant difference was found in inhibin-A 
or pro aC  levels in DS placentae. There was however, a trend towards elevated levels of 
both inhibin-A (1.29MoM) and pro aC  (2.66MoM). The reason why these differences 
were found not to be statistically significant could be due to the small number of 
samples in the study group, or the wide range of gestations with some samples obtained 
in the third trimester when placental inhibin-A levels may not show markedly elevated 
levels in DS pregnancies.
There was no significant correlation between placental and maternal serum levels of 
inliibin-A, contrasting with the association previously reported between placental and 
serum levels of hCG (Newby et al. 1997). To investigate whether the difference in
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gestation between the collection of a serum screening sample and time of TOP could be 
the reason for this lack of correlation, a series of placental homogenates and matched 
serum samples taken just prior to TOP were investigated. As can be seen from table 
3.1.6.1a, this produced a significant correlation between maternal serum and placental 
levels of inhibin-A, as would be expected when a placental product is secreted directly 
into the maternal serum.
Inhibin-A is already used as a DS screening marker in some areas in combination with 
AFP, hCG and in some cases U E 3 . It has been reported that the addition of inhibin-A to 
these combined marker tests gives an improvement in the detection rate of DS 
pregnancies by around 15-20% when compared with the use o f maternal age, AFP and 
either ihCG or fp-hCG with or without UE 3 . The detection rate for AFP, ihCG or fp- 
hCG and age screening with a 5% false positive is around 54% (Aitken et al. 1996; 
Wald et al. 1996). The addition o f inhibin-A increases this detection rate to between 
67% (Wald et al. 1996) and 75% (Aitken et al. 1996) for a 5% false positive. Although 
a slight increase in the first trimester maternal serum level o f inhibin-A has been 
reported in DS pregnancies (Wallace et al. 1994; Aitken et al. 1996) the detection rate 
is not high enough to make this a useful screening marker in the first trimester unlike 
PAPP-A or $-hC G .
Amniotic fluid levels of inhibin-A have been previously reported as being reduced in 
DS pregnancies (Wallace et al. 1997) which is the opposite o f observations in maternal 
serum and placental extracts. This may suggest that the placenta is not the major source 
of amniotic fluid inhibin-A; alternatively there could be altered placental transport of 
inhibin-A from the placenta in DS pregnancies.
Alterations in circulating levels of inhibin-A have also been reported in other 
complications of pregnancy including pre-eclampsia. It has been noted that in the third 
trimester o f pregnancy, women with preeclampsia have significantly elevated maternal 
serum concentrations of inhibin-A and in the second trimester significantly increased 
maternal serum inhibin-A is predictive of preeclampsia in later pregnancy 
(Muttuki'ishna et al. 1997; Cuckle et al. 1998). This has been suggested as being 
indicative of trophoblast hypoplasia. In contrast to the elevations in maternal serum 
inhibin-A levels in DS and preeclamptic pregnancies, trisomy 18 and trisomy 13
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affected pregnancies show reductions in maternal serum levels of inhibin-A (Crossley et 
al. 1991; Lambert-Messerlian et al. 1998b).
4.1.2 A ctivin-A
As with inliibin-A, a clear elevation of both placental (1.62MoM) and maternal serum 
(I .26M0M) activin-A is evident in DS pregnancies. These results agree with the study 
that reported a significant increase in the DS maternal serum level of activin-A to 1.25 
MoM (p<0.01) (Lambert-Messerlian et al. 1996b). These results contrast with the small 
reduction in maternal serum activin-A levels reported in a second study by the same 
group (Lambert-Messerlian et al. 1998a). A study by Cuckle et al (1999a) also found 
maternal serum levels of activin-A to be elevated to 1.19 MoM in DS pregnancies, but 
concluded that the distribution of the control and DS levels would not make this a 
suitable screening mai'ker for DS pregnancies. Significantly elevated maternal serum 
activin-A levels have also been reported in the first trimester of DS pregnancies to 
I .36M0M (Spencer et al. 2001). Again, the overlap in the distribution of control and 
DS levels make this an unsuitable serum screening marker.
Debiève et al (2001) noted a non-significant increase in placental activin-A levels in DS 
placentae to 1.45MoM. As noted above sample group size or gestational range of the 
samples could account for the lack of statistical difference between sample groups. 
Increased maternal serum activin-A levels have also been observed in other disorders of 
pregnancy, including pre-eclampsia, gestational diabetes and pre-term labour (Petraglia 
et al. 1995a; Petraglia et al. 1995b; Petraglia et al. 1999). Although these conditions 
are not associated with DS pregnancy it suggests that alterations in the normal function 
of the placenta and o f the fetus are associated with altered maternal serum levels of this 
marker. As with the inhibin-A data, no significant correlation was observed between the 
serum and placental levels o f activin-A. Again, pre-termination serum samples were 
compared with placental levels, however, unlike inhibin-A, this did not produce a 
significant correlation (table 3.1.6.1a).
As noted earlier, activin-A is unlikely to prove a useful screening marker of DS in either 
the first or the second trimester of pregnancy, despite a significant elevation in the level 
of this marker in the maternal serum of DS pregnancies having been reported in the
176
current and other studies (Cuckle et al. 1999a; Spencer et al. 2001). This is because the 
large overlap in the distribution of control and DS maternal serum levels of activin-A in 
both trimesters mean that to give a false positive rate of 5% a low detection rate would 
be achieved. In the second trimester of pregnancy, there was a significant correlation 
between the maternal serum levels of inhibin-A and activin-A shown in the current 
study and by Cuckle et al (1999a). This means that, even if there was less o f an overlap 
between control and DS cases, activin-A would be unlikely to add to a screening study 
already including inhibin-A. In the first trimester, a significant association between 
activin-A and both PAPP-A and f|3-hCG was found (Spencer et al. 2001) again 
indicating that this marker would be unlikely to increase the detection rate of the cunent 
screening strategy.
4.1.3 Im m u n oh istoch em ica l A nalysis o f  a and  (3a  Subunits
4 ,1 ,3 .! Im m unolocalisation  o f  Subunits
Inliibin and activin a  and (3a subunits were localised by immunohistochemistry (fig 
3.1.1.1a & 3.1.1.1b). The observed staining pattern for both the a  and (3a  subunits 
agrees with the immunohistochemical localisation of the activin-A dimer reported by 
Rabinovici et al (Rabinovici et al. 1992) who also noted positive staining in both 
cytotrophoblast cells and syncytiotrophoblast, as well as some stromal cells. Two 
studies (Petraglia et al. 1991; Petraglia et al. 1992) detected a  and pA subunits in all 
trophoblastic cells a finding that the present study has confirmed. McCluggage et al 
(1998) studied the localisation of the a  subunits of inhibin using antibodies from the 
same source as those used in the present study, and found this subunit to be localised to 
syncytiotrophoblasts, but not cytotrophoblast cells. A similar result was reported by 
Minami et al (1992), who noted positive staining for both a  and Pa subunits in the 
syncytial layer, but not in cytotrophoblast cells. The reason for the variations in subunit 
localisation reported by the different studies is unclear. There appears to be no 
association between the gestational range of samples or the source of specific antibody 
with the reported subunit localisation.
A study (Debieve and Thomas, 2000) on isolated trophoblast cells examined the stage 
in culture when mRNA for the a  and Pa subunits was detectable. It was noted that 
freshly isolated cytotrophoblast cells expressed a  subunit niRNA but showed very little 
pA subunit expression. The expression of a  subunits rose steadily until a peak at 72h in
177
culture then began to decline. In contrast Pa subunit expression rose quickly to a peak at 
48h in culture with the levels remaining constant until 120h when levels declined. It was 
suggested that inhibin-A production could therefore be considered a marker of 
syncytialisation, while activin-A seems to be produced during cell aggregation prior to 
syncytialisation (Debieve and Thomas, 2000). These results provide support for the 
reports that suggested inhibin a  and Pa subunits could be immunolocalised to both 
cytotrophoblast cells and syncytiotrophoblast cells, since mRNA for both subunits was 
detectable after 24h in culture at which point most cells are still mononucleated.
From these studies on the localisation of inliibin-A and activin-A in the placenta, it is 
probably fair to conclude that the subunits of inhibin-A and activin-A are produced by 
both cytotrophoblast cells and the syncytiotrophoblast. These cells are the primary site 
of production of most placental products used as maternal serum markers of DS e.g. 
hCG (Hay, 1988; Maruo et al. 1992) and PAPP-A (Tornehave et al. 1984). This 
observation indicates that when studying placental expression of DS markers, 
cytotrophoblast cells are probably the most useful to isolate and study in culture as they 
fuse to form syncytium.
4,1,3,2 Com parison o f  S tain ing In ten sity
The semi-quantitative analysis of staining intensity (table 3.1.3.2) suggests that the 
increased levels o f dimeric inliibin-A and activin-A in DS pregnancies are due to excess 
production of both a  and Pa subunits. Lambert-Messerlian et al (1998a) found that a  
subunit but not Pa subunit mRNA production was elevated in DS placental extracts. 
Using a PCR based method of measuring subunit production as Lambert-Messerlian et 
al (1998a) did is more selective than quantitative immunohistochemistry which detects 
not only the free subunits but also the intact dimers. Using end point RT-PCR can 
however prove difficult to optimise so that mRNA levels in samples are measured 
during the logarithmic stage of the PCR reaction. The study of Debiève et al (2001), 
found no difference in either a  or pA subunit mRNA levels in placental tissues from DS 
pregnancies again using end point RT-PCR analysis. This agrees with the Pa subunit 
results of Lambert-Messerlian et al (1998) but differs from the results obtained for the a  
subunit mRNA levels reported in that study. A possible reason why slightly different 
results have been reported could be due to the difference in gestational range o f the 
samples used in each study. The Debiève study included some third trimester samples
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while the Lambert-Messerlian study included samples collected only from the second 
trimester.
A similar study on the IHC staining intensity o f inhibin a  and Pa subunits in placental 
tissues has been carried out on preeclamptic and control tissues (Jackson et al, 2000). 
The staining for both subunits was significantly greater in the preeclamptic samples 
when compared with controls. This suggests that the increased maternal serum levels of 
both inliibin-A and activin-A observed in preeclamptic patients are due to increased 
placental production of both factors (Jackson et al. 2000), similar to the conclusion 
drawn in the current study about increased maternal serum levels o f inhibin-A and 
activin-A being due to increased placental production in DS.
As can be seen from table 3.1.3.2, the DS samples from earlier gestations were more 
likely to show a positive difference than those from the later gestations, particularly in 
the case of alpha subunit staining. This observation matches the trend towards higher 
placental inliibin-A and activin-A MoMs at the earlier gestations studied (fig 3.1.1.1b & 
3.1.2.1b). This may indicate that the extent of the elevation o f inliibin-A and activin-A 
levels in DS placental tissues is gestation dependent. Evidence o f this temporal variation 
can be found for maternal serum levels o f inhibin-A in the study by Aitken et al (1996). 
Similai* gestation dependent variations have been reported for both intact and free beta 
hCG in maternal serum from DS pregnancies (Aitken et al. 1993; Berry et al. 1997). 
PAPP-A levels have also been shown to differ through gestation with first trimester DS 
levels lower than normal while second trimester DS levels no different from those in the 
normal situation (Berry et al. 1997).
An obvious drawback when using IHC staining intensity as a measure of protein levels 
in tissues is the inherent inaccuracy of using a subjective rather than a strictly 
quantitative method o f ranking the degree of staining. While immunoassay or RT-PCR 
methods provide an absolute result, the manual assessment of staining intensity is 
subjective and can vary depending on the person scoring and if all areas of a section 
have been viewed. In the current study, differences between and within scorer were 
analysed to counter possible inaccuracies. Even with these controls in place, the results 
of IHC staining intensity experiments should be treated as an indication of trends in 
differences in protein expression rather than precise results like those obtained from 
ELISA or RT-PCR experiments. The main advantage of IHC is of
179
course the accuracy of tissue specific localisation of the protein in tissues, information 
that cannot be provided by strictly quantitative methods.
4.1 .4  R elation sh ip  B etw een  Inhibin-A , A ctivin-A  and  hCG
To investigate the relationship between inhibin-A, activin-A and hCG levels, 
correlations between levels of these analytes were investigated in placental and serum 
samples. Both free beta hCG and intact hCG levels had previously been measured and 
reported in a selection of these samples by Newby et al (1997). As can be seen in table 
3.1.6.1b, a significant correlation between control placental inliibin-A and fp-hCG was 
observed, with a similar, but not statistically significant trend between inhibin-A and 
ihCG. These correlations are similar to those previously reported in maternal serum for 
the same markers (Aitken et al. 1996). In DS placental homogenates, no such 
correlation was observed between inliibin-A and fp-hCG, although ihCG showed a 
similar trend to that observed in control placentae. In the case o f DS serum samples, 
correlation coefficients between inliibin-A and either ihCG or f]3-hCG were similar to 
those reported by Aitken et al (1996), however they did not reach statistical significance 
like those reported previously. This could be due to the much smaller sample group 
used in the current study.
Interestingly, activin-A levels were found only to correlate with ihCG and fg-hCG in 
DS serum samples, with no correlation evident in the placenta. Cuckle et al (1999) 
examined correlations between activin-A and f^-hCG levels in maternal serum, and 
found no correlation in DS samples, but observed a significant correlation in control 
samples. Although no definitive reason can be suggested why correlation has been 
observed in serum samples but not placental samples, it is postulated that different 
follistatin binding of activin-A in the maternal and placental compaitments could 
perhaps contribute to this effect. It is postulated that the majority o f the increased levels 
of activin-A in the placenta is bound to follistatin, and is therefore biologically inactive. 
Only unbound activin-A would be free to cross into the maternal circulation, where the 
circulating form of follistatin would then bind it. This would explain the lack of 
correlation between placental and maternal serum levels of total activin-A. If this 
situation is compared with that of inhibin-A, the highly significant correlation between 
placental and pre-termination maternal serum levels of this analyte suggests that unlike 
activin-A, it is secreted directly into the maternal serum. Like the inhibin-A data, a
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significant correlation between placental and serum levels of hCG was reported 
previously (Newby et al. 1997). The hypothesis that activin-A is held in the placenta, 
while inhibin-A is secreted upon production may also account for the smaller increase 
in maternal serum activin-A levels when compared with the elevation in serum inhibin- 
A levels (1.26 MoM compared to 2.06 MoM) found in the present study. Another 
observation that could support this theory is the greater increase in placental levels of 
activin-A when compai'ed with inhibin-A (1.62 MoM compared to 1.46 MoM). This 
hypothesis may also explain the lack of correlation between activin-A and hCG levels in 
the placenta. If only the free form of activin-A may stimulate hCG production, then 
only free activin-A levels, and not total activin-A levels would be expected to correlate 
with f[3-hCG and ihCG levels. Since hCG acts to stimulate inliibin-A production, a 
degree of correlation would be expected between either ihCG or fp-hCG and inhibin-A 
levels. In this study, a significant correlation between fp-hCG and inhibin-A was 
observed only in control placentae. However, ihCG and inhibin-A showed a degree of 
correlation similar to that of activin-A and inhibin-A in the placenta, but in this case it 
was not statistically significant.
In maternal serum, inhibin-A, activin-A and both forms of hCG all showed a degree of 
correlation with each other, although this did not always reach statistical significance. It 
is speculated that this is due to an evenly upregulated secretion of inhibin-A, activin-A, 
and both forms of hCG from the placenta of DS pregnancies, rather than any of these 
analytes possessing a particular endocrine function. The small number o f samples used 
to calculate these correlation coefficients, do however, make it difficult to draw any 
definitive conclusions. Further work, perhaps studying the distribution and levels of 
follistatin subtypes in the placenta and maternal serum, would be required to elucidate 
the mechanisms of activin-A storage and transport. One group (Cuckle et al. 1999a) 
analysed follistatin concentrations in the maternal serum of DS and control pregnancies 
in the second trimester. They found no significant difference in the level of follistatin 
between groups. This group used an assay that has a high affinity for follistatin 288 
(membrane bound form) but has considerable cross reactivity with follistatin 315 
(circulating form). It is likely that since follistatin 315 is the major form in serum that it 
will have provided a substantial contribution to the measured concentration of 
follistatin. To cany out more detailed studies, specific assays for both follistatin 
subtypes would be required. Future studies perhaps examining the level and distribution 
of follistatin 288 in control and DS placentae may provide further insights into the
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mechanisms behind elevated maternal serum concentrations of inhibin-A and activin-A 
in DS pregnancies.
4.1.5 C onclusions: In h ib in  and  A ctivin  Study
This study provides evidence that the elevation in both activin-A and inhibin-A in 
maternal serum from DS pregnancies may be due to overproduction of the proteins 
rather than increased transport from the fetal to maternal compartments. The observed 
correlation between activin-A and inhibin-A levels in placental extracts and a similar 
trend in serum samples could suggest one of two reasons for the increased hCG, 
inhibin-A and activin-A production observed in DS pregnancies. It could be that an 
independent factor (possibly coded for by a gene on chromosome 21) is increasing the 
production of activin-A, which would in turn lead to an increase in hCG production. 
The increased hCG levels would then be expected to up-regulate the rate of inhibin-A 
production as part of a negative feed back loop (fig 4 .1.5).
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Figure 4.1.5 Diagram of the negative 
feedback loop involving mhihin-A, 
activin-A and H C X j .  + indicates 
stimulation of production by one o f  
the factors and - indicates inhibition 
of production
Alternatively, the production o f the (3a subunit o f inhibin-A and activin-A could be 
upregulated by a different mechanism which would lead to increased production of both 
glycoproteins. Lambert-Messerlian et 6// (1998a) postulated that the observed increase in 
inhibin-A levels was due to upregulation in a-subunit production, while increased Pa 
subunit expression did not contribute to altered inhibin-A levels in the maternal serum 
of DS pregnancies. This was supported by their observation that neither Pa subunit 
mRNA nor activin-A production was altered. However, more Pa subunit would be 
required to maintain activin-A production since inhibin-A, and therefore the 
requirement for Pa subunits, is increased in DS pregnancies.
1 8 2
It is clear from the present and other studies that, despite the significant elevation in 
inliibin-A and activin-A in the maternal serum of DS pregnancies, inhihin-A but not 
activin-A is a useful marker of DS pregnancies in the second trimester. Increased 
placental production o f these proteins, probably by trophoblast cells, is the most likely 
reason behind the observed elevation in maternal serum inliibin-A and activin-A. The 
correlation between inhibin-A/activin-A and hCG in the placenta suggests that the 
elevation in the production of hCG by the DS placenta is related to elevated inliibin-A 
and/or activin-A production. This relationship could be due to a negative feedback 
mechanism or an independent factor that increase the production of inhibin-A, activin-A 
and hCG.
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4 .2  G r o w th  F a c to r s
4.2 .1  E piderm al G row th Factor
This study is the first to show that maternal urine and amniotic fluid levels of EGF are 
significantly lower than normal in DS pregnancies, while maternal serum levels are 
unaltered. Significantly reduced urinary but unaltered serum EGF. levels was a 
surprising observation, since urine is a filtrate of the circulation. In this study 
significantly lower levels of EGF were also noted in amniotic fluid. Other markers show 
different trends in variation between amniotic fluid and maternal serum. For example, 
FLAP levels are reduced in amniotic fluid from DS pregnancies (Newby et al. 1997), 
but are normal in maternal serum, and the inhibin-A concentration is reduced in 
amniotic fluid but elevated in maternal serum of DS pregnancies (Wallace et al. 1997). 
This may indicate different sources of EGF in maternal urine, maternal serum and 
amniotic fluid. Alternatively, the rapid clearance of EGF from the maternal circulation 
may be such that it makes differences in levels impossible to detect in serum. Maternal 
serum samples used in this study were all from the second trimester of pregnancy, while 
the urine samples were obtained from first and second trimesters. Our data suggest that 
DS urinary EGF MoM values may be lower in the first trimester of pregnancy than in 
the second (fig 3.1.4.3b), which may indicate that this is a transient alteration of levels, 
mainly observed in the first trimester of pregnancy. Low maternal urine and amniotic 
fluid EGF levels have previously been noted in pregnancies affected by intrauterine 
growth retardation (lUGR) (Hofmann et al. 1988; Lindqvist et al. 1999). A review of 
post-mortem reports for the DS fetuses investigated in the present study found no 
evidence of lUGR, consistent with previous observations (MacAfee et al. 1970; 
Kucera, 1971; Wald et al. 1993). One study has failed to find placental expression of 
EGF (Joldii et al. 1997), but both EGF and its receptors have been localised to 
trophoblastic cells of the placenta (Ladines-Llave et al. 1991). This suggests that EGF 
may have an endocrine role in the development of the placenta.
Reasons why EGF levels should be reduced in the amniotic fluid of DS pregnancies are 
speculative since the precise origin of this growth factor is unclear. It is known that 
EGF is present in fetal skin (Poulsen et ai. 1996), and also that the dermis of fetal skin 
is abnormally thickened due to increased collagen type VI production in DS 
pregnancies (von Kaisenberg et al. 1998). Such abnormal skin development may be
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associated with altered secretion of EGF, leading to changes in amniotic fluid levels of 
this growth factor. Alternatively, reduced excretion of EGF in urine by DS fetuses 
would lead to altered amniotic fluid levels of EGF since fetal urine is the principal 
contributor to the AF pool around the end of the first trimester.
4 .2 .2  T ran sform in g G row th Factor B eta 1
This is the first study to show that placental and amniotic fluid levels of TGF(3i are 
significantly lower than normal in DS pregnancies, while maternal serum levels are 
unaltered. As with EGF, it is unclear why amniotic fluid and placental levels of TGFpi 
are reduced in DS pregnancies. These results contrast with a report that total bioactive 
TGFp levels are elevated in the amniotic fluid of DS pregnancies (Bromage et al. 
2000). The latter study was carried out using a bioassay, which was hased on the ability 
of TGFp to inhibit the proliferation of mink lung fibroblasts. The current study 
measured total TGFpi concentration, that is hioactive and latent forms and found a 
significant reduction in placental and amniotic fluid levels. The study by Bromage et al 
(2000) found a significant increase in bioactive TGFp and no significant difference in 
total TGFp. The reason for the difference between these studies could be that the 
bioassay detected TGFPi and TGFpz activity, as well as other interfering substances 
(tumour necrosis factor a  and p) that may be present in amniotic fluid. The 
immunoassay used in the current study was specific for TGFpi with less than 2% cross 
reactivity with other TGFp isoforms (Proniega assay data sheet).
A few studies have been carried out investigating TGFP; levels in abnormalities of 
pregnancy other than DS. Significantly elevated maternal plasma levels o f TGFpi have 
been associated with pregnancies complicated by pre-eclampsia (Djurovic et al. 1997), 
and also in pregnant women suffering miscarriage and in non-pregnant women with a 
history of recurrent miscarriage (Ogasawara et al. 2000). The current study could not 
find any significant difference between total serum levels of this growth factor between 
either control and DS groups or pregnant and non-pregnant groups.
It is postulated that altered placental levels of TGFPi may contribute to the altered 
levels of hCG expression in DS pregnancies. TGFpi has an inhibitory effect on hCG 
production and cytotrophoblast syncytialisation, a process that is related to the rate of
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hCG production (Hay, 1988). It is possible that lower levels of TGFp i could affect this 
process by allowing more syncytialisation to take place, thereby contributing to 
increased placental hCG production leading to elevated maternal serum levels of this 
hormone in DS pregnancies. Increased syncytialisation could also provide a mechanism 
for increased production and secretion of other placental markers into the maternal 
serum in DS pregnancies (e.g. inliibin-A). However, not all placental markers show 
elevated serum levels in DS pregnancies (e.g. PAPP-A, SP-1 and the fetal/placental 
product UE3 are reduced) and the magnitude of the changes in variable between 
different markers is gestation dependant, suggesting a more complex mechanism may 
be operating.
4 .2 .3  C onclusions: G rowth Factor Study
Following the same procedure as that carried out with the inhibin and activin data, the 
relationship between EGF and TGFPi levels and previously measured hCG levels was 
investigated using Pearson’s pairwise correlation. There was no significant association 
hetween placental and AF levels of TGFpi or placental TGFpi and f]3 or ihCG. The 
levels of neither growth factor were correlated with either f|3 or ihCG levels in amniotic 
fluid. If either EGF or TGFPi were directly related to the increased placental production 
of hCG, a degree of correlation would be expected between the levels of these faetors as 
was observed for inhibin-A or activin-A and hCG. The fact that no correlation was 
observed suggests that these factors are unlikely to have a direct effect on the 
production of hCG although an indirect effect (e.g. modulation of cytotrophoblast 
differentiation) cannot be excluded.
Although based on a small series of control and DS cases, the majority of trisomie 
pregnancies selected for study had shown increased hCG levels in routine second 
trimester screening and might have been expected to show changes in EGF or TGFpi 
levels if  these growth factors were implicated in the alteration o f hCG levels. It could be 
the case, however, that abnormal fetal or placental function is the reason behind the 
changes in growth factor production, rather than altered growth factor levels being the 
cause of fetal/placental malfunction in DS. Altered TGFpi and EGF levels could affect 
the development of either the placenta or fetus in DS pregnancies, however the specific 
reason for these altered growth factor levels in these pregnancies is unclear as the gene 
for neither is located on chi'omosome 21.
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4-3 m R N A  Q u a n t if ic a t io n
To study hCG production by cultured trophoblast cells, both secretion of the protein and 
mRNA production had to be measured. These cells are difficult to isolate and culture, 
consequently RNA samples from these cells were scarce. It was therefore desirable to 
find an efficient method of mRNA quantification suitable for determining both hCG and 
a control gene mRNA production by trophoblast cultures. Until recent years, the 
principal method of specific mRNA quantification was northern blot analysis. This 
relies on accurate determination of band densities on autoradiographs using an imaging 
densitometer to compare the quantity of mRNA loaded in each lane. Northern blot 
analysis is also extremely time consuming if many samples need to be analysed because 
each RNA sample has to be separated by gel electrophoresis. The sensitivity of this 
technique is limited and it was found in the current study that only large differences in 
density could be accurately measured. The main drawback of this technique is the 
quantity of total RNA required to quantify the specific mRNA of interest in each 
sample. For one gel 0.5-20pg total RNA is generally required for each sample. In the 
case of the hCG probe used in this study, a minimum of 5pg was required to produce a 
detectable signal.
4.3.1 ELISA B ased  m RNA A ssay
This type of assay was commercially available to quantify GAPDH mRNA, which was 
used in this study as the control gene, but there was not a commercially available kit to 
quantify hCG mRNA. This meant that the commercially available base kit had to be 
adapted to allow it to be used to quantify hCGp mRNA. This method proved to be a 
quick and easy way to determine the quantity of both mRNA transcripts in each sample. 
Each assay allowed 40 samples to be analysed in duplicate and only 2pg or 4pg total 
RNA was required for each well. This meant that duplicate results for both genes of 
interest could be obtained using a total of 8pg or 16pg total RNA. In contrast a 
minimum of 20pg total RNA would be required to analyse the expression of both of 
these genes in duplicate by northern hybridisation analysis. The speed of the assay and 
the number of samples that could be dealt with at one time meant that over 60 samples 
could be assayed for both hCG and GAPDH mRNA expression in the time it would take 
to carry out two northern blots. ELISA based mRNA results were compared to those
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obtained using real time quantitative PCR. There was a significant correlation observed 
between the results obtained using each method, despite the control mRNA differing 
between methods. This proves that the ELISA based method provides accurate results. 
The fact that no specialist equipment is required for this method, only a plate reader 
capable o f measuring light absorbance like those used for a standard ELISA, makes this 
a relatively inexpensive method to use. This is of particular value if  there would be no 
long term continued requirement for measuring levels of mRNA expression.
The main drawback of this method was the time taken to optimise the assay for use with 
the customised probes. If two commercially available targets were o f interest this would 
not be a problem making this a more attractive method to use. The numbers reported by 
the custom assay were only relative to a standard set of dilutions of a stock RNA 
sample. This meant that results were in arbitrary units rather than in atomoles as is 
reported by the commercially available assays. Despite requiring less RNA than a 
northern blot, the quantity of RNA required for this method is considerably more than 
PCR based methods. The quantity of RNA is particularly crucial when tissues or cells to 
be analysed are scarce. The sensitivity of the custom assay could be further improved by 
double labelling the DIG labelled probe. This probe only received a 5’ DIG label but it 
would be possible to label both the 5’ and the 3’ ends of the probe with DIG thereby 
doubling the number of anti-DIG antibody binding sites and theoretically doubling the 
sensitivity of the assay. This would decrease the quantity o f RNA required to generate a 
signal but would of course increase the cost of probe synthesis.
4 .3 .2  R eal T im e Q uantitative PCR
The PCR based method was by far the most sensitive way of determining the level of 
mRNA expression in samples. Multiplex reactions were carried out so that both hCG 
and the control gene (PPIA) expression could he analysed concomitantly. Reverse 
transcription of 2pg RNA provided sufficient cDNA to allow up to eight multiplex 
reactions, each carried out in duplicate. This is also an extremely quick method. Each 
two hour PCR reaction can analyse 45 RNA samples. Real time quantitative PCR is the 
most accurate PCR based method of mRNA quantification because the rate o f the PCR 
reaction is monitored tlnoughout ensuring that all measurements are taken during the 
logarithmic phase of the reaction. This can often be difficult to achieve when using an
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end point method of quantitative PCR analysis particularly if there is large variation in 
the levels of expression between samples.
The main drawback is the fact that smaller academic departments are unlikely to have 
access to the TaqMan® which carries out the PCR reaction. The reagents required for 
each reaction are comparable in price to an ELISA assay meaning that, if the equipment 
is accessible within a department, this is an economical way of analysing mRNA 
expression.
4 *3*3 C onclusions: m RNA Q uantification  M ethods
The major points to consider when deciding between the three studied methods of 
mRNA quantification ai'e summarised in table 4.3.3. Probably the most efficient method 
of determining the level o f mRNA expression when the quantity of RNA is limited and 
a large number of samples have to be assayed is Real Time PCR. Access to the 
TaqMan® could be difficult because it is expensive to purchase and only departments 
that regularly quantify mRNA are likely to invest in this piece of equipment. There are 
other PCR methods using standard PCR machines that can be used. These usually 
involve stopping the PCR reaction in the logarithmic phase and employing a method of 
end point quantification. These methods, like Real Time PCR, require careful 
optimisation and are not quite as reliable as the Real Time method. If a TaqMan® is not 
available this could provide a viable alternative.
The ELISA method provided a good, reliable alternative to PCR methods of 
quantification and is certainly quicker, easier and more sensitive than northern blot 
analysis. Modification of the standard assay was time consuming but following this it 
was easy and quick to carry out. The base kit of the assay has recently been modified to 
allow the use o f collected cells rather than isolated RNA in the assay. Cells are collected 
into a lysis solution provided with the assay kit and are added directly to the ELISA 
plate. This removes the need for RNA isolation procedures, further speeding up the 
process of assaying mRNA levels in cultured cells. As more targets have pre-made kits 
available, this will become an attractive method of mRNA quantification particularly in 
laboratories where large investments for new equipment are not available.
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Northern Blot ELISA Real Time PCR
Quantity of RNA 
Minimum Time 
No. of samples 
assayed at once 
Obvious 
Drawbacks
2 0 ~ 4 0 p g  
3 d a y s  
10
•  U s e s  r a d io a c t iv ity  an d  
o th e r  h a z a r d o u s  c h e m ic a ls .
•  L im ite d  s e n s it iv ity .
•  E x p o s u r e  t im e  m a y  
n e e d  to  b e  in c r e a s e d  to  
s e v e r a l  d a y s .
8 - 1 6 p g
4 h
4 0
2 p g
2 h
4 5
•  L im ite d  n u m b e r  o f  •  T a q M a n  is an  
c o m m e r c ia l ly  a v a ila b le  e x tr e m e ly  e x p e n s iv e
ta r g e ts  &  o p tim is a t io n  in v e s tm e n t .
o f  c u s to m  ta r g e t  is  a 
le n g th y  p r o c e s s .
•  A s s a y  k its  are  
m o d e r a te ly  e x p e n s iv e .
•  R e a g e n t s  are  
m o d e r a te ly  e x p e n s iv e .
Table 4.3.3 Summary o f  points to consider when comparing three methods o f  mRNA 
quantification.
4 .4  T r o p h o b la s t  C u ltu r e
As mentioned in previous sections, the primary sites of synthesis of placental derived 
maternal serum markers of DS pregnancies are trophoblasts. It was one of the main 
aims of this project to optimise a method of isolating and culturing cytotrophoblast cells 
to allow the study of hCG production and secretion by these cells as they differentiate to 
form syncytium. The method that was chosen was the widely used Kliman (1986) 
method. Term placentae were used to optimise this method with the ultimate aim of 
transferring this method to mid trimester DS and control placentae.
4.4 .1  V iab ility  and  Purity o f  T rophoblast Cells
Following initial isolation, approximately 1.5-3.5x10^ cells per gram (wet weight) of 
tissue were isolated, which were approximately 90-95% pure and greater than 90% 
viable. This is in line with the previously reported yields and purity by those routinely 
working with isolated trophoblast cells (Kliman et al. 1986; Bax et al. 1989; Truman et 
al. 1989; Frank et al. 2000; Frank et al. 2001). Following 24h in culture, the 
percentage of cells which failed to adhere to the culture surface was typically less than 
10% which again is similar to the viability of trophoblast cells previously reported. For 
many experimental procedures this degree of purity is sufficient and cells without any 
further purification steps were used in this study to assess the effects of 
cryopreservation on trophoblast function. It was discovered that
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occasional batches of trypsin provided poor cell yields as has been noted before (Franlc 
et al. 2000; Franlc et al. 2001).
One problem that was encountered during isolation procedures was clumping of 
trophoblast cells making them difficult to resuspend and seed onto the culture surface 
evenly. This problem has previously been reported when using the Kliman method of 
cell isolation followed by the use of Percoll gradients to further purify cytotrophoblast 
cells (Karl et al. 1992). It was suggested in the latter study that a further short 
trypsin/DNase treatment of the cells was an effective solution, however in the current 
study it was discovered that refrigerating the cells between isolation steps and using 
cold culture medium until the point when the cells were seeded onto the culture surface 
eliminated clumping. Another modification, which was made to the original Kliman 
(1986) method, was to reduce the number of 30min digestion steps from thiee to two. It 
was observed that the third digestion step seemed to remove larger clumps of cells from 
the villous fragments rather than the single cells that were largely removed during the 
first two digestion steps. These clumps of cells interfered with the Percoll purification 
step by clumping near the top of the gradient and trapping some of the mononuclear 
cells thereby preventing their collection. Using two digestion steps resulted in a purer 
cytotrophoblast isolation without any noticeable reduction in cell yield.
The primary contaminants in the isolated cells were blood leukocytes as indicated by 
positive reactivity with anti CD45 antibodies. Similar contamination has been reported 
by others (Blaschitz et al. 2000). Further immunopurification of trophoblast 
preparations resulted in a preparation that was greater than 98% pure. One study has 
reported that anti HLA immunopurification of trophoblast cells markedly increases their 
ability to differentiate when compared to non-purified cells as monitored by 
immunocytochemical staining and hCG and hPL secretion (Cervar et al. 1999). It has 
heen reported that anti CD9 purified trophoblast preparations fail to differentiate 
properly in culture as monitored by immunocytochemistry and lower hCG secretion, 
and that these cells require administration of EGF to induce syncytialisation (Momsh et 
al. 1997). As can been seen from figures 3.2.2.2c and 3.2.2.2d there appeared to be 
little difference in syncytialisation between pre and post immunopurification cultures in 
this study. There also appeared to be little difference in the rate o f hCG and FLAP 
production, although there was a tendency towards higher secretion of hCG in 
immunopurified cells. It is difficult to find a reason for such a variation in results
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between these studies. The present study and the study by (Cervar et al. 1999) both 
used anti HLA class I immunopurification and were based on results from 3 and 17 
placentae respectively. The study hy Morrish et al (1997) used anti CD9 
immunopurification and appears to be based on fewer placentae than the (Cervar et al.
1999) study, perhaps a maximum of five placentae for some aspects, although other 
results appear to be based on only 1 or 2 placentae. Although different antibodies were 
used to remove contaminating cells in these studies, it is unlikely that this would make 
any difference to the function of the remaining cytotrophoblast cells. In the current 
study, it was observed that anti CD9 antibodies did not appear to bind to all 
contaminating cells. Nevertheless, Morrish et al (1997) reported a degree of purity 
similar to the Cervar (1997) and the current studies, indicating that the different 
antibodies are unlikely to provide a reason for the altered cytotrophoblast behaviour.
Immunopurified cells were required for studying the effects of interferon on hCG 
secretion from trophoblasts because it has been reported that leukocytes and 
macrophages, which are the main contaminants of trophoblast cultures (Blaschitz et al.
2000), produce interferons (De Maeyer and De Maeyer-Guignard, 1998). This would 
give a background level o f interferon, which may interfere with the study of the effects 
of administered interferon on these cells. The use of macrophage conditioned medium 
has also been shown to affect hCG secretion from trophoblast cultures although one 
study showed an increase in hCG secretion (Khan et al. 2000) while another showed a 
decrease in hCG secretion (Cervar et al. 1999) when macrophage conditioned medium 
was used to culture cells.
4 .4 .2  E ffect o f  C ryopreservation  on  Cells
Due to the uncertainty inherent in the time of collection of placentae for cytotrophoblast 
cell isolation and the difficulties of scheduling a series of 24h medium changes, it would 
be desirable if isolated cells could be cryopreserved for recovery at a convenient time. 
This would especially be the case where placentae from mid trimester TOP were being 
collected as these often occur out of normal working hours. The effect of 
cryopreservation on isolated term placental cytotrophoblast cells was therefore 
investigated to assess whether cytotrophoblast cells could be stored in this way to allow 
recovery at a convenient time point, which would allow a set o f experiments to be 
carried out simultaneously on different cultures.
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It is clear from section 3.3.1.2 that trophoblast cells do not behave normally after 
recovery from cryopreservation. Lower rates of hCG secretion were noted in 
cryopreserved cultures as was failure of morphological differentiation assessed by light 
microscopy, although no difference in FLAP secretion was observed. There was also no 
difference in the quantity of DNA or protein in the culture wells between fresh and 
cryopreserved cells. This indicated that similar numbers of cells remained in the wells 
during the culture period o f both fresh and frozen cells. The difference in hCG secretion 
camiot therefore be attributed to some effect caused by correcting the hCG results by 
total protein measurements but must be due to alterations in the secretion of this 
hormone. One possibility that could account for this difference could be that 
contaminating cells survive the cryopreservation procedure better than cytotrophoblast 
cells and begin to increase in number during the culture period. ICC analysis of 
vimentin positive cells at 24h and 96h after recovery of cells from frozen storage did not 
reveal any obvious increase in contaminating cell number when compared with the 
matching fresh culture.
The freezing protocol used was that described by Yui et al (1994) who did not report 
such problems. Other groups have also reported results on trophoblast cells recovered 
from frozen storage, however no definitive study on the effects o f cryopreservation on 
trophoblast function has been reported. The reason why trophoblast cells perform so 
poorly following cryopreservation could be because these are primary cells that do not 
grow and divide in culture, only differentiate. Some cells would be expected to die 
following cryopreservation. If cells actively divide, then cells lost during this process 
will be replaced but this would obviously not be the case where trophoblasts are 
concerned. Trophoblast cells also have a limited lifespan, consequently it is impossible 
to give the cells some time to recover in culture before working with them as could be 
done with actively dividing cells. It was decided that for the purpose of this study, only 
freshly isolated cells would be used because cryopreserved cells did not behave in a 
predictable manner following recovery. Perhaps for some studies cryopreserved cells 
would be suitable but for studying the effects of factors on hCG secretion, using a 
system where the hCG secretion is obviously different from that seen in freshly isolated 
cells does not seem appropriate.
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4  5  I n c r e a s e d  hC G  in  D S  P r e g n a n c ie s
4.5.1 S yn cytia lisa tion  o f  DS C ultured C ytotrophoblast 
C ells
Since the commencement of this research, further studies have been reported where the 
mechanisms behind altered maternal serum levels of hCG in DS pregnancies have been 
examined. One group have studied cultured trophoblast cells isolated from control and 
DS placentae. The formation of syncytium, as the culture time progressed, was 
monitored by immunocytochemical analysis of desmoplakin localisation. Desmoplakin 
surrounds individual cytotrophohlasts but reactivity diminishes as the cytotrophoblast 
cells fuse to become a continual syncytial layer (see fig 3.2.2.2c for the normal 
situation). It was found in both reports by this group that DS cells failed to syncytialise 
as control trophoblast cells did. This failure of syncytialisation in DS cultures was 
accompanied by lower rates of hCG mRNA production and protein secretion (Frendo et 
al. 2000; Evain-Brion et al. 2000). These results were based in the first report on 8 
control and 8 DS placentae collected from second trimester terminations (Evain-Brion 
et al. 2000). The second report was based on 10 control and 15 DS placentae collected 
from both the seeond and third trimesters (Frendo et al. 2000). These results on 
cultured cells were confirmed in both reports hy measuring the mRNA expression of 
markers, which increase during the process of syncytialisation, in total placental 
homogenates from the 8 control and DS placentae using real time PCR analysis. They 
found that levels of hPL, hCGa, hCG(3, placental growth hormone and leptin mRNA 
were all significantly lower in DS placentae (Frendo et al. 2000; Evain-Brion et al.
2000) suggesting that in vivo formation of syncytiotrophoblast is also defective. They 
conclude that these findings may aid in understanding the reasons behind elevated 
maternal serum levels of hCG in DS pregnancies. This was a particularly surprising 
finding since most studies carried out prior to these studies indicated that elevated 
maternal serum levels of hCG largely reflected increased placental production of the 
hormone (Eldar-Geva et al. 1995; Newby et al. 1997). This discrepancy with the 
previous studies on placental production o f hCG were not addressed by Frendo et al 
(2000) with the study of Eldar-Geva et al (1995) only being cited to support the finding 
of reduced syncytialisation in DS pregnancies.
194
The larger study carried out by this group includes some third trimester placentae which 
would probably not be expected to show altered levels of hCG because these alterations 
are gestation specific. The second trimester maternal serum screening programme based 
on maternal serum hCG levels is most reliable at 15 weeks of gestation when the largest 
difference in hCG levels between control and DS samples is evident. The difference 
between control and DS serum levels o f hCG decline as gestation progresses until 
around 20-22 weeks o f gestation when little difference between control and DS groups 
is observed. Consideration must therefore be given to the gestation at which placentae 
are obtained when investigating the alterations in maternal serum levels of placental 
derived markers.
The placentae selected as controls for the above studies (Frendo et al. 2000; Evain- 
Brion et al. 2000) were not from pregnancies terminated for psycho/social reasons, 
which would perhaps proved the most appropriate normal controls, but were obtained 
from pregnancies with abnormalities other than chromosomal, including severe bilateral 
or low obstructive uropathy, skeletal abnormalities and cardiac anomaly. Although 
these abnormalities are fetal and not placental they could conceivably alter the secretion 
of hCG when compared to the normal situation. No information is given as to the 
maternal serum marker levels of these pregnancies. If this information was reported, as 
well as confirming that the “control” placentae were from appropriate pregnancies, it 
would be helpfril in the interpretation of the placental results because the reported 
differences in placental marker expression could be correlated with the situation in 
maternal serum.
The same group suggested that this failure to syncytialise was due to over-expression of 
the chromosome 21 product, copper zinc superoxide dismutase (SOD-1) (Evain-Brion 
et al. 2000; Frendo et al. 2001). Both reports indicated that DS placentae expressed 
higher levels of SOD-1 than gestation matched controls. They also transfected normal 
term trophoblast cells with a plasmid containing the SOD-1 gene that caused increased 
SOD-1 expression similar to that in DS cells. It was observed that the transfected cells 
showed inhibition in syncytialisation and hCG secretion similar to that found in DS 
trophoblasts. They also found that levels o f hPL, hCGa, hCGp and placental growth 
hormone but not leptin mRNA were significantly lower in the SOD-1 transfected cells. 
Because transfection of cells with SOD-1 expressing vector was not totally effective, 
the second study tagged SOD-1 with green fluorescent protein (GFP) so the transfected
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protein could be visualised in trophoblast cells in culture. They noted that the cells that 
showed positive GFP-SOD-1 reactivity did not syncytialise while cells on the same 
culture plate that did not express the GFP-SOD-1 fused to form syncytium. This study 
indicates that the defects in syncytialisation observed in DS placental cells could be 
attributed in part to the over expression of SOD-1 (Evain-Brion et al. 2000; Frendo et 
al. 2001). It is unclear however, how many placentae these results are based upon. It is 
thought that over-expression of SOD-1 leads to increased oxidative stress. This could 
then cause damage to the trophoblast cells preventing syncytialisation, and in vivo may 
cause increased proliferation of trophoblasts explaining the observation of increased 
numbers o f cytotrophoblast cells in DS placental sections as has been noted previously 
(Roberts et al. 2000).
The results of these studies (Frendo et al. 2000; Evain-Brion et al. 2000) are surprising 
since they conflict with the findings of previous studies on hCG levels in DS placentae 
which show elevated placental protein levels and mRNA expression of hCG in DS 
pregnancies (Eldar-Geva et al. 1995; Newby et al. 1997). As mentioned earlier these 
differences between studies were not addressed in the recent studies (Frendo et al. 
2000; Evain-Brion et al. 2000) although the reason why maternal serum levels of hCG 
showed an increase in hCG while the placenta showed decreased levels in DS were 
discussed. It was suggested hy Frendo et al (2000) that the increased level of hCG 
observed in maternal serum was due to increased glyeosylation of hCG making it less 
susceptible to degradation rather than increased production of the hormone by placental 
cells.
4 .5 .2  H yperglycosylated  hCG (H-hCG)
H-hCG has the same peptide structure as ihCG but has larger N- and O- linked 
oligosaccharides on the p subunit. H-hCG is also known as invasive trophoblast antigen, 
alluding to the possible source of H-hCG. It is thought that invasive cytotrophoblast 
cells secrete H-hCG rather than villous trophoblasts, as is the case for ihCG (Cole et al.
1999). This cell specific production also explains the gestational variation in the 
contribution of H-hCG to the total hCG secreted during pregnancy, with peak 
production at the point in gestation when peak cytotrophoblast invasion is occurring 
(table 4.5.2).
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Gestation ihCG P-Core hCG Contribution of H-hCG
(nmol/mmol creatinine)
4-6 weeks 7-8 9-11 26%
6-8 weeks 8-9 11-15 11%
8-14 weeks 9-2 15-40 2.9%
14 weeks-term 2-3 15-5 2%
Table 4.5.2 ihCG and fd-core hCG concentrations in maternal urine throughout normal 
pregnancy and the percentage contribution o f  H-hCG. Values obtained from  de 
Medeiros et al. (1992) and those cited as unpublished data by Shahabi and Cole (Cole 
et al. 1999).
H-hCG has been reported as a useful maternal urine screening marker for DS 
pregnancies with a greater degree of elevation in urine (up to 9MoM) when compared 
with other forms of hCG such as fp or P core hCG (Cole et al. 1998; Cole et al. 1999; 
Cuckle et al. 1999b; Bahdo-Singh et al. 2000). These studies of H-hCG mainly 
focused on the second trimester of pregnancy, although a smaller elevation in first 
trimester urinary H-hCG to 3.6MoM has been reported (Weinans et al. 2000). In the 
second trimester, only 2 to 2.9% of control hCG production is accounted for by H-hCG 
(table 4.5.2). The placental studies (Evain-Brion et al. 2000) that suggested 
overglycosylation rather than overproduction of hCG was the main cause of elevated 
maternal serum levels of this hormone also focused on the period in gestation where 
only 2% of total hCG is hyperglycosylated. It is fair to speculate that in the DS cases 
used by Evain-Brion et al. (2000) perhaps up to nine times more H-hCG was being 
produced by cytotrophoblast cells based on the reported degree o f elevation in maternal 
urine of DS pregnancies. The results of the placental studies (Evain-Brion et al. 2000) 
suggest a 6-20 fold reduction in hCG production by DS placentae. Although it is 
possible that the increased levels in hCG are in part due to altered degradation of H- 
hCG, it is difficult to attribute inereased hCG levels entirely to this mechanism 
particularly if placental hCG secretion is reduced as was suggested (Evain-Brion et al.
2000). If  slower degradation was the only reason behind elevated maternal serum levels 
of hCG rather than over production by the placenta, then decreased levels of hCG would 
be expected in maternal urine samples from DS pregnancies at some point in gestation, 
although the levels could begin to increase as more hCG is eventually broken down. 
This is not the case. Elevated maternal urine levels of both fp-hCG and p core hCG (the
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terminally degraded form of hCG) have been widely reported in both the first and 
second trimesters of DS pregnancies. This indicates that synthesis of this hormone is 
more likely to be increased rather than inhibition of H-hCG degradation being the 
reason behind elevated maternal serum levels of hCG.
Further studies hy the same group (Guibourdenche et al. 2001) reported that hCG 
secreted from cultured DS trophoblasts had a significantly greater fraction of H-hCG 
than controls. The mRNA levels of two enzymes involved in the glyeosylation of 
proteins (sialyl-transferase- 1 and fucosyl-transferase-1) were also studied in control and 
DS trophoblast cultures. Levels of mRNA for both enzymes were significantly elevated 
in DS cells suggesting altered glyeosylation o f hCG by DS villous trophoblasts. It is 
thought that H-hCG is primarily produced by invading cytotrophoblast cells rather than 
villous trophoblasts (Cole et al. 1999). The study of Guibourdenche et al. (2001) that 
reported altered production of H-hCG in DS examined cells isolated from placentae 
using a protocol that results in preparations of mainly villous cytotrophoblast. As has 
been reported, these isolations of DS cytotrophoblast cells do not fuse to form 
syncytium over the culture period as control cultures do and produce a marker of 
invasive cytotrophoblast (Fl-hCG). It could be that different populations of cells are 
being isolated from the control and DS placentae or that once isolated, DS 
cytotrophoblast cells follow the invasive pathway rather than the pathway of 
differentiation as the control cultures did. These studies do not further immunopurify 
their cytotrophoblast preparations, and only vimentin and cytokeratin 7 
immunocytochemistry is used to determine the purity of the isolated cells. EVT express 
cytokeratin 7 and the limited antibody panel used in these studies would not be able to 
determine the specific lineage of the cytotrophoblast cells. It is therefore possible that 
for some reason the DS cytotrophoblast preferentially underwent the invasive route 
while the control cytotrophoblast syncytialised. This would not only explain increased 
H-hCG production but also the observation of decreased hCG and hPL secretion 
(markers of syncytialisation) by the DS cytotrophoblast cultures. It has been suggested 
that placental immaturity could be a reason behind increased hCG production because 
levels in DS maternal serum are similar to those in control pregnancies two to three 
weeks earlier in gestation (Canick et al. 1988; Chard, 1991; Waller et al. 1993). If this 
was the case then the number of cytotrophoblast cells destined for the invasive 
phenotype may be greater in DS pregnancies because invasion decreases as pregnancy 
advances.
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4 .5*3 LH/hCG R eceptor E xp ression  in  DS P lacen tae
A further study (Jauniaux et a l  2000), which suppoils previous findings on increased 
(3-hCG subunit expression in DS placentae, also reported increased LH/hCG receptor 
expression in DS placentae from 12-16 weeks gestation. Receptor expression was 
analysed by iinmunohistochemistry and in situ hybridisation. LH/hCG receptors and 
receptor mRNA were primarily localised to the syncytiotrophoblast layer with weaker 
staining of the cytotrophoblast cells. Increased hCG expression has previously been 
shown to have a negative regulatory effect on the synthesis of LH/hCG receptors. 
However, in the first trimester o f pregnancy, LH/hCG receptors are truncated and 
probably do not function as the full length receptor would. It would be expected that in 
DS pregnancies, which have a high hCG concentration, that the elevated hCG would 
down regulate receptor expression leading to decreased receptor expression in DS 
placentae. Because the opposite was observed in DS placentae by Jauniaux et al. (2000) 
it was suggested in this as well as previous studies that increased hCG levels and 
increased LH/hCG receptor expression was merely a reflection of placental immaturity 
in DS pregnancies. If the maturity of the DS placenta was equivalent to a normal 
placenta o f two to three weeks earlier in gestation then the self regulatory mechanism of 
hCG on its receptors may not be functional yet in the DS placentae.
4 *5*4 P lacen ta l/F eta l Im m aturity  in  DS
Placental and/or fetal immaturity has previously been suggested as a reason behind 
altered maternal serum marker levels (Canick et al. 1988; Chard, 1991; Waller et al. 
1993). Estriol precursors and AFP are synthesised by the fetus and it has been suggested 
that immaturity of fetal organs, in particular the adrenal cortex and liver could be the 
reason behind reduced maternal serum levels of both of these markers in DS (Canick et 
al. 1988). It was observed that the reduction in maternal serum AFP is consistent with 
the concentration observed around two to three weeks earlier in gestation (Canick et al. 
1988; Waller et al. 1993). One study analysed the association between maternal serum 
AFP and fetal birth weight and found no association between restricted birth weights 
and reduced maternal serum AFP (Waller et al. 1993). A similar observation was made 
regarding the elevation in maternal serum hCG, with the degree o f elevation matching 
the concentration observed earlier in pregnancy. Because hCG is a placental product, 
placental rather than fetal immaturity is the suggested cause for elevated maternal serum
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levels of this marker (Wald et al. 1988). Placental immaturity could also contribute to 
reduced maternal serum UE3 levels and could explain increased levels of inhibin-A.
However, other placental derived maternal serum markers of DS do not follow this 
pattern. The maternal serum concentration of SP-1 in normal pregnancy increases 
steadily throughout pregnancy, but second trimester maternal serum SP-1 in DS is 
significantly increased (Graham et al. 1992). If placental immaturity was the sole 
reason behind altered marker levels then SP-1 would be expected to be decreased in DS. 
There is little pathological evidence of placental or fetal immaturity in DS. Normal fetal 
and placental size and weight has been reported previously tlii'oughout gestation 
(MacAfee et al. 1970; Kucera, 1971; Wald et al. 1993; Kuhn et al. 1995). At the 
microscopic level, irregular maturation o f trisomie placentae has been reported 
including immature villi (table 1.4.4.2). Taken together, it appears that fetal/placental 
immaturity is unlikely to be the main reason for altered maternal serum marker levels in 
DS pregnancies although defects in the maturation of specific placental cells (e.g. 
cytotrophoblast) could have a role to play.
Although there have been reports to the contrary, most o f the available evidence 
supports increased placental production of hCG as the reason behind elevated maternal 
serum levels of this marker in DS pregnancies.
4 .5 .5  IFN an d  hCG S ecretion  from  T rop hob last C ultures
IFNa and IFN(3 are the predominant forms of IFN found in the placenta and fetus 
during pregnancy (Chard et al. 1986; Bennett et al. 1999). It is thought that these forms 
of IFN play a role in protecting the fetal/placental unit from rejection by the mother. 
The placental membranes have a high concentration o f IFN type I receptors and they are 
specifically localised to the syncytiotrophoblast as is IFNa, indicating that IFN a and 
IFNp have an important role to play at the fetal/maternal interface (Howatson et al. 
1988; Paulesu et al. 1991; Paulesu et al. 1997; Bemrett et al. 1999). If prevention of 
immune rejection is the main function of IFNa, the syncytiotrophoblast is an obvious 
target since this forms the main barrier between mother and fetus. In contrast, IFNy 
levels are low during pregnancy (Vassiliadis et al. 1998) although first trimester 
trophoblasts have been shown to express IFNy and IFNGRl (Paulesu et al. 1994). 
Maternal serum concentrations in early pregnancy are similar to those in the non­
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pregnant state and rise only slightly as gestation progresses to a peak during labour. 
Elevated maternal serum IFNy concentrations are associated with first trimester 
spontaneous abortion (Vassiliadis et al. 1998).
Increased IFN-Rl or IFNGR2 expression in DS placentae could have some bearing on 
the early rejection of some of these fetuses. The increased receptor expression could 
also have an effect on the production of maternal serum markers of DS pregnancies, 
particularly those synthesised by placental trophoblastic cells (e.g. hCG, inhibin-A and 
PAPP-A). There have been no previous reports of the effects of IFN a or IFNp on the 
synthesis of such markers by placental trophoblast cells although IFNy has been 
reported to reduce hCG secretion from term trophoblast cultures (Marth et al. 1989). 
There has been one report on the effects of IFNa administration to hCG secreting 
bladder carcinoma cell lines (lies and Chard, 1989). This study found that IFN a induced 
hCG secretion from these cells in a dose dependant manner. It was postulated that this 
effect may also be present when IFNa was administered to cytotrophoblast cell cultures 
and it was the aim of the current study to test this hypothesis. If  IFN a did, in fact induce 
this response then receptor over-expression in DS placental trophoblasts could perhaps 
provide a reason for increased hCG secretion from DS placentae.
Section 3.4 suggests that despite possessing functional IFN receptors, placental 
trophoblasts are insensitive to IFNa administration at term as a mechanism of altered 
hCG secretion. IFN a plays an immunomodulatory role in many cell types, inducing the 
expression of MHC class I antigens. However, IFNa fails to induce this response when 
administered to term trophoblast cell lines (JEG-3 and JAR) (Cross et al. 1999) and it 
was discovered that this insensitivity to IFN a was due to the failure of a step in the 
IFN a signalling pathway. Upon IFN a stimulation, receptors were activated and STAT 
signalling was induced, however the formation of the ISGF3/p48 complex which should 
enter the nucleus and bind the ISRE failed. Whether this response is missing in normal 
human trophoblasts and whether hCG release from trophoblasts would be involved in 
this particular pathway, is unknown. It is apparent from the current study that term 
placental trophoblasts do not respond to IFNa administration by secreting more hCG, 
however cells from the mid-trimester may behave in a different way. It is at this stage of 
pregnancy when differences in hCG levels between DS and controls are largest and 
therefore the peak responsiveness to the factor that causes this increase would be
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expected. The study of trophoblasts isolated from mid-trimester placentae is required 
before the postulated effect of increased IFN receptor expression in DS placentae on 
hCG production could be discounted.
4 .6  F u tu r e  R e s e a r c h
4.6 .1  P lacen tal P rod u ction  o f  DS M aternal Seru m  M arkers
The results of this and previous studies on placental function clearly indicate that the 
production of cytokines, growth factors and hormones is abnormal in placentae from DS 
pregnancies. The current study indicated that in the case of inhibin-A and activin-A the 
alterations in maternal serum levels of these markers largely reflect increased 
production by the placenta. These findings match the earlier reports studying maternal 
serum levels of hCG in relation to placental production of this hormone (Eldar-Geva et 
al. 1995; Newby et al. 1997). There have, however, been several studies relating to 
placental production of hCG in DS pregnancies that are not in accordance with these 
findings (all studies are summarised in table 4.6.1). These differences in findings 
indicate that further work in this field is required to elucidate whether changes in 
maternal serum marker levels in DS pregnancies reflect altered placental production or 
if a more complex mechanism exists.
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E ld a r - G e v a B r iz o t N e w b y J a u n ia u x E - B /F r e n d o
P la c  ih C G S ig n , e le v a te d S m a ll  in c r e a se
P la c  f p h C G S ig n , e le v a te d S ig n , e le v a te d
P la c  a l i C G N o  d if f e r e n c e
M S  f p h C G S ig n , e le v a te d S ig n , e le v a te d
M S  ih C G S ig n , e le v a te d
h C G  I H C S tr o n g e r
h C G  s e c r e t io n S ig n , e le v a te d S ig n , d e c r e a s e d
in vitro
P m R N A L a r g e
in c r e a se
N o  d if f e r e n c e S ig n , d e c r e a s e d
a  m R N A S m a ll
in c r e a se
N o  d if fe r e n c e S ig n , d e c r e a s e d
C y t o t r o p h o b la s t In h ib ite d In h ib ite d /
d i f f e r e n t ia t io n D e la y e d
L H /h C G S tr o n g e r
r e c e p t o r
N o . o f  C a s e s 4  D S , 3 C 11 D S , 3 0  C 51 D S , 5 2  C 8 D S , 4 2  C 15 D S , 10  C
G e s t a t io n s 1 7 -2 3  w e e k s 1 1 -1 5  w e e k s 1 0 -2 4  w e e k s 1 2 -1 6  w e e k s 1 2 -3 5  w e e k s
Table 4,6,1 Summary o f  findings from  studies o f  placental hCG production in DS 
pregnancies. Papers summarised are: Eldar-Geva et al (1995); Brizot et al (1995); 
Newby et al (1997); Jauniaux et al (2000); Evain-Brion et al (2000); Frendo et al 
(2000). Plac^placental, MS=maternal serum, sign-statistically significant and 
control.
4 .6 .2  C hrom osom e 21 Specific  M arkers and  th e  DS 
P lacenta
The current study used the analysis of growth factor levels as a method of analysing 
fetal/placental function in normal and DS pregnancies. Although this method did yield 
some interesting observations about the variations in growth factor levels in these 
pregnancies, uncertainty remains as to whether these differences are a cause of altered 
fetal/placental fimction in DS or are themselves the effect of altered function due to a 
different mechanism.
An alternative approach in future studies would be to focus on the effects of altered 
expression of chi*omosome 21 specific markers on the function o f the placenta in DS
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pregnancies. In the latter part of the current study the possible effect of increased 
expression of chromosome 21 products, IFN-Rl and IFN-R2, on hCG secretion by 
trophoblast cultures was investigated. Although this study indicated that IFNa 
administration did not seem to alter hCG secretion from these cells, only term placentae 
were available for analysis. Further analysis, using mid trimester placentae may yield a 
different result since, as noted above, this is the stage of pregnancy where the median 
shift in hCG levels in DS pregnancies is at a maximum. The effect of IFNa 
administration to DS trophoblasts at this stage would provide further insight into the 
differences in IFN-Rl and IFN-R2 expression and hCG secretion from these cells. 
Similar investigations could be carried out using IFNP to determine its effects on hCG 
secretion from trophoblasts since it shares the same receptors as IFNa.
Other chi'omosome 21 specific markers that could be studied in DS placentae include 
SODl, IFNGR2 and STCH. SODl (as examined by Frendo et al. (2000)) is normally 
protective against cellular oxidative damage caused by free radicals. At around 10-12 
weeks of gestation, there is a dramatic increase in oxidative stress in the placenta due to 
the massive increase in oxygen tension caused by the onset of maternal circulation into 
the intervillous space. It is thought that SODl has an important role to play in 
minimising damage to the fetus caused by free radicals during this time and tlu'oughout 
the rest of gestation. Over-expression of SODl could prove protective to the placenta 
and fetus during this period of pregnancy. However, increased SODl activity results in 
increased production of hydrogen peroxide, and if this accumulates in cells due to 
inadequate clearance by glutathione peroxidase or catalase, this could, in turn, lead to 
increased cellular damage rather than extra protection caused by SODl over-expression. 
Increased damage to trophoblast cells caused by over-expression of SODl was the 
reason proposed by Frendo et al (2000; 2001) for reduced syncytialisation and reduced 
hCG secretion from DS trophoblast cultures. To determine if the situation in vivo 
matches the in vitro results reported by Frendo et al. (2000; 2001), investigation of the 
localisation of SODl in control and DS placental sections and the concentration of 
SODl and its products in DS and control placentae could be areas area of future 
research.
The IFNGR2 is required for cells to respond to IFNy. The effects of IFNy on hCG 
secretion has been examined in at least two studies (Marth et al. 1989; Yanushpolsky et 
al. 1993). It was noted that IFNy administration caused a reduction in hCG secretion
204
from normal term trophoblasts but no alteration in hCG secretion from JAR cells. 
Neither this factor nor its receptors have been studied in DS placentae and both may 
provide an interesting target for future study.
Despite being outside the DS “critical region” of chromosome 21 it is proposed that 
STCH may be an interesting factor to study in DS placentae since the majority of DS 
cases would probably have an extra copy of this gene. STCH plays an important role in 
the normal protein folding events within cells (see section 1.6.4). Since most factors that 
are elevated in the maternal serum of DS pregnancies are proteins, STCH over 
expression may have a role to play in this elevation in protein marker production. If a 
difference was found in the function of STCH in DS pregnancies having a trisomy of 
the majority of chi’omosome 21, DS pregnancies not having a trisomy of this area of 
clu’omosome 21 could then be studied to determine the importance of this factor in the 
pathophysiology of DS pregnancies.
4 .6 .3  C onclusion
Without the intervention of screening and prenatal diagnosis, around 800 children with 
Down's syndrome would be born each year in the UK. As primary prevention is not 
possible, avoidance of an affected birth depends upon prenatal recognition of Down's 
syndrome in the fetus and selective termination of affected pregnancies. In the last 
decade, progress has been made in the non-invasive identification of features of the 
Down's syndrome pregnancy which mark it out as different from unaffected 
pregnancies. These include biophysical markers in the first trimester (eg. nuchal 
translucency) and several biochemical markers in the mother's blood in the first and 
second trimesters. Currently, routine screening is carried out mainly in the second 
trimester using combinations of two or tluee maternal serum markers to identify 
pregnancies at increased risk. This approach is neither 100% sensitive nor specific and 
the predictive value of combinations of markers depends upon the interpretation of the 
magnitude of the change in marker concentration compared to the base-line levels found 
in unaffected pregnancies. There have been few studies carried out to discover the 
mechanisms that underlie these marker changes and this has imposed certain limitations 
on the process of selection of the best markers.
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The markers currently in use have been selected largely on an empirical basis, often 
depending on the availability of suitable assays. Many more, as yet unexplored, 
pregnancy markers are present in maternal serum and some may prove to be more 
effective for screening than those currently in use. A more informed selection of new 
markers might be possible if the effect of the additional gene dosages, due to trisomy of 
clnomosome 21, on the production and secretion of pregnancy markers into the 
maternal circulation was more fully understood. Recently a few studies have appeared 
in the literature with the focus of the research on the placenta, the site of production of 
most of the screening markers in routine use, and the interface between fetus and 
mother.
Until recently, the function of the normal placenta was primarily studied at the 
anatomical level rather than at celluiai* level; consequently the control o f hormone and 
cytokine production in the normal human placenta has been the subject of investigations 
for only a relatively short period. The recent advances in isolating and culturing 
placental cytotrophoblast cells have allowed these cells to be monitored in vitro as they 
differentiate to form syncytium. From numerous studies it is well established that 
trophoblast cells are the main site of production of many placental proteins present in 
maternal serum (eg. hCG, PAPP-A, inhibin-A, activin-A, SP-1, PLAP, hPL) and that 
the rate of cytotrophoblast differentiation is closely related to the rate of production of 
many of these proteins. Since the characteristic changes in DS pregnancies are observed 
for multiple markers and none has a structural gene on chromosome 21, simple gene 
dosage effects can be ruled out. Rather, a more generalised effect due to increased 
dosage of one or more as yet unidentified genes on chromosome 21 on cytotrophoblast 
maturation seems more likely. Recent studies using trophoblast cultures have uncovered 
many factors that affect the in vitro differentiation o f cytotrophoblasts and hCG 
production at different periods of gestation. These factors include cytokines (eg. 
interleukins), hormones (eg. insulin and hCG), and growth factors (eg. EGF, TGFa and 
TGFP).
Evidence for an effect on trophoblast maturation was sought in the first phase of the 
present study by investigation o f factors that are known to affect hCG secretion. This 
pointed to changes in the levels o f specific placental growth factors and cytokines in DS 
pregnancies reinforcing the idea that there is disruption o f the complex mechanism 
controlling placental growth and function. As noted above, the basis of such changes
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must lie in the additional dosage effect of certain clnomosome 21 genes and two 
candidates, INF-Rl and INF-R2, have been investigated in the present study using term 
trophoblast cultures. Although no evidence of an enhanced effect on trophoblast 
differentiation or hCG secretion by administration of IFNa was found, caution must be 
exercised in the interpretation of such results as the data were obtained at term and there 
is abundant evidence that the marker changes are gestation related. Such cautions also 
apply to reports in the literature of other studies (e.g. on SODl) where gestation effects 
were not adequately controlled for. It is clear from the present study and others that 
many variables influence the levels of the markers used to monitor pregnancies for DS 
and this increases the difficulty of interpretation of results.
The mapping of the full human genome has uncovered a wealth of candidate genes on 
clii’omosome 21 although the function of many of these genes is unknown. Perhaps one 
of these genes could provide the key to answer the DS pathophysiology question and 
lead to more effective screening in pregnancy.
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